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ABSTRACT 
Pyrrole (P)-Imidazole (I) containing polyamides are small synthetic molecules which 
can target predetermined DNA sequences with high affinity and modulate gene 
expression by interfering with the binding of transcription factors to DNA. Hairpin and 
H-pin analogues show enhanced DNA binding affinity and selectivity compared to 
monomers, but are associated with poor cellular uptake. To address this problem, a new 
class of unlinked polyamide precursors containing appropriately designed pendant 
reactive and biocompatible functional groups is presented in this thesis. The ability of 
these agents to interact in situ and potentially form either H-pin or Hairpin conjugates 
was tested with DNase I footprinting analysis. The effects of modification on the 
formamido-imidazole-pyrrole-imidazole (f-IPI) polyamide and related analogues, by the 
addition of an amino group, on DNA binding affinity and sequence selectivity were also 
evaluated. 
 
Dbf4 is the regulatory subunit of Cdc7 kinase, which is essential for the initiation of 
DNA replication. Human Cdc7/Dbf4 (HuCdc7/Dbf4) kinase activity is critical for cell 
proliferation and high expression levels occur in multiple solid human malignancies. F-
IPI can target the MIuI Cell cycle Box (MCB) sequence 5’-ACGCGT-3’which is the 
critical site for transcription factor binding and activation of expression of the 
HuCdc7/Dbf4 core gene in mammalian cells. DNA sequence selective binding of f-IPI 
to the MCB sequence was shown in DNase I footrpinting experiments. A f-IPI-induced, 
dose-dependent inhibition of protein binding to the MCB was demonstrated in an 
Electrophoretic Mobility Shift Assay (EMSA). RT-PCR and immunoblotting analysis 
confirmed the inhibitory effects of f-IPI on HuDbf4 in MDA-MB231 cells. Small 
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interfering RNA-mediated depletion of HuDbf4 decreased cell survival and 
proliferation, and induced G1 arrest in MDA-MB231 cells. F-IPI treatments also showed 
a dose-dependent reduction of cell survival and proliferation and induced G1 arrest. 
Although the f-IPI H-pin analogue exhibited better DNA binding affinity and protein 
inhibition, no marked effects at mRNA and protein levels were detected in cells, likely 
attributed to its large size.  
 
The unlinked f-IPI analogues containing reactive groups [i.e f-IP(C3NH2)I and f-
IP(C3Cl)I] able to interact in situ and form H-pin were tested in the Dbf4 promoter 
model system.  f-IP(C3NH2)I presented the same DNA binding affinity and protein 
inhibition to the MCB as the combination of f-IP(C3NH2)I and f-IP(C3Cl)I (potential 
hybrid) but it produced much higher effects than f-IP(C3Cl)I. RT-PCR and 
immunoblotting analysis showed that the potential hybrid produced greater reduction of 
HuDbf4 mRNA and protein levels than either f-IP(C3NH2)I or f-IP(C3Cl)I. In addition, 
the potential hybrid demonstrated greater G1 arrest than each polyamide alone. 
 
Finally, a series of fluorescent f-IPI analogues are presented, providing an intrinsic 
probe for monitoring the cellular uptake of polyamides. Aza-Hx-PI was shown to target 
the same sequence as f-IPI (DNase I footprinting), inhibit protein binding (EMSA) and 
reduce the levels of HuDbf4 in cells. Time and dose-dependent nuclear localisation was 
detected by confocal microscopy.  
 
Overall the data presented in this thesis highlight the potential of small molecule 
polyamides as modulators of gene expression.
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CHAPTER 1  
INTRODUCTION 
1.1 The aetiology of cancer 
Cancer is characterized by an “uncontrolled growth” of cells caused by multiple 
changes in gene expression. This uncontrolled cell proliferation can ultimately evolve 
into a population of cells which can invade tissues (“invasion”) and metastasize to 
distant sites (“metastasis”), causing significant morbidity and, if untreated, death of the 
host. These three malignant properties of cancers differentiate them from benign 
tumors, which are self-limited, and do not invade or metastasize. Cancer can be viewed 
as a disease of abnormal gene expression. There are a number of mechanisms by which 
this altered gene expression occurs, for example via a direct modification of DNA, such 
as a gene mutation, translocation, amplification, deletion, loss of heterozygosity, or via 
mechanisms resulting from abnormal gene transcription or translation. The outcome is 
an imbalance of cell replication and cell death in the tumor cell population which can 
lead to an expansion of tumor tissue, in contrast to normal tissues where cell 
proliferation and cell loss are in a state of equilibrium.  
 
A large number of aetiological agents have been recognized that cause genetic damage 
and lead to neoplastic transformation. They fall into three general categories 1) 
Chemical Carcinogens. The role of chemicals in tumour development is widespread and 
was recognized because of links to occupational exposure. For example, inhalation of 
hardwood dusts has been associated with adenocarcinoma of the nasal sinuses, first 
described in workers in the furniture factories of High Wycombe (Hounam and 
Williams, 1974). Cigarette smoke contains over 4,000 chemical compounds and these 
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include over 70 that have been found to cause cancer (Cancer Research UK, 2012). 2) 
Radiation. Radiant energy, whether as ultraviolet rays or ionizing radiation, will 
transform cells in vitro and induce tumours in vivo in both humans and animals. As with 
most chemical carcinogens, radiation is mutagenic and thought to cause malignant 
transformation by DNA damage. There are usually many years between exposure to the 
initiating dose of radiation and the appearance of malignancy. 3) Tumour viruses cause 
transformation as a consequence of their ability to integrate their genome into the host 
cell DNA. Usually the virus is responsible for the production of a transforming protein, 
coded for by an oncogene, which maintains the transformed state within the cell (Butel, 
2000).  
 
1.2 Hallmarks of cancer 
 
In 2011, Hanahan and Weinberg reviewed their original definition of the hallmarks of 
cancer, which are composed of six distinctive and complementary cellular capabilities 
during the course of multistep tumorigenesis (Hanahan and Weinberg, 2011). Briefly, 
the six hallmarks are identified by the following characteristics (Figure 1.1): 
 
 Sustaining proliferation signaling  
One of the most fundamental characteristics of cancer cells is to sustain chronic 
proliferation. Normal tissues regulate the production and release of growth-promoting 
signals that are associated with the cell growth-and-division cycle, hence balancing cell 
number and further maintaining normal tissue architecture and function. Cancer cells 
evade the regulation of these signals leading to uncontrolled cell proliferation.  
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 Evading growth suppressors 
Cancer cells interrupt powerful programs that negatively regulate cell growth and 
proliferation in various ways. Tumour suppressor genes play a key role in many of these 
programs. For example, one of the prototypical tumor suppressors encodes the RB 
(retinoblastoma-associated) protein, which controls whether or not a cell should proceed 
through its growth-and-division cycle in response to a variety of extracellular and 
intracellular signals (Deshpande et al., 2005; Burkhart and Sage, 2008). However, 
cancer cells have evolved a dysfunction of the RB pathway, a critical gatekeeper of cell-
cycle progression, allowing persistent cell proliferation. 
 
 Resisting cell death 
Tumor cells have developed various ways to constrain or circumvent apoptosis. Most 
common is the loss of the TP53 tumor suppressor function that triggers apoptosis in 
response to substantial levels of DNA breaks and other chromosomal abnormalities and, 
alternatively, insufficient survival factor signaling or hyperactive signaling. 
Alternatively, tumors may achieve a similar outcome by increasing expression of 
antiapoptotic regulators (Bcl-2, Bcl-W) or of survival signals (lgf1/2), by 
downregulating proapoptotic factors (Bax), or by short-circuiting the extrinsic ligand-
induced death pathway.  
 
 Enabling replicative immortality 
Tumor cells formed from the eventual immortalization of rare variant cells can maintain 
telomeric DNA at lengths sufficient to circumvent senescence or apoptosis, achieved 
most commonly by increasing telomerase levels or, less frequently, via an alternative 
recombination-based telomere maintenance mechanism. Alternatively, the tumor-
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associated neovasculature, generated by the process of angiogenesis, proceeds to the 
immortalization of rare variant cells, which become tumors cells.  
 
 Activating invasion and metastasis 
The best-characterized alterations associated with cancer cells in terms of their shape 
and attachment to other cells and to the extracellular matrix (ECM), involves the loss of 
E-cadherin, a key cell-to-cell adhesion molecule which helps assemble epithelial cell 
sheets and maintains the quiescence of the cells within these sheets. The capability of 
invasion and metastasis has been frequently observed and associated with the 
downregulation and occasional mutational quiescence of E-cadherin in human 
carcinomas.  
 
 
Figure 1.1 The hallmarks of cancer taken from Hanahan and Weinberg, 2011 
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More recently, two emerging hallmarks have been proposed to be important for the 
development of cancer and involve the reprogramming of the energy metabolism and 
the evasion of immune destruction (Figure 1.2). 
 
 Reprogramming Energy Metabolism 
The corresponding adjustment of energy metabolism is essential for fueling cell growth 
and division. Cancer cells can reprogram their glucose metabolism, and thus their 
energy production, by limiting their energy metabolism largely to glycolysis, given the 
relatively poor efficiency of generating ATP by glycolysis compared to the more 
efficient mitochondrial oxidative phosphorylation. However, a functional rationale for 
the glycolytic switch in cancer cells has been unclear. The altered energy metabolism is 
proving to be as widespread in cancer cells as many of the other cancer-associated traits 
that have been accepted as hallmarks of cancers.  
 
 Evading immune destruction 
The immune system plays an important role in resisting or eradicating formation and 
progression of incipient neoplasias, late-stage tumors, and micrometastases. Solid 
tumors manage to avoid detection by the immune system or constrain the extent of 
immunological killing, thus evading eradication.  
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Figure 1.2 Emerging hallmarks and enabling characteristics taken from Hanahan and 
Weinberg, 2011 
 
1.3 The epidemiology of cancer 
Cancer is a leading cause of death worldwide. In the United Kingdom, cancer has now 
become the first cause of death exceeding cardiovascular disease. There are around 
298,000 new cases of cancer (excluding non-melanoma skin cancer) diagnosed in the 
UK every year, and more than one in three people will develop some form of cancer 
during their lifetime. The overall incidence rates for cancer in Great Britain increased by 
25%, with a 14% increase in men and a 32% increase in women, between 1978 and 
2007. However, in the last decade incidence rates have remained fairly constant. There 
are more than 200 different types of cancer, but four of them - breast, lung, bowel and 
prostate together account for almost half (47%) of all cancer deaths. More than one in 
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five (22%) of all cancer deaths result from lung cancer, largely due to smoking. 
Colorectal cancer is the second most common cause of cancer death (10%) and despite 
being extremely rare in men, breast cancer is the third most common cause of cancer 
death (8%) (Cancer Research UK website).  
 
1.4 Cancer treatment 
The success of cancer treatment is variable and depends on several factors including the 
type and the specific characteristics of the cancer; the health status of the patient; and 
whether the objective of the treatment is to eradicate the patients' cancer, prevent 
metastasis or relieve symptoms. Often different types of treatment are used in 
combination, either simultaneously or sequentially. Generally, the three levels of 
decision-making used when formulating a treatment policy for an individual are: 1) the 
decision to treat or not to treat; 2) treatment intent, whether radical (aiming to long-term 
control or cure for the patient) or palliative (to improve the quality of life for a patient 
with no impact upon their survival), and; 3) specific aspects of treatment policy 
regarding local, systemic and supportive therapy (Figure 1.3) (Spence and Johnston, 
2001). However, the practice of clinical cancer management demands more than the 
simple application of these instructions.  
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Figure 1.3 Treatment options adapted from Spence and Johnston, 2001. 
 
1.4.1 Surgery 
Surgery is one of the main treatments for cancer. It may be the only treatment needed 
and can be effective for cancer that is completely contained in one area and has not 
metastasized. The local treatment of malignant disease apart from the use of surgery, 
can also involve radiotherapy or a combination of the two. Surgery is essentially a local 
treatment while radiotherapy offers locoregional treatment covering a wider area less 
constrained by anatomical boundaries and the surgical technique. Optimum initial 
management of the primary tumor and regional metastases is vital if a later relapse is to 
be avoided. 
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1.4.2 Radiotherapy 
1.4.1.1 General principles of radiotherapy 
Radiation therapy involves the use of ionizing radiation for the treatment of patients 
with malignant neoplasia (and occasionally benign conditions). Ionizing radiation can 
be delivered by X-ray beams, beams of ionizing particles, e.g. electrons, or by beta or 
gamma irradiation produced from the decay of radioactive isotopes (Neal and Hoskin, 
2009). The aim of radiation therapy is to treat a defined tumour volume under a 
precisely measured dose of radiation with minimal damage to surrounding healthy 
tissue, resulting in eradication of the tumour, better quality of life, and prolongation of 
survival. Once a diagnosis of cancer has been established, 50-70% of patients will 
receive radiation therapy at some point during their illness (Tannock et al., 2005).     
 
1.4.1.2 Biological actions of ionizing radiation 
1.4.1.2.1 Radiation-induced critical DNA damages 
Alpha particles break the sugar phosphate backbone of the DNA, the beta particles 
break hydrogen bonds, and X-rays damage the bases. These three types of radiation in 
fact can lead to three types of direct damage. However, heavy charged particles such as 
alpha particles are more likely to cause direct damage compared to low charged 
particles such as X-rays, which inflict damage mostly by indirect effects. In addition to 
interacting directly with DNA, ionizing radiation can impair or damage cells indirectly 
by creating free radicals, such as hydroxyl radical, which can lead to the destruction of a 
cell.  
 
Ionizing radiation causes a wide range of DNA lesions, including damages to nucleotide 
bases, DNA single-strand breaks (SSBs) and double-strand breaks (DSBs). The 
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damaged bases can be repaired through the base excision repair pathway. A SSB occurs 
when only one of the sugar phosphate backbones is broken. Most of the SSBs induced 
by ionizing radiation can be repaired via DNA ligation. DSBs are believed to be the 
most detrimental lesions produced in chromosomes by ionizing radiation (Jackson, 
2002), because such breaks are more difficult to repair and thus more likely to result in 
permanent damage (Helleday et al., 2007).   
 
1.4.1.2.2 Activation of radiation-response genes 
Ionizing radiation causes cellular DNA damage affecting the expression of a number of 
genes involved in the DNA damage response in cells. Ionizing radiation induces the 
expression of early-response genes initialized by damage to the plasma membrane or to 
nuclear DNA. Transcription factors including c-myc, p53, c-fos/c-jun, and nuclear 
factor-kappa B (NF-kB) proteins have been reported to be induced by cellular exposure 
to ionizing radiation (Hallahan et al., 1995; Ahmed, 2004; Ahmed et al., 1997). These 
proteins bind to specific DNA sequences and can in turn activate the transcription of 
cytokines, growth factors, and cell-cycle-related genes. 
 
1.4.1.2.3 Radiation-induced cell- cycle arrest 
Ionizing radiation can delay the cell cycle progression of mammalian cells. Such delays 
could allow for the repair of DNA damage in cells prior to undergoing either DNA 
replication or mitosis and could prevent the acquisition of genetic instability or mutant 
cellular phenotypes (Hartwell and Kastan., 1994; Schmitt et al., 2007). In fibroblasts, 
irradiation may cause loss of the reproductive potential by the induction of a permanent 
G1 arrest (Little et al., 1994). However, the capacity for the p53 protein to mediate G1 
arrest is reduced in human tumour cells, suggesting that G1-modulating factors may also 
35 
 
be important in the radiation-induced cell-cycle response of transformed cells (Li et al., 
1995). Cell-cycle arrest during the S phase in irradiated cells is poorly understood, but 
probably involves inhibition of replicon initiation, which is required for DNA synthesis. 
The cyclin-B and the p34 
cdc2
 protein kinase are associated with the control of the G2 
phase. Molecular alterations that have been associated with the onset and duration of the 
G2 delay following radiation treatment include (1) decreased expression or stability of 
the cyclin-B protein; (2) altered phosphorylation of the p34 
cdc2
 protein; and (3) 
cytoplasmic sequestration of the cyclin-B protein, thereby preventing the formation of 
nuclear cyclin-B/p34 
cdc2
 complexes (Maity et a., 1994; Smeets et al., 1994; Royou et 
al., 2008; Metting and Little, 1995).  
 
1.4.1.2.4 Radiation-induced cell death 
The major objective of the irradiation of malignant tissue is the inhibition of the 
continued reproductive ability of cells. For the majority of normal and tumour cells, 
death secondary to mitotic catastrophe (a combination of deficient cell-cycle 
checkpoints and cellular damage) accounts for most of the cell kill following irradiation. 
However, irradiation to some radiosensitive cells such as lymphocytes, spermatocytes, 
thymocytes, and intestinal crypt cells leads to the cells undergoing an early (within a 
few hours) interphase death that can be associated with the biochemical and 
morphologic characteristics of apoptosis (i.e., cell membrane blebbing, the formation of 
nuclear apoptotic bodies, and specific DNA fragment patterns) (Radford and Murphy, 
1994; Sarkaria and Bristow, 2008). The intracellular targets for the induction of the 
apoptotic response may be either the cell membrane or the DNA or both, depending on 
the cell type. The involvement of the cell membrane in triggering radiation-induced 
apoptosis is supported by the observation that ionizing radiation can initiate a 
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sphingomyelin-dependent signaling pathway within the cell membrane of endothelial 
cells which, in turn, can induce apoptosis in the absence of DNA damage (Verheij et al., 
1996). 
 
1.4.3 Chemotherapy 
Medical oncology is the cancer speciality that focuses on the systematic management of 
the cancer patient with chemotherapy and other systemic treatments. The smallest size 
of tumour likely to be detectable is approximately 1 cm in diameter and contains about 
10
8
-10
9 
tumour cells, depending on the contribution of the stroma and other elements to 
the tumour bulk. Such tumour lumps have significant potential to develop secondary 
tumours and metastatic disease at distant sites throughout the body, even at an early 
stage. Patients die due to the systemic spread of the disease rather than as a result of 
local recurrence in the primary organ. Therefore, anti-cancer treatment must include an 
effective systemic approach. Today, approximately 60-70% of cancer patients will 
require chemotherapy as part of the treatment of their disease (Rewari et al., 2004).  
 
1.4.3.1 Adjuvant and neoadjuvant therapy 
Cancer chemotherapy is the treatment of malignant disease with drugs rather than 
radiation or surgical removal. The drugs used are often highly toxic since they are not 
exclusively selective for cancer cells, resulting in unwanted side effects. Systemic 
therapy used after optimal locoregional therapy (surgery/radiotherapy) has been found 
to enhance local control and to reduce the potential of metastasis. The radiotherapy or 
systemic therapy is commonly given as adjuvant treatment after surgery for many types 
of cancer (e.g, breast and lung cancer). In certain circumstances chemotherapy is 
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administered prior to locoregional therapy in an attempt to significantly reduce the 
tumour cell burden. This approach is termed neoadjuvant therapy.   
 
1.4.3.2 General principles of chemotherapy 
The effective use of cancer chemotherapy requires an understanding of the tumour cell 
kinetics, the tumour cells’ doubling time, cancer pharmacology and drug resistance. A 
variable proportion of the tumour cells will actively divide at any one time. This may 
range from 90% in some tumours, for example, lymphomas, to less than 20% in others 
such as certain solid tumours (e.g. colon and breast cancer). Cytotoxic chemotherapeutic 
agents are generally preferentially toxic towards actively proliferating cancer cells, 
however, they will also affect normal cells undergoing rapid proliferation (for example, 
cells of the buccal mucosa, bone marrow, gastrointestinal mucosa and hair folicles), 
contributing to the toxicity of chemotherapy (Gerber, 2008; Mitchison, 2012).   
 
1.4.3.3 Classification of chemotherapeutic agents 
1.4.3.3.1 Alkylating agents 
Antitumour alkylating agents are the largest class of anticancer drugs. These cell cycle 
non-specific agents impair cell function by acting through the covalent bonding of alkyl 
groups (R-CH2) to chemical moieties in DNA after being metabolized in the body 
(McCune and Slattery, 2002; reviewed in Hartley, 2001). In general, they act through 
the generation of highly reactive, positively charged intermediates, which then combine 
with an electron-rich nucleophilic groups such as an amino, carboxyl, sulfhydryl, 
phosphate or hydroxyl moiety (McCune and Slattery, 2002). Alkylating agents can be 
classified as either monofunctional or bifunctional, depending on whether they have one 
or two reactive groups. Alkylation by monofunctional agents produces monoadducts. 
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With bifunctional agents, an initial alkylation producing monoadducts is followed by a 
second reaction in which crosslinks are formed. The second reaction is often slow, and 
only around 1 in 20 monoadducts form crosslinks. DNA crosslinks can be formed 
within a single strand of DNA (intrastrand), between the two complementary strands of 
DNA (interstrand), or between a DNA base and a reactive group on a protein (DNA-
protein) (Figure 1.4A and B) (McHugh et al., 2001).  
 
1.4.3.3.1.1 Nitrogen Mustards 
The first documented clinical use of chemotherapy was in 1942, when the alkylating 
agent nitrogen mustard (mechlorethamine) was used to obtain a brief clinical remission 
in a patient with lymphoma (Gilman, 1946). The family of drugs, deriving from the 
prototype alkylating agent nitrogen mustard, includes chlorambucil, cyclophosphamide, 
melphalan and ifosfamide. Chlorambucil is a phenylbutyric acid derivative of 
mechlorethamine and is relatively stable in aqueous solution and enters cells by simple 
diffusion. It is used to treat chronic lymphocytic leukaemia, lymphoma, Hodgkins 
disease and multiple myelomas (Takimoto, 2008). Cyclophosphamide is the most 
versatile and useful nitrogen mustard. It is a prodrug, requiring metabolic activation and 
conversion to an active nitrogen mustard, phorporamide mustard. It has a favourable 
therapeutic index and the broadest spectrum anti-tumour activity of all alkylating 
agents. It is mainly used for non-Hodgkins lymphomas (Moore, 1991; Ayash et al., 
1992). Melphalan is the phenylalanine derivative of mechlorethamine and is less 
reactive due to its slower rate of chloride ionization. Each of them is bifunctional, with 
two chloroethyl groups that form the reactive electron-deficient groups responsible for 
alkylation of DNA. Ifosfamide is a prodrug and an analogue of cyclophosphamide that 
contains a chloroethyl group on the nitrogen atom of the oxazaphosphorine ring. It is 
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used primarily to treat sarcomas, and both testicular and non-small cell lung cancers 
(Takimoto, 2008). 
 
A 
 
B 
 
Figure 1.4 Monoalklation and crosslinking chemistry of bifunctional nitrogen mustards. 
A, Chlorine is a leaving group that facilitates nucleophilic attack of nitrogen to form an 
imminium ion (R3N) in a strained ring system. This readily undergoes alkylation at N7 
of guanine to form a monoalkylation adduct (see B). This process can then be repeated 
to form the DNA crosslink. Crosslinking can occur either between two complementary 
strands of DNA (interstrand) or within a strand of DNA (intrastrand) (see B) (adapted 
from Hurley, 2002).  
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1.4.3.3.2 Platinum-based compounds 
Platinum compounds are amongst the most frequently used class of anti-cancer drugs, 
showing a mechanism of action that is similar to the mechanism of action of alkylating 
agents. The biological activity of cisplatin (cis-diamminedichloroplatium) was 
discovered serendipitously in 1965 by Rosenberg experimenting on the effect of electric 
fields on the cell division of bacteria (reviewed in Rosenberg et al., 1977). Cisplatin 
possesses two chloride ions, which can be displaced in aqueous solution to form a 
reactive electrophilic species (Figure 1.5A). The kinetics of cisplatin’s chloride ligand 
displacement reactions lead to DNA crosslinking activities (Figure 1.5B), causing DNA 
bending and interfering with DNA replication, transcription and other nuclear functions 
and arresting cancer cell proliferation and tumour growth (Jakupec et al., 2003). 
Cisplatin primarily reacts with the N7 atom of purine bases in the DNA major groove 
resulting in the formation of 1,2-d(GpG) (65%), 1,2-d(ApG) (25%), and 1,3-
d(GpNpG) (6%) intrastrand cross-links, and interstrand cross-links (1-2%) between 
guanines in the complementary DNA strands (Figure 1.5B) (Damsma et al., 2007; 
Boulikas et al., 2007).  
 
The use of cisplatin and its effectiveness in cancer chemotherapy has been thoroughly 
documented. It is used as a principal component for the treatment of testicular, ovarian 
and bladder cancer. In addition, cisplatin is being used as first line chemotherapy 
against cancers of the lung, head-and-neck, stomach, colon, bladder, cervix, uterus and 
as second line treatment against other advanced cancers such as cancers of the breast, 
pancreas, liver, kidney and prostate (Boulikas and Vougiouka, 2003; 2004). Cisplatin 
exhibits severe nausea and vomiting, renal damage and neurotoxicity. Analogues have 
been synthesized in an attempt to produce agents with the same high level of antitumour 
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activity but less intense side-effects. Of these analogues only carboplatin and oxaliplatin 
are widely used clinically. However, neither carboplatin or oxaliplatin have achieved 
the broad-spectrum effectiveness of cisplatin (Judson and Kelland, 2000; reviewed in 
Kelland, 2007).   
 
1.4.3.3.3 Antimetabolites 
Antimetabolites are structurally similar to naturally occurring metabolites, which 
interfere with normal cellular function, particularly involved in DNA and RNA 
synthesis. The cytotoxic activity of the antimetabolites derives either by competing with 
normal metabolites for the catalytic or regulatory site of a key enzyme or by substituting 
for a metabolite that is normally incorporated into DNA and RNA. As a result of this 
mechanism of action, antimetabolites exert their activity when cells are in the S phase 
and show little effect on resting cells. Therefore, these drugs are most effective against 
tumours that have a high growth fraction (Ruiz van Haperen and Peters, 1994). Many of 
the clinically useful antimetabolites are purine (e.g., 6-thioguanine) or pyrimidine (e.g., 
5-fluorouracil) analogues that either inhibit the formation of the normal nucleotides or 
interact with DNA and prevent normal cell division from occurring (Moore et al., 1995; 
Pizzorno et al., 2000). 
 
Most antimetabolites are cell cycle-specific and exhibit a nonlinear dose-response 
curve, such that after a certain dose, no more cells are killed despite increasing the drug 
dose (fluorouracil is an exception) (Pizzorno et al., 2000). As they do not interact 
directly with DNA, they do not cause problems such as carcinogenesis seen with DNA-
binding drugs like the alkylating agents. 
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A 
 
B 
 
Figure 1.5 Structures of platinum compounds. A. Structures of cisplatin. In an aqueous 
solution, the chloride ions can be displaced to leave an electrophilic aquated species, 
which is the reactive form of these compounds. B. DNA adduct formation with cisplatin 
leaving two amino groups coordinated on the platinum atom (Boulikas et al., 2007).   
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1.4.3.3.4 Natural Products 
Natural products are compounds isolated from plants, fungi, or bacteria or derivatives of 
such products. Within this category are drugs, which interfere with the topoisomerase I 
(topo I) (e.g., camptothecins) or topoisomerase II (topo II) (e.g., etoposide) enzymes, 
which bind directly to DNA (Baldwin and Osheroff, 2005; Bodley et al., 1989).  
 
Camptothecin is an extract of the tree Campotheca accuminata that exerts antitumour 
activity by inhibiting topo I (Rothenberg, 1997). Topo I is an enzyme that catalyses the 
transient cleavage and resealing of a single strand of DNA during transcription and 
replication (Wang, 1991). A number of water-soluble Camptothecin semisynthetic 
derivatives have been investigated and demonstrated significant clinical activity, such as 
topotecan and irinotecan (CPT-11) (Rothenberg, 1997), which have well-established 
antitumour activities against various primary tumours (Timur et al., 2005; Wong and 
Berkenblit, 2004).  
 
Etoposide is a semisynthetic glycoside derivative of the antimitotic agent 
podophyllotoxin derived from the mandrake plant. Podophyllotoxin binds to tubulin and 
inhibits polymerisation, however, etoposide inhibits the topo II enzyme and is widely 
used for treating various cancers (Baldwin and Osheroff, 2005). Topo II catalyzes a 
transient breakage and reunion of double-stranded DNA during transcription and 
replication, and is also responsible for chromosome segregation during mitosis (Cuvier 
and Hirano, 2003; Valkov and Sullivan, 2003). Two topo II isozymes have been 
identified in human cells namely, topo IIα and topo IIβ (Berger, 1996). Topo IIα is a 
homodimer which catalyses the ATP-dependent strand-passing reactions and functions 
in DNA replication and chromosome condensation and segregation (Li and Liu, 2001). 
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It contains two major domains, the N-terminal ATPase domain and the 
breakage/reunion C-terminal domain. Topo IIα is essential for cell growth and is a cell 
proliferation and tumour marker. Topo IIβ is also a homodimer which although 
exhibiting similar enzymatic activities to topo IIα in vitro, is constitutively expressed at 
a constant level throughout the cell cycle (Li and Liu., 2001; Burden and Osheroff, 
1998; Baldwin and Osheroff, 2005).   
 
1.5 DNA as an anti-cancer drug target 
DNA has long been the molecular target for chemotherapeutic agents as illustrated in 
Figure 1.6. These drugs can block DNA replication and transcription either by direct 
binding to DNA or to DNA-binding proteins such as topoisomerases (Hurley, 1989). 
Many natural and synthetic anticancer agents with the ability to interact with DNA were 
discovered as a consequence of chemical warfare during World Wars I and II that 
spawned the modern era of cancer therapy (Kohn, 1996), but most have a limited degree 
of sequence specificity and often exhibit severe toxicity to normal tissue. Therefore, a 
new generation of chemotherapeutic agents that target DNA-associated processes is 
anticipated to be more specific, selective and effective (Hurley, 2002; Baraldi et al., 
2007). 
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Figure 1.6 Types of DNA-interactive agents and their molecular interactions with DNA 
(adapted from Hurley, 2002).  
 
1.5.1 Structure and biology of the DNA minor groove 
The double helix of DNA is composed of two complementary, antiparallel 
polydeoxyribonucleotide strands associated by specific hydrogen bond interactions 
between nucleotide bases (Watson and Crick, 1953). The minor groove is narrow and 
shallow, approximately 10 Å in width in comparison with the deeper and wider major 
groove, which is about 24 Å in width (Figure 1.7A) (Saenger, 1984). The helical 
grooves are determined by the sugar phosphate backbone of double strands that stick 
out at 120° angles from each other instead of 180° (Saenger, 1984). The chemical 
features of the molecular surfaces in the DNA sequence provide the basis for molecular 
recognition by small molecules and proteins (Figure 1.7B) (Cai et al., 2009).  
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Figure 1.7 Structural features of the DNA double helix. A Molecular structure of 
double helical B-DNA showing major and minor groove. Sugar phosphate backbones 
are presented in red and orange. B Chemical features and electrostatic potential surfaces 
(red-negative electrostatic potential, blue-positive electrostatic potential, green-neutral) 
of Watson-Crick base pairings. 
 
 
1.5.2 The DNA minor groove as a target 
Proteins recognize hydrogen bond donors and acceptors as well as hydrophobic methyl 
groups (Panasik et al., 2005; Fleming and Rose, 2005). In nature, the minor groove 
represents a vulnerable site of attack, which is normally unoccupied or is bound by 
small molecules of less than 1000 Da, while most of the DNA interactive proteins bind 
to the major groove. The minor groove of double helical B-DNA has been considered as 
a target of great interest for developing new agents of non-covalent, reversible, highly 
specific interactions of small molecules at thymine-adenine (TA)-rich sequences, 
showing antibacterial and antiviral activities (Kielkopf et al., 1998; Baraldi et al., 2004). 
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The DNA minor groove binders have been widely studied and constitute an attractive 
lead for the design of novel antitumor molecules.  
 
1.5.2.1 Diarylamides and their derivatives 
Since the 1930s, the efficacy of diarylamides has been well known for the treatment of 
trypanosomiasis and leishmaniasis (Baraldi et al., 2004). In the early 1970s, 
diarylamides derivatives such as DAPI (DNA fluorochrome 4'-6-diamidine-2-phenyl 
indole), berenil, stilbamidine, and pentamidine were discovered with the aim of finding 
even more effective antiparasitic drugs. DAPI was shown to bind to the minor groove 
with the phenyl and indole rings parallel to the groove walls in the AT-rich regions of 
B-DNA (Larsen et al., 1989). However, the clinical use of DAPI as an anti-microbial 
agent has been constrained by its undesirable side effects. Berenil was characterized by 
high affinity for the three-base pair sequence ATT and has been used in veterinary 
medicine for the treatment of trypanosomiasis (Newton, 1975; Yoshida and Banville, 
1990). Pentamidine is perhaps the most well-known anti-microbial DNA minor groove 
binder and has been shown to preferentially bind to AT-rich regions in the B-DNA 
minor groove containing at least five consecutive AT base pairs (Nguyen et al., 2002; 
Baraldi, 2004). The efficacy of pentamidine has been shown in the treatment of 
Pneumocystis jiroveci, although the mechanism of its action is still unclear. Yet, like the 
other anti-microbial minor groove binders, pentamidine displays toxicity such as 
nephrotoxicity, cardiotoxicity, and hepatotoxicity. Consequently, new pentamidine-type 
molecules have been sought with the aim of increasing the overall efficacy, decreasing 
the toxicity and improving the minor groove binding affinity to treat Pneumocystis 
pneumonia (Cai et al., 2009). The oncogenic PRL phophatases that have an essential 
role in many cancers has been shown to be a target of pentamidine.  
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1.5.2.2 Bis-bezimizazoles 
Hoechst 33258 (also known as Pibenzimol) is a fluorescent reagent with a head-to-tail 
bis-benzimidazole and binds in the minor groove of B-DNA selective for AT sequences 
(Harshman and Dervan, 1985). Hoechst 33258 was initially founded to have moderate 
in vivo activity against murine leukemia (Gravatt et al., 1994). It is readily taken into 
cells (Bontemps et al., 1975) and binds extremely tightly to DNA (Loontiens et al., 
1990), thus inhibiting transcription specific genes.  
 
1.5.2.3 CC-1065 and Duocamycin 
CC-1065 and Duocamycin are antitumour antibiotics, which exhibit their biological 
effect through binding to double-stranded B-DNA within the minor groove at AT-rich 
sequences and selectively alkylating the N-3 position of adenine (Krueger et al., 1991; 
Boger, 1995). CC-1065 exhibited high potency and a broad spectrum of antitumour 
activity, however it could not be used in humans because it results in delayed death in 
experimental models. Duocamycin, on the other hand, showed weaker antitumour 
activity, partially attributed to its low water solubility (Yasuzawa et al., 1988). 
Adozelesin was the first of the CC-1065 derivatives to enter clinical trials. A phase II 
study of adozelesin in untreated metastatic breast carcinoma was halted due to slow 
accrual and lack of efficacy (Cristofanilli et al., 1998). Later, studies have focused on 
the potential use of adozelesin or similar drugs as anti-malarial agents (Woynarowski et 
al., 2007). KW-2189 is a highly water-soluble derivative of Duocamycin B2. No 
objective responses were observed when treating patients with both advanced renal cells 
carcinoma and malignant melanoma in phase II trials (Small et al., 2000; Markovic et 
al., 2002).  
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1.6 Netropsin, distamycin A and derivatives 
1.6.1 Netropsin and Distamycin A 
A large number of minor groove binders have been designed and tested by researchers 
over the past decades. The majority of these were synthesized based on the naturally 
occurring netropsin and distamycin A agents originally termed lexitropsins. Netropsin 
and distamycin A are derived from the Streptomyces species S. netropsis and S. 
distamyces (Finlay et al., 1951; reviewed by Arcamone 1993), respectively. They 
comprise of two and three pyrrole moieties with either an N-terminal guanidinium or 
formyl group and a C-terminal propylamidine (Figure 1.8). Netropsin and distamycin A 
have shown potent biological effects exhibiting antiviral and antimalarial activities but 
without any significant antitumour properties (Arcamone, 1993; Sharma et al., 2002). 
They bind non-covalently to the minor groove of DNA, thereby preventing DNA and 
RNA synthesis by inhibition of the corresponding polymerase reaction and display 
pronounced sequence specificity (Zimmer et al., 1971; Chandra et al., 1972).   
 
Figure 1.8 The minor groove binding antibiotics netropsin and distamycin A. 
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Netropsin and distamycin A show a highly selective reversible interaction with AT 
sequences containing four or five A/T base pairs, respectively (Lane et al., 1983; Fox 
and Waring 1984; Kielkopf et al., 1998). Binding is limited to AT tracts by netropsin 
and distamycin A due to the interruption of the guanine 2-amino group in the minor 
groove causing a steric clash with the N-methylpyrrole C3 hydrogen, preventing 
binding to GC-rich regions (Figure 1.9) (Wartell et al., 1974). Distamycin A, 
characterized by the presence of an oligopeptidic pyrrolecarbamoyl frame ending with 
an amidino moiety, has sequence specificity and high affinity due to a combination of 
interactions (Figure 1.10) including hydrogen bonding, van der Waals contacts and 
electrostatic interactions with a strong preferential binding to AT rich sequences in the 
minor groove of DNA (Pelton et al., 1989).  
 
 
Figure 1.9 A schematic diagram showing the guanine 2-amino group protruded in the 
minor groove, as indicated by the dashed box. The available hydrogen bond donors and 
acceptors in the minor groove are also detailed.  
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Figure 1.10 Bonding components contributing to the sequence-specific binding of 
distamycin A to (AT)5 as adapted from Bailly and Chaires 1998. Heavy arrows indicate 
hydrogen bonding from donor to acceptor, whilst dashed lines indicate close van der 
Waals non-bonded contacts between the ligand and the DNA.   
 
The cytotoxicity of netropsin and distamycin A limited their clinical use (Rehm et al., 
2009; Pulido et al., 2009). However distamycin A was associated with the treatment of 
malarial and angiogenesis diseases based on gene expression of small molecules 
targeted sequence and control of gene switches. It is always the aim of the medicinal 
chemists to design and synthesize analogues of netropsin and distamycin A, having high 
DNA binding affinity and sequence selectivity so that these newly synthesized 
compounds can be used as drugs which have therapeutic value (reviewed in Khalaf, 
2009).     
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1.6.2 Distamycin-derived nitrogen mustards 
Netropsin and distamycin provide a platform for the rational design of DNA binding 
ligands (Dervan, 2001). The main representatives of minor groove binders that have 
been clinically tested in the past are tallimustine (TAM), a hybrid of a benzoic acid 
nitrogen mustard moiety and distamycin A (Figure 1.11) (Pezzoni et al., 1991; D'Incalci 
et al., 1997).  
 
 
 
 
Figure 1.11 Chemical structure and different functional moieties of the benzoyl 
nitrogen mustard tallimustine (adapted from Cozzi et al., 2001). 
 
DNA Footprinting and NMR studies showed that the pyrrole rings of TAM are stacked 
in the AT-rich domain of the B-DNA minor groove, so that the alkylating moiety of the 
benzoic acid nitrogen mustard would be able to alkylate the nucleotide residues present 
in the B-DNA minor groove (Marchini et al., 2001). Both of the components seem to 
contribute to the drug’s biological properties as TAM possesses higher cytotoxicity 
against L1210 murine leukemia than distamycin A or classical benzoic acid nitrogen 
mustard (Arcamone et al., 1989; D'Allessio et al., 1994). The possibility could also be 
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considered that distamycin-driven DNA binding increases the TAM concentration near 
the DNA target, avoiding alkylation of other biological nucleophiles, e.g. glutathione 
(Denny et al., 2001). TAM showed promising antitumor activity in clinical development 
up to phase II, however, it exhibited severe myelotoxicity (Ghielmini et al., 1997) and 
its further development was discontinued. However, the utilization of TAM as a model 
compound advanced the design of new minor groove alkylating agents having 
demonstrated the possibility of gaining potent antitumor activity by combining a 
chemically reactive moiety (benzoic acid nitrogen mustard) with a DNA selective 
binding-frame. (Cozzi et al., 1997). 
 
1.6.3 Distamycin-derived α-halogenoacrylamides 
A class of cytotoxic distamycin derivatives possessing a potential alkylating moiety of 
low chemical reactivity such as α-bromo or chloro-acrylamido tethered to a distamycin 
A or distamycin A-like frame has been identified (D'Allessio et al., 1994; Cozzi et al., 
2000). The first lead compound of this series, PNU-151807 (Figure 1.12A), the α-
bromoacrylamido derivative of a four-pyrrole distamycin A analogue, revealed high 
cytotoxicity and in vivo activity. In addition, PNU-151807, unlike TAM, was unable to 
alkylate minor groove AT-rich sequences in different in vitro experiments but interacted 
non-covalently with the DNA minor groove, suggesting that α- bromoacryamido 
distamycin derivatives are a new class of minor groove binders acting through a 
mechanism distinct from direct DNA alkylation (Marchini et al. 1999).  
 
Preclinical studies showed the antitumor activity of PNU-151807 with a significantly 
better cytotoxicity/myelotoxicity ratio over TAM.  For instance, PNU-151807 in 
leukaemic cells was found to be a more potent agent compared with TAM and was also 
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demonstrated to block activity of cell-cycle dependent kinases at least in vitro while 
TAM or distamycin A were not (Marchini et al. 1999). As a result, the activity and the 
atypical mechanistic features of PNU-151807 elicited the synthesis of new 
halogenoacrylic derivatives of distamycin in the aim of optimising their toxicological 
profile and potentially helping to define their mechanism of action (Cozzi et al., 2000). 
 
Brostallicin (PNU-166196) (Figure 1.12B), an α-bromoacrylamido-
tetrapyrrolecarbamoyl derivative ending with a guanidino moiety, showed a outstanding 
favorable cytotoxicity/myelotoxicity ratio both in vivo and in vitro, and a broad 
spectrum of activity in tumor cell lines in vitro and tumor xenografts in vivo compared 
to other minor groove binders (e.g. TAM and PNU-151807) (Cozzi et al. 2000). 
Brostallicin has undergone phase I and phase II clinical trials in both Europe and the US 
involving more than 230 patients in single agent and combination trials (Leahy et al., 
2007; Cai et al., 2009). Brostallicin has been generally well tolerated with mild to 
moderate, reversible myelosuppression being the primary adverse event. It has had 
predictable and predominantly hematologic toxicities, which rarely required growth 
factor support. Responses have been reported in metastatic soft tissue sarcoma and 
ovarian cancer resistant/refractory to platinum-based chemotherapty (Leahy et al., 2007; 
Lorusso et al., 2008). Brostallicin is therefore considered as a novel minor groove 
binder with unique pharmacological properties and a favorable toxicological profile.  
 
1.7 Pyrrolobenzodiazepine hybrids and conjugates 
The Pyrrolo[2,1-c][1,4]benzodiazepines (PBD) group of drugs includes the naturally 
occurring antitumor antibiotics anthramycin, sibiromycin, tomaymycin, neothramycin 
and DC-81 (Figure 1.13) produced by Streptomyces species. These agents exhibit their 
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DNA interactive activity and resultant biological effects through the N10-C11 
carbinolamine/imine moiety in the central B-ring which is capable of covalently binding 
to the C2-NH2 of guanine residues in the minor groove of DNA (Baraldi et al., 2007). 
X-ray and footprinting studies of covalent DNA-PBD adducts have demonstrated a high 
selectivity for 5'-purine-G-purine sequences (Kopka et al., 1994; Hertzberg et al., 1986; 
Hurley et al., 1988). Both anthramycin and sibiromycin were found to have antitumour 
activity against a range of transplanted tumours, however, the clinical use was limited 
due to dose-limiting cardiotoxicity, presumably due to the presence of a C9 oxygen 
(Korman and Tendler, 1965; Cargill et al., 1974). Many other naturally occurring PBDs 
do not include a C9 oxygen and exhibit cardiotoxicity. Only neothramycin has been 
tested clinically for the treatment of superficial carcinoma of the bladder (Tsugaya et al., 
1986). 
 
In the past decade, PBD hybrid or conjugate compounds, combining derivatives of PBD 
monomers with a distamycin A-like minor groove binder or intercalators (e.g. 
naphthalimides), have been designed, synthesized, and tested with the aim of combining 
high DNA binding affinity and sequence selectivity (Baraldi et al., 2000; Tietze et al., 
2003; Wells et al., 2006). The numerous PBD hybrids and conjugates exhibited their 
antitumour activities against tumour cell lines and high DNA binding affinity in vitro 
(Cipolla et al., 2009). However, there is a lack of any in vivo data on these molecules. 
One exception is a PBD-indole conjugate, IN6CPBD (Figure 1.13), which induced 
apoptosis in human melanoma A375 cells in vitro, possessed enhanced DNA sequence 
selectivity, and also exhibited great efficacy and superior safety in suppressing the 
growth of established melanoma in vivo (Lee et al., 2009).  
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B 
 
Figure 1.12 α-bromoacrylamido-tetrapyrrolecarbamoyl derivatives. A. PNU 151807 
and B. Brostallicin. 
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Figure 1.13 The basic pyrrolebenzodiazepine (PBD) structure, the structure of naturally 
occurring PBDs and PBD-indole conjugate IN6CPBD  
 
 
1.8 Introduction of a GC recognition element 
Polyamide structural derivatives of netropsin and distamycin A have been synthesized 
to capitalize on their strongly selective minor groove binding properties. Many research 
groups have reported more selective and specific polyamide molecules with the aim of 
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recognizing G/C base pairs alongside A/T (Kopka et al., 1985; Kielkopf et al., 1998; 
Dervan et al., 2001). Modification of the inherent specificity of netropsin for AT base 
pairs was achieved through the introduction of a GC recognition element, conducted by 
replacing the N-methylpyrrole rings of netropsin with imidazole, thiazole, triazole, 
pyrazole or oxazole heterocycles (Figure 1.14). Consequently, the modified compounds 
can bind selectively to DNA sequences with a mixed base pair content (Kopka et al., 
1985; Lown et al., 1986; Kielkopf et al., 1998).  
 
 
 
Figure 1.14 Representation of putative GC recognition heterocycles indicated by heavy 
arrows (Bailly and Chaires, 1998).  
 
 
Imidazole was considered a favorable candidate for GC recognition as it is able to fit 
neatly alongside guanine in the minor groove, favouring the formation of a hydrogen 
bond between the guanine N2-amino and the imidazole nitrogen (Kopka et al., 1985; 
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Lown et al., 1986). DNA footprinting data have shown that mono-, di-, and 
triimidazole-containing oligopeptides (Figure 1.15) analogues of netropsin exhibited an 
increased ability to tolerate GC base pairs and a progressively decreasing preference for 
AT regions (Lown et al., 1986).  
 
 
 
Figure 1.15 The development of GC recognition, showing the evolution of (A) 
netropsin into( B) a dicationic mono, di and triimidazole adapted from Lown  et al, 
1986.  
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1.9 Recognition of the DNA minor groove by pyrrole-
imidazole polyamides 
1.9.1 Pairing rules 
Targeting predetermined DNA sequences by cell-permeable small molecules provides a 
promising approach for the regulation of gene expression (Gottesfeld et al., 1997, 2000). 
More than two decades of research in the laboratories of Peter Dervan led to the 
establishment of the ‘pairing rules’ for minor groove recognition by polyamides 
containing pyrrole (Py) and imidazole (Im) grooves (Wade et al., 1992; Mrksich et al., 
1992; Gottesfeld et al., 1997; Dervan et al., 1999, 2003). The development of the 
pairing rules resulted from the surprising finding that the netropsin-based analogue, 1-
methylimidazole-2-carboxamido-netropsin (2-ImN) (Figure 1.16), is bound to the 5bp 
sequence 5'-WGWCW-3' (where W=A or T) more strongly than that to the 5'-
WGWWW-3', which was an anticipated site for a 1:1 polyamide-DNA complex (Wade 
et al., 1992; Dervan and Edelson, 2003). In addition, from affinity cleavage experiments 
2-ImN binds with twofold symmetry rather than a single orientation as expected the 1:1 
model. This surprising result was rationalized by NMR, which shows that distamycin 
can bind to DNA in a 2:1 as well as a 1:1 stoichiometry depending on the concentration 
(Pelton and Wemmer, 1989; Dervan and Burli, 1999).  
 
Figure 1.16  1-methylimidazole-2-carboxamido-netropsin (2-ImN) 
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The Im/Py pair has been extensively studied by analyses of binding in hundreds of 
different DNA sequence contexts and crystal structures, confirming the existence of a 
hydrogen bond between the imidazole nitrogen and the exocyclic amine of guanine 
(Kielkopf et al., 1998). On the basis of these results, the Dervan group formulated a set 
of 'pairing rules' for polyamides binding to DNA (Table 1.1) (Wade et al., 1992; White 
et al., 1997).  
 
Table 1.1  Pairing code for minor groove recognition by polyamides*. 
Pair                       G•C                              C•G                                T•A                               A•T 
Im/Py                         +                                  -                                       -                                    - 
Py/Im                          -                                  +                                      -                                    -  
Py/Py                          -                                   -                                      +                                   + 
Hp/Py                          -                                  -                                      +                                    - 
Im/Im                          +                                 +                                     -                                     - 
* + favored recognition; - disfavored recognition.   
 
A pyrrole opposite an imidazole (Im/Py) will specifically distinguish a GC from CG 
base pair, owing to the energetic preference for a linear hydrogen bond, coupled with 
unfavorable angle to an Im over the cytosine side of the base pair (Figure 1.17) 
(Kielkopf et al., 1998; Dervan et al., 2003). The antiparallel ring pairing of pyrrole 
stacked against pyrrole (Py/Py) in the corresponding ligand is partially degenerate and 
binds for A•T and T•A, due to the similarity of these bases in the minor groove. To 
break the A•T and T•A degeneracy by Py/Py, the N-methyl-3-hydroxypyrrole (Hp) 
monomer was designed as a thymine-selective recognition element when paired across 
from Py. An Hp/Py pairing was shown to specifically distinguish T•A from A•T, G•C 
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and C•G. The selectivity of Hp derives from a combination of hydrogen bond with the 
thymine O2 and the shape-selective discrimination of the asymmetric cleft between the 
thymine O2 and adenine C2 (Figure 1.17) (White et al., 1998; Kielkopf et al., 1998, 
2000). Imidazole-imidazole paring (Im/Im) will bind either a GC or a CG base pair. 
DNA-binding polyamides containing N-methylpyrrole (Py), N-methylimidazole (Im), 
and N-methyl-3-hydroxypyrrole(Hp) are crescent-shaped and can bind to the minor 
groove as antiparallel dimers (2:1 model). 
 
A                                                                  B 
 
Figure 1.17 Molecular recognition of the minor groove of DNA. (A) Minor groove 
hydrogen-bonding patterns of Watson–Crick base pairs. Circles with dots represent lone 
pairs of N(3) of purines and O(2) of pyrimidines, and circles containing an H represent 
the 2-amino group of guanine. The R group represents the sugar–phosphate backbone of 
DNA. Electron lone pairs projecting into the minor groove are represented as shaded 
orbitals. (B) Binding model for the complex formed between ImHpPyPy--ImHpPyPy-
-Dp and a 5'-TGTACA-3' sequence. Putative hydrogen bonds are shown as dashed 
lines (taken from Dervan and Burli, 1999). 
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1.9.2 The effects of a terminal formamido group on DNA sequence 
recognition 
Pyrrole-imidazole-containing polyamides can bind the minor groove of DNA and 
selectively target specific DNA sequences through a stacked antiparallel dimer 
(Wemmer et al., 2000; Lacy et al., 2002).  It has been suggested that there are two 
different low energy ways to form the stacked dimer: (i) a fully overlapped stacking 
mode in which the N-terminal heterocycles of the dimer stack on the amide groups 
between the two heterocycles at the C-terminal and (ii) a staggered stacking mode in 
which the N-terminal heterocycles are shifted by approximately one unit in the C-
terminal direction (Figure 1.18) (Kopka et al., 1997; Lacy et al., 2002). The formamido 
(f-) group at the N-terminus of distamycin A and related triamides play a major role in 
controlling the staggered binding motif of a 2:1 ligand/DNA complex, while the 
unsubstituted analogues bind in the overlapped mode. Later studies of the binding of f-
ImPyIm to its cognate sequences (5’-ACGCGT-3’) showed its exceptionally high 
affinity and selectivity compared to its parent compound distamycin A and a non-
formamido equivalent (Buchmueller et al., 2005). The order of the heterocycles at the 
‘core’ of the triamide has been shown to be important for DNA binding affinity and 
selectivity in the staggered dimeric binding motif. Therefore, a set of central pairing 
rules have been developed with the two central units ranked as follows: -ImPy- > -
PyPy- >> -PyIm- ≈ -ImIm- (Figure 1.18B) (Buchmueller et al., 2005). 
                                                                  
Although monomer polyamides can form a 2:1 ligand/DNA complex within the minor 
groove, this is not always energetically favorable and there is also a concern that the 
monomers without a formamido group may split into the extended staggered motif, 
hence, creating a reading frame different to that they were designed for (Pelton et al., 
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1990; Chen et al., 1994).  In addition, the monomers may also bind in a mixed 2:1 and 
1:1 motif, thus, reducing the overall affinity.  
 
 
Figure 1.18 Staggered and overlapped orientations of triamide dimers that form within 
the DNA minor groove. (A) Overlapped dimers are preferred by non- formamido 
triamides. In the overlapped orientation, all three heterocycles are engaged in 
heterocycle–heterocycle stacking. (B) Staggered dimers are preferred by formamido 
triamides. In the staggered orientation, heterocycles stack (pair) to form the ‘central 
pairing’ (box). The central pairing is composed of two adjacent sets of stacked 
heterocycles. The C-terminal heterocyclic group is not included in the central pairing 
and is stacked on the formamido moiety, to form the ‘terminal pairing’.  
 
1.9.3 Affinity and specificity 
The affinity and specificity of unlinked three-ring dimers are modest. To compete with 
nature's proteins, such as transcription factors, the affinity of these synthetic molecules 
had to be improved by about three orders of magnitude. Tethering two monomer 
polyamides with a suitable linker, as in the ‘Hairpin’ motif that covalently links two 
antiparallel polyamide strands, results in molecules with increased DNA affinity and 
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specificity. The 'standard' motif is the eight-ring hairpin, in which the monomers are 
linked ‘head’-to-‘tail’ using a flexible γ-aminobutyric acid moiety (Figure 1.17B, 
ImHpPyPy--ImHpPyPy--Dp) (Dervan et al., 2003). Eight-ring hairpins targeting 6bp 
were found to have affinity and sequence specificity similar to that of DNA-binding 
proteins (i.e. Kd < 1nM ) (Trauger et al., 1996). More selective hairpin polyamides have 
been developed by Dervan group
 
(Dervan et al., 2001; 2003), which demonstrated 
excellent binding affinity but their usage has been restricted by problems of cellular and 
nuclear uptake and limited water solubility. An alternative motif is a cross-linked ‘H-pin’ 
structure where the central heterocycles of two polyamides are linked via either a 
methylene or preferably an ethylene glycol bridge (Figure 1.19A&B; ImPyIm H-pin and 
f-ImPyIm H-pin). H-pins without a formamido group at the N-terminus linked via alkyl 
chains of varying lengths (C3-C12) have been investigated as minor groove duplex DNA 
binders that interact in a 1:1 overlapped motif (the two polyamides’ constituent 
heterocycles are stacked against each other and the linker directly joins two central 
heterocycle across the polyamides, Figure 1.19A) (Chen et al., 1994; Mrksich et al., 
1993;1994). Weak binding affinity of the former H-pin type was reported (Dervan et al., 
1999, 2001) in comparison with the exceptional affinity of the linked monomer f-
ImPyIm that binds to its cognate DNA sequence as a dimer in a staggered binding motif 
(the polyamide units are stacked in an off-centered staggered fashion and the linker 
joins two adjacent heterocycles in a diagonal arrangement, Figure 1.19B), covering 
more base pairs. In more recent biological studies (O'Hare et al., 2002), it has been 
demonstrated that at least a five-carbon linker for two f-ImPyIm ligands was required to 
cross the minor groove width and linkers of eight or nine carbons can further increase 
the already exceptional binding affinity (O'Hare et al., 2007). Poor cellular uptake of 
large H-pin polyamides has restricted their further utility as gene control agents, 
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although such H-pin polyamides have a great DNA-binding affinity and specificity. In a 
recent paper, it was reported that the f-PyImPy H-pin polyamides most likely does not 
enter the nucleus, because the anticipated biological effect (i.e. upregulation of topo IIα) 
was not observed in treated cells (Franks et al., 2010). In contrast, f-PyImPy was able to 
enter the nucleus, interact with the target site within the ICB2, inhibit NF-Y binding, 
and activate gene expression (Le et al., 2006). 
 
 
 
Figure 1.19 Diagram to show the overlapped H-pin motif (A), and staggered H-pin 
motif (B), the red line connecting the two polyamide unit’s represents the H-pin linker.  
 
1.9.4 Gene regulation by rationally designed polyamides  
1.9.4.1 Inhibition of gene expression 
According to the set of pairing rules, the optimal heterocycle pairs required for DNA 
sequence recognition at predetermined sites have been extensively studied and 
identified (Kielkopf et al., 1998; Wade et al., 1992; White et al., 1997, 1998). Such 
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sequence-reading polyamides have the potential to be used as gene control agents 
through inhibition of native transcription factors (Dervan et al., 2003; Melander et al., 
2004). Figure 1.20 presents a model of how the inhibition of key transcription factor 
(TF) binding is derived by polyamide binding to TF sites within various promoters, thus 
interfering with the recruitment of RNA polymerases (Dervan amd Burli, 1999).  
 
One of the examples reported was the transcription inhibition by blocking the 5S RNA 
gene-specific transcription factor TFIIIA binding to its cognate sequences by Py/Im 
hairpin polyamides. As a result, transcription of 5S RNA genes by RNA polymerase 
was suppressed in vitro and in cultured Xenopus kidney cells (Gottesfeld et al., 1997). 
Polyamides were later used to target viral genes transcribed by RNA polymerase II. The 
HIV-1 enhancer/promoter contains binding sites for multiple TFs, including TBP, Ets-1 
and LEF-1. Two hairpin polyamides designed to bind DNA sequences immediately 
adjacent to the binding sites for these TFs speciﬁcally inhibited binding of each TF and 
HIV-1 transcription in a cell free assay (Dickinson et al., 1998). A polyamide-
chlorambucil conjugate IR-Chl showed to be an inhibitor of cell proliferation in various 
cell lines with no apparent cytotoxicity and little or no murine animal toxicity 
(Dickinson et al., 2004; Tsai et al., 2007; Alvarez et al., 2006). IR-Chl targets the coding 
region of the histone H4 gene both in vitro and in SW620 human colon carcinoma cells 
and down-regulates H4 transcription (Dickinson et al., 2004; Chou et al., 2008). Later, 
newly synthesized conjugates between pyrrole-imidazole polyamides and the alkylating 
moiety seco-CBI were shown to alkylate within the coding regions of the histone H4 
genes. Chronic myelogenous leukemia K562 cells treated with a conjugate 5-CBI down-
regulated the histone H4 gene and induced apoptosis efficiently (Minoshima et al., 
2010). Matsuda and co-workers further exhibited that a Py/Im polyamide targeted to the 
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transforming growth factor-1 promoter inhibited gene expression in vivo (rat renal 
cortex) (Matsuda et al., 2011). Figure 1.21 presents examples of DNA-binding proteins 
that have been inhibited by Py/Im hairpin polyamides. The more recent studies by 
Dervan's group further demonstrated that Py/Im polyamides could inhibit DNA binding 
of transcription factors in cells. Py/Im hairpin polyamide [ImPyPyPy-(R)
α-aminoγ-
ImPyPyPy] binds to the consensus sequence 5'-GGTACAnnnTGTTCT-3' in the 
androgen response elements (ARE) found in the prostate-specific antigen (PSA) 
promoter, inhibits expression of PSA and several other androgen receptor (AR)-
regulated genes in cultured prostate cancer cells, and reduces AR occupancy at the PSA 
promoter and enhancer (Nickols et al. 2007). This polyamide was also found to bind to 
the consensus sequence in the glucocorticoid response elements (GRE) present in the 
promoter of the well-characterized GC-induced leucine zipper (GILZ) gene, inhibits 
expression of GILZ in cultured alveolar epithelial cells (A549), and reduces 
glucocorticoid receptor occupancy at the GILZ promoter in vivo (Muzikar et al., 2009). 
Another polyamide [ImImPyPy-(R)
α-aminoγ-PyPyPyPy] was designed to bind to κB sites, 
thus preventing nuclear factor κB (NF-κB) binding and consequently reducing the 
expression of various NF-κB-driven genes including IL6 and IL8 (Raskatov et al., 2012). 
The pharmacokinetics and toxicity of ImPyPyPy-(R)
α-aminoγ-ImPyPyPy and its analogue 
was tested in mice and micromolar levels were found in mouse plasma for up to 48 h 
following either intraperitoneal or subcutaneous injection (Synold et al., 2012).  
Jevgenij and co-workers further showed that a Py/Im hairpin polyamide is capable of 
trafficking to the tumour site following subcutaneous injection and represses CCL2 and 
SERPINE1 transcription in vivo (Raskatov et al., 2012).  
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Figure 1.20 The inhibition of gene transcription by polyamides. (A) Model of the 
transcriptional machinery required for the initiation of gene transcription by RNA 
polymerase II (RNA Pol II). (B) Polyamides binding proximal to a transcription factor 
(TF) site within the promoter. Gene transcription is inhibited (Dervan amd Burli, 1999).  
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Figure 1.21 Examples of regulation of gene expression by competitive binding of Py-
Im hairpin polyamides to binding sites of transcription factors. The coloured boxes 
indicate the binding site of the italicized protein. The promoter is identified below the 
DNA sequences. The back and open circles represent Im and Py rings respectively. 
Diamonds represent -Ala residues. Plus signs next to diamonds represent 3-
(dimethylamino)propylamine (Dp). The curved line connecting the sides of two circles 
represent the -turn. The half circle represents a propanolamine-NH(CH2)CH3OH 
group. Approximate Kd values are given next each polyamide. Open boxes indicate 
mismatches between the Dp tail and GC, base pairs (Dervan and Edelson, 2003).  
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1.9.4.2 Gene activation 
Polyamides have also been used for upregulating transcription by recruiting or 
depressing the transcriptional machinery. For example, a hairpin polyamide was shown 
to block binding of the repressor IE86 to DNA, thereby upregulating transcription of the 
human cytomegalovirus MIEP (Dickinson et al., 1999). Polyamide-peptide conjugates 
can mediate transcriptional activation by functioning as artificial transcription factors 
(Mapp et al., 2000). Another example involves the expression of topoisomerase IIα 
(topo IIα) as a determinant of response to chemotherapeutic agents targeting this 
enzyme such as etoposide and doxorubicin (Burden et al., 1998). Confluent cancer cells 
express low levels of topo IIα that contributes to resistance to these agents (Isaacs et al., 
1996; Tolner et al., 2001). The topo IIα promoter is regulated through transcription 
factors that interact with five inverted CCAAT boxes (ICBs) (Isaacs et al., 1996). In 
confluent cancer cells, repression of transcription is mediated mainly by the binding of 
the ubiquitously expressed CCAAT-binding protein NF-Y to ICB2 within the topo IIα 
promoter (Ronchi et al., 1995). Sequence-reading polyamides such as JH-37 and the 
pyrrolobenzodiazepine-polyamide conjugate GWL-78 have been designed to bind to the 
flanking regions of selected CCAAT sites within the topo IIα promoter, thus blocking 
the repressive binding of NF-Y , and upregulating topo IIα  expression (Hochhauser et 
al., 2007; Kotecha et al., 2008).  
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1.10 Experimental aims: 
A new class of unlinked polyamide precursors that contain appropriately designed 
pendant reactive and biocompatible functional groups was designed and is presented 
here. It was hypothesized that these relatively small polyamide precursors (molar mass 
500g/mol) will more readily penetrate cells compared to relatively large H-pin/hairpin 
polyamides, localize in the nucleus and bind to their DNA targets in the stacked, 
staggered motif, forming H-pin or Hairpin structures in situ.  
 
The aim of the project is to test this approach of the in situ reaction of two rationally 
designed polyamide monomers capable of potentially forming either H-pin or Hairpin 
conjugates in the nucleus.  
 
Additionally, the experimental work aims to investigate the effect of the presence of an 
additional amino group in selected polyamides on DNA binding affinity and specificity. 
The binding characteristics of PPPP(H)-N-dimethyl-3-aminopropylamine and IPPP(H)-
N-dimethyl-3-aminopropylamine, and a novel fluorescent polyamide HxPI were also 
evaluated.  
 
The sequence 5'-ACGCGT-3' (MCB) which occurs in the core HuDbf4 promoter is 
utilized in this thesis as a model system for investigating the effects of gene targeting by 
the polyamide f-IPI. The binding of f-IPI to the MCB in vitro and the cellular effects of 
f-IPI treatment (e.g. downregulation of HuDbf4, cell cycle effect, cell survival, 
proliferation and apoptosis) were assessed.  
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Subsequently, the targeting of the MCB in the promoter by the polyamides f-
IP(C3NH2)I and f-IP(C3Cl)I was assessed as part of the in situ formation of H-pin 
approach.     
 
Lastly, polyamides containing the fluorescent Hx moiety were designed and tested with 
the aim of monitoring cellular uptake and nuclear localization. HxPI was additionally 
tested as a potential gene-control agent for the targeting of the HuDbf4 promoter model.  
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CHAPTER 2  
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Primers for the generation of the probes for DNase I footprinting  
Name Sequence (5'-> 3') Tm [°C] 
Primer 17 GTCGTTAGGAGAGCTCACTTG 60 
Primer 19 CTCCAGAAAGCCGGCAACTCAG 64 
Table 2.1: List of primers 
2.1.2 MCB oligonucleotides for the EMSA studies 
Name Dbf4 Promoter Sequence (5'-> 3') Tm 
[°C] 
MCB Wild Type 
forward 
GCGTGACGCGTTTTCAAATCTTCAACC 65 
MCB Wild Type 
reverse 
GGTTGAAGATTTGAAAACGCGTCACGC 65 
MCB Mutant forward GCGTGAtGaGTTTTCAAATCTTCAACC
* 
62 
MCB Mutant reverse GGTTGAAGATTTGAAAACTCATCACGC
* 
62 
Table 2.2: List of MCB oligonucleotides 
*
 the italic font is mutated sequence 
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2.1.3 DNA sequences of the templates used for the PCR-generation of 
the fragments for footprint analysis 
Polyamides  IM17/19 Sequence (5'-> 3') Cognate site 
(5'-> 3') 
f-IPI, f-IP(C2NH2)I, f-
IP(C3Cl)I, Ph-IPI, Ph-
IP(C3NH2)I, Aza-HxPI, Aza-
HxP(C3NH2)I and Aza-
HxPI(C3NH2) 
CTGTCCAGAAAGCCGGCACTC
AGTCTACAAACGCGTCATCTT
GATCACCGGTGTTCACAGAAA
TTTCTCTAGATCTACACGTAA
CTCTAGTAGCGCTCTTCAAGC
AAGTGGAGCTCTCCTAACCGA
C sense  
ACGCGT 
f-IPI, f-IP(C2NH2)I, f-
IP(C3Cl)I, Ph-IPI,Ph-
IP(C3NH2)I Aza-HxPI, Aza-
HxP(C3NH2)I and Aza-
HxPI(C3NH2) 
GTCGGTTAGGAGAGCTCCACT
TGCTTGAAGAGCGCTACTAGA
GTTACGTGTAGATCTAGAGAA
ATTTCTGTGAACACCGGTGAT
CAAGATGACGCGTTTGTAGA
CTGAGTGCCGGCTTTCTGGAC
AG  
anti-sense  
ACGCGT 
Table 2.3: List of polyamides, the targeted IM17/19 sequence and the cognate site 
[Pyrrole(P) and Imidazole (I)] 
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Polyamides  IM18/20 Sequence (5'-> 3') Cognate site 
(5'-> 3') 
f-IPP 
f-IP(C3NH2)P 
CTGTCCAGAAAGCCGGCACTCAGTCTACA
AACGCGTCATCTTGATCATGCATGTTCAC
AGAAATTTCTCTAGATCTACACGTAACTCT
AGTACTAGTCTTCAAGCAAGTGGAGCTCT
CCTAACCGAC 
sense  
ATGCAT 
f-IPP 
f-IP(C3NH2)P 
GTCGGTTAGGAGAGCTCCACTTGCTTGAA
GACTAGTACTAGAGTTACGTGTAGATCTA
GAGAAATTTCTGTGAACATGCATGATCAA
GATGACGCGTTTGTAGACTGAGTGCCGGC
TTTCTGGACAG 
anti-sense  
ATGCAT 
Table 2.4: List of polyamides, the targeted IM18/20 sequence and the cognate site 
 
Polyamides  HMC-click Sequence (5'-> 3') Cognate site 
(5'-> 3') 
PPP-b-NH2 
PPP-Benz-NO2 
CTGTCCAGAAAGCCGGCACTCAGTCTAC
AAATAGATCATCTTGATCATATATGTTC
ACAGACAGATCTCTAGATCTAGATATA
ACTCTAGTAAATTTCTTCAAGCAAGTGG
AGCTCTCCTAACCGAC 
sense 
ACAGAT 
AAATTT 
PPP-b-NH2 
PPP-Benz-NO2 
GTCGGTTAGGAGAGCTCCACTTGCTTGA
AGAAATTTACTAGAGTTATATCTAGATC
TAGAGATCTGTCTGTGAACATATATGA
TCAAGATGATCTATTTGTAGACTGAGTG
CCGGCTTTCTGGACAG 
anti-sense 
ATCTGT 
AAATTT 
Table 2.5: List of polyamides, the targeted HMC-click sequence and the cognate site 
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Polyamides  Click-6 Sequence (5'-> 3') Cognate site 
(5'-> 3') 
f-IP(C3N3)I, f-PP(C3-
alkyne)P, f-IP(C3-
alkyne)I and f-
PP(C3N3) 
CTGTGTCCAGAAAGCCGGCACTC
AGCTACAAACGCGTCATCGATCA
AATTTGTTCACAGACTCATGTCTA
GCTACACTTAAGTCTAGTCTCAAG
TGTCATCTCACTAGTTCGTCAAGT
GGAGCTCTCCTAACCGAC sense 
ACGCGT 
AAATTT 
WCWCWW
* 
f-IP(C3N3), f-PP(C3-
alkyne)P, f-IP(C3-
alkyne)I and f-
PP(C3N3) 
GTCGGTTAGGAGAGCTCCACTTG
ACGAACTAGTGAGATGACACTTG
AGACTAGACTTAAGTGTAGCTAG
ACATGAGTCTGTGAACAAATTTG
ATCGATGACGCGTTTGTAGCTGA
GTGCCGGCTTTCTGGACACAG 
anti-sense 
ACGCGT 
AAATTT 
WCWCWW
* 
Table 2.6: List of polyamides, the targeted Click-6 sequence and the cognate site 
* Where W means A or T. 
Polyamides  KM-A Sequence (5'-> 3') Cognate 
site 
(5'-> 3') 
PPPX 
IPPX 
CTGTCCAGAAAGCCGGCACTCAGTCT
ACAAAAATTTCATCTTGATCATATAT
GTTCACAGAGCTCTCTCTAGATCTAG
ATCTAACTCTAGTACATGTCTTCAAG
CAAGTGGAGCTCTCCTAACCGAC 
sense 
AAATTT 
AGATCT 
ACATGT 
PPPX 
IPPX 
GTCGGTTAGGAGAGCTCCACTTGCTT
GAAGACATGTACTAGAGTTAGATCT
AGATCTAGAGAGAGCTCTGTGAACA
TATATGATCAAGATGAAATTTTTGTA
GACTGAGTGCCGGCTTTCTGGACAG 
anti-sense 
AAATTT 
AGATCT 
ACATGT 
Table 2.7: List of polyamides, the targeted KM-A sequence and the cognate site 
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Polyamides  Tope IIα Promoter Sequence (5'-> 3') Cognate 
site 
(5'-> 3') 
f-PIP 
f-P(C3CN)IP 
f-PI(C3N3)IP 
f-PI(C3NH2)IP 
CTGTCCAGAAAGCCGGCACTCAGTTTCCTC
AGGAAAACGAAGCTAAGGCTCCCATTCCC
CTCGCTAACAACGTCAGAACAGAGGACAG
TTTTTAGATTTCAGGGATCTTAAATAGATT
GGCAGTCCTGGAGAATAAACATCCTTTGC
TTTTCTCCTGCACACTTTTGCCTCAGGCCA
CCCCTTCCCGCTCCAAAGCCCATCTCTTCC
AAGCTTTCCGCACGAGAAAACAAGTGAGC
CCTTCTCATTGGCCAGATGCCCTGTCAATC
TCTCCGCTATGACGCCGAGTGGTGCCTTTT
GAAGCCTCTCTAGTCCCGCCTCCAGCTAAC
CTGATTGGTTTATTCAAACAAACCCCGGCC
AACTCAGCCGTTCATAGGTGGATATAAAA
GGGCAAGCTACGATTGGTTCTTCTGGACG
GAGACGGTGAGAGCGAGTCAGGGATTGGC
TGGTCTGCTCTCGGGCGGGCTAAAGGAAG
GTTCAAGTGGAGCTCTCCTAACCGAC sense 
TACGAT 
(5'-flank of 
ICB2) 
 
f-PIP 
f-P(C3CN)IP 
f-PI(C3N3)IP 
f-PI(C3NH2)IP 
GTCGGTTAGGAGAGCTCCACTTGAACCTTC
CTTTAGCCCGCCCGAGAGCAGACCAGCCA
ATCCCTGACTCGCTCTCACCGTCTCCGTCC
AGAAGAACCAATCGTAGCTTGCCCTTTTA
TATCCACCTATGAACGGCTGAGTTGGCCG
GGGTTTGTTTGAATAAACCAATCAGGTTA
GCTGGAGGCGGGACTAGAGAGGCTTCAAA
AGGCACCACTCGGCGTCATAGCGGAGAGA
TTGACAGGGCATCTGGCCAATGAGAAGGG
CTCACTTGTTTTCTCGTGCGGAAAGCTTGG
AAGAGATGGGCTTTGGAGCGGGAAGGGGT
GGCCTGAGGCAAAAGTGTGCAGGAGAAA
AGCAAAGGATGTTTATTCTCCAGGACTGC
CAATCTATTTAAGATCCCTGAAATCTAAAA
ACTGTCCTCTGTTCTGACGTTGTTAGCGAG
GGGAATGGGAGCCTTAGCTTCGTTTTCCTG
AGGAAACTGAGTGCCGGCTTTCTGGACAG 
anti-sense 
ATCGTA 
(5'-flank of 
ICB2) 
 
Table 2.8: List of polyamides, the targeted Tope IIα Promoter sequence and the cognate 
site 
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Polyamides  Dbf4 Promoter Sequence (5'-> 3') Cognate site 
(5'-> 3') 
f-IPI 
f-IP(C2NH2)I 
f-IP(C3Cl)I 
CTGTCCAGAAAGCCGGCACTCAGGC
GTGAGACGGGGCGGGGCGCGCGTA
TCGGCGCCGCGGCCGCGTGACGCG
TTTTCAAATCTTCAACCGCCGCAGC
CCACTCGTTTCAAGTGGAGCTCTCCT
AACCGAC sense 
ACGCGT 
f-IPI 
f-IP(C2NH2)I 
f-IP(C3Cl)I 
GTCGGTTAGGAGAGCTCCACTTGAA
ACGAGTGGGCTGCGGCGGTTGAAGA
TTTGAAAACGCGTCACGCGGCCGC
GGCGCCGATACGCGCGCCCCGCCCC
GTCTCACGCCTGAGTGCCGGCTTTCT
GGACAG anti-sense 
ACGCGT 
Table 2.9: List of polyamides, the targeted Dbf4 Promoter sequence and the cognate 
site 
 
Polyamides  HxSeq (5'-> 3') Cognate site 
(5'-> 3') 
Hx-PI CTGTCCAGAAAGCCGGCACTCAGTCT
ACAAACGCGTCATCTTGATCATGCAT
GTTCACAGAAATTTCTCTAGATCTAC
ACGTAACTCTAGTACTAGTCTTCAAG
CAAGTGGAGCTCTCCTAACCGAC 
sense 
WCWWCW 
W=A or T 
Hx-PI GTCGGTTAGGAGAGCTCCACTTGCTT
GAAGACTAGTACTAGAGTTACGTGT
AGATCTAGAGAAATTTCTGTGAACAT
GCATGATCAAGATGACGCGTTTGTAG
ACTGAGTGCCGGCTTTC TGGACAG 
 anti-sense 
WGWWGW 
Table 2.10: List of polyamides, the targeted HxSeq sequence and the cognate site 
 
 
 
 
81 
 
2.2 Methods: 
2.2.1 Generation of radiolabelled probe for DNase I footprinting 
analysis 
The forward primer17 5’- GTCGTTAGGAGAGCTCACTTG-3’ (4 µl pmol) was 5’-
radioactively labeled with γ-[32P] (3 µl), 1 µl of T4 polynucleotide kinase (NEB, UK), 2 
µl of 10× NEB buffer and 2 µl of water. The mixture was incubated at 37 °C for 1 hour 
during which an extra 0.5 µl of T4 kinase was added. T4 kinase was inactivated by 
heating at 65 °C for 20 min. 
 
2.2.2 Polymerase chain reaction (PCR) 
4 pmol of reverse primer19 5’-CTCCAGAAAGCCGGCAACTCAG-3’, 2 µl of MgCl2 
(1 mM), 2 µl of 10 mM dNTPs (Promega, UK), 1 U Flexi GoTaq polymerase 
(Promega,UK), 10 µl of 5 × GoTaq buffer, 10 µl of γ-[32p]-labeled forward primer17 
and the DNA templates (20 ng each) (DNA fragment sequences are listed in the section 
2.1) were mixed together in a final volume of 50 µl. The PCR reaction was performed 
as follows: an initial denaturation step for 3 min at 95 °C, [1 min at 94 °C, 1 min at 63 
°C, and 1 min at 72 °C] for 35 cycles and 72 °C for 15 min. The resulting DNA 
products were purified using the Mermaid Kit (Q-biogene). DNA fragments greater than 
200bp in length were purified using the GENECLEAN III kit (Q-biogene) according to 
the manufacturer’s instructions.   
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2.2.3 DNase I footprinting experiments 
DNase I reactions were performed in a total volume of 8 µl. The labeled DNA fragment 
(2  µl, 200 counts per second; cps) was incubated for 30 min at room temperature in 4 
µl 1 × TN binding buffer (10 mM Tris Base, 10 mM NaCl, pH 7) containing the 
required drug concentration. The drug treated-DNA was then cleaved by the addition of 
2 µl of DNase I solution (20 mM NaCl, 2 mM MgCl2, 2 mM MnCl2, DNase I 0.02 U/ 
µl, pH 8.0) and the reaction was stopped after 3 min by freezing the samples on dry ice 
for a minimum of 30 min. The samples were subsequently lyophilized. 
 
2.2.4 Polyacrylamide gel electrophoresis 
DNA samples were resuspended in 5 µl of formamide loading dye (95% formamide, 20 
mM EDTA, 0.05% bromophenol blue, and 0.05% cyanol blue), denatured by heating at 
94 °C for 3.5 min and cooled on ice prior to loading a pre-run polyacrylamide (6% or 
10%) gel (Sequagel, National Diagnostics, UK) containing urea (7.5 mM). 
Electrophoresis was conducted for 2 hours at 1650 V (~70 W, 50 °C) in 1 × TBE buffer 
(89 mM Tris base, 89 mM boric acid, 2.5 mM Na2EDTA, pH 8.3). The gel was then 
transferred onto Whatman 3MM paper and Whatman DE81 paper and dried under 
vacuum at 80 °C for 2 h. The gel was exposed overnight to medical X-Ray film in 
(Super RX, Fuji) and developed by Konica Medical Film Processor SRX-101A, 
 
2.2.5 Cell culture 
The human breast cancer cell line MDA-MB231 was cultured in Dulbecco’s modified 
Eagle’s minimal essential medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and 1% glutamine (Sigma, UK) in a 37 °C incubator with 5% CO2.   
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2.2.6 Nuclear protein extraction from MDA-MB231 cells 
Nuclear extracts from exponentially growing MDA-MB231 cells obtained by using the 
Nuclear Extract Kit (Active Motif, UK) according to the manufacturer’s instructions. 
Briefly, each flask was washed with 8 ml ice-cold phosphate buffered saline 
(PBS)/phosphatase inhibitors (1.6 ml of 10 × PBS, 13.6 ml of distilled water and 0.8 ml 
of phosphatase inhibitors). Cells were scraped off collected and split into pre-chilled 15 
ml conical tubes. The cell suspension was centrifuged for 5 min at 500 rpm at 4 °C and 
the supernatant was discarded. The cell pellet was gently resuspended in 500 µl of 
1×Hypotonic Buffer by pipetting up and down several times and the suspension was 
incubated for 15 min on ice in a pre-chilled microcentrifuge tube. 25 µl of detergent was 
added and vortexed 10 sec at highest setting. The suspension was centrifuged for 30 sec 
at 14,000×g in a pre-cooled microcentrifuge at 4 °C and the supernatant was discarded. 
The pellet was then resuspended in 50 µl of Complete Lysis Buffer and the suspension 
was incubated for 30 min on a 150 rpm rocking platform set at 4 °C and centrifuged for 
10min at 14,000×g at 4 °C. The supernatant (nuclear fraction) was transferred into a 
pre-chilled microcentrufuge tube and was stored at -80 °C. The protein concentration of 
the nuclear extract was assayed by a Bio-Rad micro protein assay kit (Bio-Rad, USA). 
 
2.2.7 Electrophoretic Mobility Shift Assay (EMSA) 
2.2.7.1 Annealing and labeling of oligonucleotides  
The Oligonucleotides (MWG biotech, Germany) containing the MluI Cell-cycle Box 
(MCB, ACGCGT) were used in EMSAs and their sequences are shown as below: MCB 
wild type, 5’-GCGTGACGCGTTTTCAAATCTTCAACC-3’ (sense); MCB mutant, 5’-
GCGTGATGAGTTTTCAAATCTTCAACC-3’ (sense, the italic font is mutated 
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sequence). Sense and antisense oligonucleotides were annealed at an equimolar ratio 
containing in the final volume of 50 µl. The mixture was incubated for 3 min at 95 °C 
and then 1 min at 30 °C and lastly stored at 4 °C overnight. The double-stranded 
oligonucleotides (0.5 µl) were 5’-end labeled with 1.5 µl of T4 kinase (NEB, UK) using 
4 µl of γ-[32p] ATP and mixed with 4 µl of 5 × NEB buffer made up with water to the 
final volume of 20 µl.  They were incubated at 37 °C for 1 h and subsequently purified 
on Bio-Gel P-6 columns (Bio-Rad, UK). 
 
2.2.7.2 Gel shift reactions 
EMSAs reactions were conducted in a final volume of 20 µl. 0.4 pmol of radiolabeled 
probe was incubated for 30 min in a buffer containing 5 mM MgCl2, 2.5 mM K-EDTA, 
20% glycerol, 250 mM NaCl, 2.5 mM DTT, 50mM Tris-HCl (pH 7.5), and 0.9 µl of 1 
mg/ml poly(dI-dC).poly(dI-dC) (Sigma, UK) and 1× protease inhibitor mix (Complete) 
(Roche, Germany) as well as the required drug concentration. Nuclear extracts (20 µg) 
were then added and the mixture was further incubated for 1 h.  Subsequently, 5 µl of 
loading buffer [25 mM Tris-Cl (pH 7.5), 0.02% bromphenol blue, 10% glycerol] was 
added and the samples were separated on a 4% polyacrylamide gel in 0.5 × TBE 
containing 2.5% glycerol at 4 °C. After drying the gels, the radioactive signal was 
visualized by exposing the gels to medical X-Ray film (Super Rx, Fuji) and developed 
by Konica Medical Film Processor SRX-101A. 
 
 
2.2.8 Purification of total RNA from MDA-MB231 cells 
 
MDA-MB231 cells grew in 60mm well at cell density of 2.5 × 10
6
. RNA purification 
was carried out using RNeasy Mini kit (Qiagen, UK). Cells were trypsinized and 
collected as a cell pellet in a 15 ml falcon tube prior to lysis. 350 µl of buffer RLT was 
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added and the lysate was passed at least 5 times through a blunt 20-gauge needle (0.9 
mm diameter) in order to homogenize. 350 µl of 70% ethonal was added to the 
homogenized lysate. 700 µl of the sample was transferred to an RNeasy spin colume 
and centrifuged for 15 s at 8000×g. The flow-through was discarded and 700 µl of 
buffer RW1 was added to the spin column and centrifuged for 15 s at 8000×g. 500 µl 
buffer RPE was added and centrifuged for 15 s at 8000×g and then another 500 µl was 
added and centrifuged for 2 min at 8000×g. The spin column was transferred with 30-50 
µl of water and centrifuged for 1min at 8000×g. The flow-through was collected in a 
new 1.5 ml tube. The concentration of purified RNA was determined by measuring the 
absorbance at 260 nm. 
 
2.2.9 Reverse transcription 
Reverse transcription was carried out as described in the manufacturer’s instructions 
(Qiagen).  The reverse transcriptase reaction was carried out at 37°C for 1 h using 2 µg 
of RNA, 2 µl of 10 × reverse transcriptase buffer (Qiagen), 2 µl of 5 mM dNTP mix 
(Qiagen), 2 µl of 10 µM Oligo-dT primer (Invitrogen), 0.5 µl of 20 U/µl RNase 
inhibitor (Applied Biosystems), 1 µl of Omnicript Reverse transcriptase (Qiagen), and 
nuclease-free water in a final volume of 20 µl.  
 
2.2.10 Real-time PCR 
2.2.10.1 Taqman primers/probe 
Real-time PCR was carried out using an ABI PRISM 7000 Sequence Detection System 
from Applied Biosystems. Dbf4 forward and reverse primers and probe were designed 
by Taqman (Hs00988147_g1) and the primers to detect Dbf4 promoter yield an RT-
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PCR product of 103bp. The cycling conditions used were 95 °C for 10 min to denature 
and 40 cycles of 95 °C for 15 s and 58 °C for 1 min to amplify the target (Dbf4) 
sequences.  GAPDH primer/probe mix (1 µl; Applied biosystems) was used as an 
internal control in all reactions. The reaction mix was prepared using 10 µl of Taqman 2 
× PCR master mix (Applied Biosystems), 1 µl of 20 × primer/probe mix and 1 µl of 
cDNA (1-100 ng) template in a final volume of 20 µl. The results were analyzed using 
the mathematical qualification approach described by PfaffI (PfaffI, 2001) and ABI user 
Bulletin 2 (ABI PRISM 7700 sequence detection system manual). 
 
This statistical method is based on the relative expression ratio of the target gene (Dbf4) 
compared to that of internal control gene (GAPDH). Standard curves were constructed 
for both the internal and target genes, and slopes of these were used to ensure that both 
primer sets were equally efficient. The threshold cycle values (Ct) and the efficiencies 
of the reactions were used to compare the relative expression levels of the target gene in 
various samples. Levels of Dbf4 RNA in untreated, exponentially growing cells were 
set at a value of 100% and all test samples were expressed at values relative to this.  
 
2.2.11 Western blot analysis 
2.2.11.1 Cell line and culture conditions 
MDA-MB231 cells were grown in DMEM (Autogen Bioclear, UK) supplemented with 
10% FBS and 1% glutamine and incubated at 37°C in 5% CO2  
 
2.2.11.2 Whole-cell protein extraction  
MDA-MB231 cells were seeded in 6 well plates at 2 × 10
5
 cells/ml and allowed to grow 
for 24 h before drug treatment. 24 h drug-treated and untreated cells were washed twice 
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with ice cold PBS and subsequently scraped from 6 well plates and then centrifuged in a 
4°C at 13,000 rpm for 5 min. The supernatant was discarded and the pellet was 
resuspended in 50-100 µl lysis buffer (25 × protease inhibitor, 10 × phosphatase 
inhibitor and 10 U/ µl Merck benzonase nuclease added in 1ml of sigma cell lytic M 
cell lysis reagent) and stored at -80 °C.  
 
2.2.11.3 Protein Assay 
Protein was determined by the BCA assay (Pierce) according to the manufacturer's 
protocol using bovine serum albumin as a standard. 
 
2.2.11.4 Immunoblotting 
30-40 µg of protein lysate was mixed with 5× loading (laemelli) buffer (250 mM Tris 
HCl, pH 6.8, 500 mM DTT, 10% SDS, 0.5% Bromophenol Blue, 50% glycerol and 
distilled water were used to make a 5 times stock). The protein lysates were spun for a 
few seconds and boiled for 5 min at 100 °C, and then centrifuged for 5 sec. The protein 
lysates were loaded on NuPAGE
®
 Novex 10% Bis-Tris pre-casted mini gels 
(Invitrogen) along with a marker as a reference (Rainbow protein marker, GE 
healthcare, UK) and run in 1× NuPAGE® MOPS SDS Running Buffer using the XCell 
SureLock
TM
 Mini-Cell module (Invitrogen).  
 
The protein lysates were separated on the 10% Bis-Tris mini gel and were subsequently 
transferred electrophoretically (Trans-Blot cell, invitrogen) onto methanol activated 
polyvinylidene difluoride membranes (Immobilon-P, Sigma-Aldrich) and run in 1× 
transblot buffer [100 ml of running buffer stock × 10 (30.3 g Tris Base, 144.1 g Glycine 
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and distilled water to 1 litre-pH 8.30), 200 ml MetOH and distilled water to 2 litre] at 35 
V for 2.5 h.  
 
Membranes were blocked with 5% BSA in TBS buffer containing 0.1% Tween 20 (pH 
7.5) for 1 hour. Proteins were probed using the appropriate primary antibody (see 
dilutions and preparation in Table 2.1.3) and incubated at 4 °C shaker overnight. 
Membranes were washed twice with TBS-Tween buffer in 30 min and subsequently 
were probed with HRP-conjugated polyclonal antibodies (Mouse or Rabbit – 1/1000, 
Cell Signaling) using 5% skimmed milk dissolved in TBS with 0.1% Tween 20 as 
blocking reagent for chemiluminescence detection (ECL system, Amersham 
Biosciences, UK). The chemiluminescent signal was visualized by exposing the blots to 
Kodak X-OMAT
TM
LS film for various exposure times (15 seconds to 1 hour). For all 
experiments, calnexin was used as a loading control for the cytoplasmic fraction.  
 
Stripping membranes to remove pre-bound antibody was done by rehydrating 
membranes in TBS-tween and washed 3 times for 5 min. Membranes were then 
incubated in Restore
TM
 Plus western blot stripping buffer (100mM β-mercaptoethanol, 
2% SDS and 62.5 mM Tris HCl pH 6.8, Thermoscientific) for 15 min and washed in 
TBS-tween 3 times for 10 min. The membranes were blocked and reprobed as described 
above 
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Antibodies Dilutions Dilution buffer Supplier 
Anti-Dbf4 1/500 5% BSA Abcam 
Anti-Cdc7 1/1000 5% BSA Cell signaling 
Anti-Calnexin 1/1000 5% BSA Cell signaling 
Anti-Mouse (ab6728) 1/1000 5% Milk Cell signaling 
Anti-Rabbit (ab6721) 1/1000 5% Milk Cell signaling 
Table 2.10: List of antibodies 
 
2.2.12 Cell cycle analysis 
Cell cycle profiles were determined by propidium iodide (PI) staining of DNA content 
and flow cytometry. Exponentially growing cells were treated with required drug 
concentrations for 24 h. Untreated- and treated-cells were harvested by trypsinizing, 
pelleted by centrifugation for 5 min at 800 rpm, and ~1 × 10
6
 cells were washed in 2 ml 
ice cold PBS. Cell pellets were then fixed by drop-wise addition to 70% ice-cold 
ethanol and stored overnight at 4 °C. The ethanol fixed cells were centrifuged for 5 min 
at 800 rpm, and the cell pellets were then resuspended in 1 ml staining solution 
containing 50 µg/ml of PI (Sigma) and 100 µg/ml of RNase A (Sigma) in 0.05% Triton 
X-100 PBS. After at least 30 min of incubation in the dark at room temperature, the cell 
suspension was analyzed by the CyAn ADP High-Performance Flow Cytometer. Data 
were analyzed by Summit V4.3 software.  
 
2.2.13 Small interfering RNAs and Transfection 
2.2.13.1 siRNA Transfection efficiency 
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Cells were plated in 100 µl of growth medium (DMEM supplemented with 10% FBS 
and 1% glutamine) in 96 well plate without antibiotics such that they would be 30-50% 
confluent at the time of transfection. For the transfection samples, a series of 
concentrations (1, 3, 5 and 10 pmol) of Silencer Fam GAPDH siRNA were diluted in 25 
µl Opti-MEM® I Reduced Serum Medium (final concentration of siRNA when added 
to the cells is 33 nM). 0.25 µl of Lipofectamine 2000 reagent (invitrogen) was added in 
25 µl Opti-MEM® I Reduced Serum Medium and incubated for 5 min at room 
temperature. After 5 min incubation, GAPDH siRNA diluent was incubated with 
Lipofectamine 2000 diluent for 20 min at room temperature. The GAPDH siRNA-
Lipofectamine 2000 complexes were added to each well containing cells and medium 
and then mixed gently by rocking the plate back and forth.  The transfected cells were 
observed and assessed using fluorescence microscopy.  
 
2.2.13.2 Dbf4 siRNA transfection 
siRNA specific to Dbf4 and scrambled control (Origene) were used on synchronized 0.8 
× 10
5
 cells. 10 pmol of Dbf4 siRNA (Origene) was optimized for each RNA 
interference in 96 well plates. Dbf4 siRNA transfection followed the same procedure as 
described above. 100 pmol of Dbf4 siRNA and 5 µl of Lipofectamine 2000 were diluted 
in 250 µl of Opti-MEM buffer for the RNA interference in 6 well plates. siRNA 
treatments were tested in cell survival, apoptosis and proliferation assay at the various 
time points.  
 
2.2.14 CellTiter-Glo Luminescent cell viability assay 
The CellTiter-Glo Luminescent cell viability assay (Promega, UK) is a homogeneous 
method to determine the number of viable cells in culture based on the quantitation of 
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the ATP present, which signals the presence of metabolically active cells. After Dbf4 
siRNA transfection, cells were incubated with a volume of CellTiter-Glo reagent equal 
to the volume of cell culture medium present in each well for 10 min according to the 
manufacturer’s protocol. The number of surviving cells was measured by luminometer 
(Thermo Scientific Varioskan Flash).  
 
2.2.15 Caspase-Glo 3/7 apoptosis assay 
The Caspase-Glo® 3/7 Assay is a homogeneous, luminescent assay that measures 
caspase-3 and -7 activities. The assay provides a luminogenic caspase-3/7 substrate, 
which contains the tetrapeptide sequence DEVD, in a reagent optimized for caspase 
activity, luciferase activity and cell lysis. After Dbf4 siRNA transfection, blank, 
negative control cells or treated cells in culture medium were incubated with Caspase-
Glo 3/7 reagent in each well for 1.5 h according to the manufacturer’s protocol. The 
number of apoptotic cells was then measured by luminometer (Thermo Scientific 
Varioskan Flash). 
 
2.2.16 BrdU cell proliferation assay 
The BrdU cell proliferation assay detects 5-bromo-2’-deoxyuridine (BrdU) incorporated 
into cellular DNA during cell proliferation using an anti-BrdU antibody. At Dbf4 
siRNA post-transfection, cells were tested using BrdU cell proliferation assay kit (Cell 
signaling, UK) according to the manufacturer’s protocol. Briefly, cells were incubated 
with BrdU solution for 18 h and then the medium was removed. 100 µl of 
fixing/denaturing solution were added to each well incubated for 30 min at room 
temperature before discarding the solution. 100 µl of BrdU detection solution were 
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added and kept at room temperature for 1 h prior to 3 times wash. Subsequently, anti-
mouse lgG, HRP-linked antibody (100 µl, Cell signaling) was used to recognize the 
bound BrdU detection antibody. After 3 times wash, HRP substrate TMB (100 µl) was 
added to develop color. The magnitude of the absorbance for the developed color is 
proportional to the quantity of BrdU incorporated into cells, which is a direct indication 
of cell proliferation. The absorbance was measured at 450 nm by luminometer (Thermo 
Scientific Varioskan Flash). 
 
2.2.17 Immunostaining for confocal microscopy  
A total of 3 × 10
4
 MDA-MB231 cells were plated in chambered slides. Cells were then 
treated with rationally designed polyamides at the various time points. Slides were fixed 
with 2.5% paraformaldehyde for 10 min followed by 3 times PBS washes, 
permeabilized with 0.5% Triton X-100 for 10 min followed by 3 times PBS washes, 
stained with 20 µg/µl propidium iodide (Sigma) for 3 min followed by 1 time PBS 
wash, and then incubated with water for 10 min before drying for 10-15 min at room 
temperature. Slides were covered with coverslips (24 × 60mm, VWR), which were 
sealed at the edge with clear nail varnish. Cells were visualized by confocal microscopy 
(objective: × 40; Leica TCS SP2). Nuclear slice images were acquired by sequential 
scanning by using the LAS AF Lite program. 
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CHAPTER 3 
EVALUATION OF NOVEL POLYAMIDE CONTAINING 
BIOCAMPITABLE REACTIVE GROUPS FOR IN SITU H-
PIN FORMATION 
3.1 Introduction 
Pyrrole (P)- and imidazole (I)-containing polyamide analogues of distamycin A bind in 
the minor groove of DNA in a stacked, antiparallel 2:1 (polyamide/DNA) motif (Mitra 
et al., 1999; Pelton and Wemmer, 1989,1990). Early studies have formulated a set of 
'pairing rules' for DNA base pair recognition; A/T and T/A base pairs are recognized by 
P/P pairs, G/C base pairs by I/P pairs, and C/G base pairs by P/I pairs (Kopka et al., 
1985; Mrksich et al., 1992; Wade et al., 1992; Lown et al., 1986). This recognition is 
analogous to a simple, single-letter language in which one heterocyclic pair reads one 
DNA base pair.  
 
Formamido(f)-IPI binds selectively as a 2:1 stacked dimer in the minor groove of 5'-
ACGCGT-3' (Buchmueller et al., 2006). Replacement of the f-group by a pyrrole or aryl 
groups at the N-terminus leads to binding in the overlapped fashion, with decreased 
binding affinity. Although the monomer polyamides can form a 2:1 polyamide/DNA 
complex within the minor groove, this is not always energetically favorable.  There is 
also a concern that the monomers without a formamido group may split into an 
extended staggered motif, hence, creating a reading frame different to the one predicted 
(Pelton et al., 1990; Chen et al., 1994).  In addition, the monomers may also bind in a 
mixed 2:1 and 1:1 motif, thus, reducing the overall affinity. To address the problem, 
94 
 
Hairpin and H-pin analogues have been designed, showing enhanced DNA binding 
affinity and selectivity. However, poor cellular uptake of large hairpin/H-pin 
polyamides has restricted their further development (Best et al., 2003; Dickinson et al., 
2004; Franks et al., 2010). 
 
A new class of unlinked polyamide precursors that contain appropriately designed 
pendant reactive and biocompatible functional groups was designed and synthesized by 
our collaborator Dr Moses Lee (Hope College). It was hypothesized that these relatively 
small polyamide precursors (molar mass ~500g/mol) will more readily penetrate cells in 
comparison with relatively large H-pin/hairpin polyamides, localize in the nucleus to 
their DNA target sequence in the stacked, staggered motif, and have the potential to 
form covalent H-pin or Hairpin structures in situ.  
 
The aim of the project is to test the novel approach of in situ reaction of two rationally 
designed polyamide monomers capable of potentially forming either H-pin or Hairpin 
conjugates in the nucleus. The general approach is shown in Figure 3.1. There are four 
particular chemical reactions tested in the DNase I footprinting analysis. -C3NH2 
reactive group could interact with -C3Cl through a nucleophilic substitution reaction; -
C3N3 reactive group could interact with -C3CN through a 1,3-dipolar cycloaddition 
reaction; -C3N3 reactive group could interact with -C3-alkyne through an azide-alkyne 
Huisgen reaction; -NH2 reactive group could interact with carbamate carbonyl through 
an acyl transfer reaction (illustrated in Figure 3.1).   
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Figure 3.1 Biocompatible reactive groups for in-nucleus H-pin formation. Low 
molecular weight sequence selective polyamide reagents containing appropriate pendant 
reactive and biocompatible functional groups combine on the DNA in situ to form H-
pin structures at specific DNA sequences.   
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3.2 Results 
3.2.1 DNA sequence specific binding of f-IPI, analogues f-IP(C3NH2)I, 
f-IP(C3Cl)I, and their combination 
The binding of the formamido-imidazole-pyrrole-imidazole compound (f-IPI), its 
analogues f-IP(C3NH2)I, f-IP(C3Cl)I, and their combination on a 127bp DNA fragment 
was investigated by DNase I footprinting. The chemical structure and DNA sequence 
binding models of f-IP(C3NH2)I, f-IP(C3Cl)I, and their combination are shown in Figure 
3.2A&B. The selectivity of these polyamides was determined in a DNA fragment 
engineered to contain the cognate site 5’-ACGCGT-3’, the noncognate sites 5’-
ACCGGT-3’ and 5'-ACACGT-3', and the control AT-rich site 5’-AAATTT-3’ (Figure 
3.2C). Our footprinting studies of f-IPI have been reported previously (Buchmueller et 
al., 2006) and it is included here for comparison (Figure 3.3A). Binding of f-IP(C3NH2)I 
to the established cognate sequence (5’-ACGCGT-3’) is observed at 0.05 µM similar to 
f-IPI. The stronger footprint for f-IP(C3NH2)I at this concentration suggests a slightly 
higher DNA binding affinity than that of f-IPI (Figure 3.3A&B). Binding of f-
IP(C3NH2)I at the non-cognate binding site 5’-ACCGGT-3’ and 5'-ACACGT-3' occurs 
at 1 µM while no significant binding is observed at the AT-rich site 5’-AAATTT-3’ at 
concentrations <10 µM (Figure 3.3B).  
 
Binding of f-IP(C3Cl)I to the cognate sequence occurs at a higher dose (1 µM) than f-
IP(C3NH2)I however f-IP(C3Cl)I appears to have enhanced sequence selectivity as no 
significant binding is observed at any other sites at concentrations as high as 20 µM 
(Figure 3.3C). The different pendant groups on the central pyrrole unit of f-IPI can 
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therefore influcence DNA binding affinity while retaining specificity for the cognate 
sequence. 
 
The combination (1:1 mixture) of f-IP(C3NH2)I and f-IP(C3Cl)I (Figure 3.3D) was also 
tested with DNase I footprinting. The binding of the combination of the two polyamides 
to the cognate sequence occurs at 0.05 µM (Figure 3.3D). 0.025 µM of each polyamides 
f-IP(C3NH2)I and f-IP(C3Cl)I was mixed to achieve the final concentration of the 
combined compound 0.05 µM. 
 
These footprinting experiments showed that f-IP(C3NH2)I has comparable binding 
affinity to the cognate site as its parent compound f-IPI but exhibits 20-fold better 
binding affinity than f-IP(C3Cl)I. When 0.025 µM of f-IP(C3NH2)I were mixed with 
0.025 µM of f-IP(C3Cl)I, binding occurs at 0.05 µM as was the case for f-IP(C3NH2)I 
alone. The question raised from these results is how the presence of the lower binding 
affinity compound f-IP(C3Cl)I shows the same effect in the combination treated f-
IP(C3NH2)I at half the concentration? One possibility is that f-IP(C3NH2)I and f-
IP(C3Cl)I combine in situ to form a favorable 2:1 structure, which can account for the 
higher binding affinity in the in situ reaction. However, it is difficult to prove whether 
the actual H-pin compound is covalently formed with just DNase I footprinting analysis. 
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C   IM17/19         
     
          Primer 19                Cognate site     Non-cognate site      
5’-CTGTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCACCGGTGTTCACAG 
3’-GACAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTGGCCACAAGTGTC 
   Non-cognate site      
AAATTTCTCTAGATCTACACGTAACTCTAGTAGCGCTCTTCAAGCAAGTGGAGCTCTCCTAACC 
TTTAAAGAGATCTAGATGTGCATTGAGATCATCGCGAGAAGTTCGTTCACCTCGAGAGGATTGG                                                                                                                           
 
GAC-3′ 
CTG-5’-32p 
Primer 17 
 
Figure 3.2 A, Chemical structures of f-IP(C3NH2)I and f-IP(C3Cl)I, and reactive groups 
(red) of the two monomer polyamides designed to form H-pin structure through a 
nucleophilic substitution reaction B, Binding models of f-IP(C3NH2)I, f-IP(C3Cl)I and 
potentially formed hybrid. C, DNA fragment IM17/19. The bottom strand is 5’-labelled 
with 
32
P. DNA cognate and non-cognate sequence binding sites are labeled with blue 
color. 
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C                                                                          D 
 
 
Figure 3.3 DNase I footprinting was performed with a radiolabeled probe containing 
the IM17/19 DNA sequences. The probe was incubated with increasing concentrations 
of f-IPI (A), f-IP(C3NH2)I (B), f-IP(C3Cl)I (C) and combination of f-IP(C3NH2)I and f-
IP(C3Cl)I  (0.01-20 µM) (D). Asterisks indicated the concentration of polyamide at 
which cleavage protection is initially observed. The cognate sequence binding sites are 
highlighted by double solid bars. Control DNA lanes lack DNase I treatment and G+A 
lanes denote the position of the purine nucleotides. 
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3.2.2 DNA sequence binding affinity of f-PIP, analogues f-P(C3CN)IP,  
f-P(C3N3)IP and their combination 
The chemical structures and DNA sequence binding models of f-P(C3CN)IP, f-
P(C3N3)IP and their combination are shown in Figure 3.4A&B. DNase I footprinting 
studies of f-PIP binding to a DNA fragment corresponding to the topo IIα promoter 
(Figure 3.4C) have been previously reported and the titration experiment indicated that 
a footprint at the 5’-TACGAT-3’ site (5’-flank of ICB2 shown in Figure 3.4B) begins to 
appear at a concentration of 30 µM (Le et al., 2006). f-PIP is included here for 
comparison purposes with its derivatives (Figure 3.5A). The autoradiograms given in 
Figure 3.5B&C showed that both f-P(C3CN)IP and f-P(C3N3)IP footprint at the 5’-
TACGAT-3’ site at 30 µM, revealing similar affinity to f-PIP. However, nonspecific 
binding of f-P(C3N3)IP occurs at 30 µM. The combination (1:1 mixture) of f-P(C3CN)IP 
and f-P(C3N3)IP (Figure 3.5D) was also tested with DNA footprinting. The binding of 
the combination of the two polyamides to the cognate sequence occurs at 30 µM 
polyamides (Figure 3.5D), by adding and mixing 15 µM of each polyamides f-
P(C3CN)IP and f-P(C3N3)IP to achieve the final concentration of the combined 
compounds 30 µM. Identical binding affinity is therefore observed with all the 
compounds. Consequently, it is difficult to prove that the two unlinked monomers form 
a covalent H-pin structure, and do not just bind in a 2:1 motif. Unlike f-IPI and its 
analogues f-IP(C3NH2)I and f-IP(C3Cl)I, the two different pendant reactive groups (-
C3CN and -C3N3), retain the same DNA binding affinity as the parent compound f-PIP. 
In this case, the pendant groups are on the first heterocycle of f-PIP adjacent to the 
formamido group suggesting that modification at this position does not affect binding 
affinity.  
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C 
Topo IIα promoter 
 
 
Figure 3.4 A, Chemical structures of f-P(C3CN)IP and f-P(C3N3)IP, and reactive groups 
(red) of the two monomer polyamides designed to form H-pin structure through a 
dipolar cycloaddition reaction. B, Binding models of  f-P(C3CN)IP, f-P(C3N3)IP and 
potentially formed hybrid at the 5’-TACGAT-3’ site (5’-flank of ICB2). ICB2 labeled.  
C, The 496bp topo IIα promoter. The bottom strand is 5’-labelled with 32P. The ICB1, 
ICB2, ICB3, and ICB4 sites are indicated. ICB1, 5’-CAGGGATTGGCTGG-3’; ICB2, 
5’-CTACGATTGGTTCTT-3’; ICB3, 5’-ACCTGATTGGTTTAT-3’; ICB4, 5’-
TTCTCATTGGCCAGA-3’. DNA binding sites are labeled with blue color. 
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C                                                          D   
 
Figure 3.5 DNase I footprinting was performed with a radiolabeled probe 
corresponding to the topo IIα promoter. The probe was incubated with increasing 
concentrations of f-PIP (A), f-P(C3CN)IP (B), f-P(C3N3)IP (C) and combination of f-
P(C3CN)IP and f-P(C3N3)IP (D), respectively (0.3-300 µM).  
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3.2.3 DNA sequence specific binding of f-IP(C3N3)I, f-PP(C3-alkyne)P, 
and their combination 
The combination of two polyamide monomers f-IP(C3N3)I and f-PP(C3-alkyne)P can 
potentially form an H-pin heterodimer and therefore target a new binding site, as the 
heterodimer has a cognate sequence different to those of the two monomers as 
illustrated in Figure 3.6A. The chemical structures of f-IP(C3N3)I and f-PP(C3-alkyne)P 
and their binding models are shown in Figure 3.6A&B. DNase I footprinting was 
performed to assess the DNA sequence selectivity and binding affinity of f-IP(C3N3)I, f-
PP(C3-alkyne)P, and their combination using a 136bp base pair 5’-[32P]-radiolabeled 
fragment (Figure 3.6C) containing the corresponding cognate sequences 5’-ACGCGT-
3’, 5’-AAATTT-3’, and 5’-WCWCWW-3’ (where W is A or T), respectively. The 
autoradiogram depicted in Figure 3.7A indicates that binding of f-IP(C3N3)I to its 
cognate sequence 5’-ACGCGT-3’ is initially observed at 5 µM while nonspecific 
binding begins to appear at the 5’-ACTCAT-3’, 5’-ACACTT-3’, 5’-TCTCAA-3’ and 
5’-TCACTA-3’ sites at concentrations >20 µM. Cleavage protection at the cognate 
sequence (5’-AAATTT-3’) for f-PP(C3-alkyne)P is observed at 5 µM and nonspecific 
binding occurs at the 5’-ACACTT-3’ (15 µM) and 5’-TCACTA-3’ site (>10 µM) 
(Figure 3.7B). The potential hybrid generates a footprint at 10 µM at the cognate sites 
5’-ACTCAT-3’, 5’-ACACTT-3’, 5’-TCTCAA-3’ and 5’-TCACTA-3’ by adding and 
mixing 5 µM of each polyamides f-IP(C3N3)I and f-PP(C3-alkyne)P to achieve a 10 µM 
final concentration of the combined compound (Figure 3.7C). The hybrid heterodimer 
has a higher binding affinity for the cognate sites 5’-ACTCAT-3’, 5’-ACACTT-3’, 5’-
TCTCAA-3’ and 5’-TCACTA-3’ (10 µM) than either f-IP(C3N3)I or f-PP(C3-alkyne)P. 
These results suggest that the two monomers f-IP(C3N3)I and f-PP(C3-alkyne)P can 
interact to form a heterodimer. 
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DNA fragment Click 6 
 
                                                                         f-IP(C3N3)      f-PP(C3-alkyne)P 
    Primer 19                    cognate site         cognate site 
5’-ACTGTGTCCAGAAAGCCGGCACTCAGCTACAAACGCGTCATCGATCAAATTTGTTCACAGAC 
3’-TGACACAGGTCTTTCGGCCGTGAGTCGATGTTTGCGCAGTAGCTAGTTTAAACAAGTGTCTG 
 
TCATGTCTAGCTACACTTAAGTCTAGTCTCAAGTGTCATCTCACTAGTTCGTCAAGTGGAGCTCT 
AGTACAGATCGATGTGAATTCAGATCAGAGTTCACAGTAGAGTGATCAAGCAGTTCACCTCGAGA 
                                                        Primer 17 
CCTAACCGACTTT-3′ 
GGATTGGCTGAAA-5’-
32
p 
 
Figure 3.6 A, Binding models of f-IP(C3N3)I, f-PP(C3-alkyne)P and potentially formed 
hybrid. B, Chemical structures of f-IP(C3N3)I and f-PP(C3-alkyne)P, and reactive 
groups (red) of the two monomer polyamides designed to form H-pin structure through 
an azide-alkyne Huisgen reaction. C, DNA fragment Click-6. The bottom strand is 5’-
labelled with 
32
P.  DNA cognate sequence binding sites of the hybrid are labeled with 
blue color. 
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Figure 3.7 DNase I footprinting was performed with a radiolabeled probe containing 
the Click-6 sequences. A, B and C, The probe was incubated with increasing 
concentrations of f-IP(C3N3)I (A), f-PP(C3-alkyne)P (B), and their combination (C), 
respectively (0.5-50 µM). Asterisks indicated the concentration of polyamide at which 
cleavage protection is initially observed. The cognate sequence binding sites are 
highlighted by double solid bars. G+A lanes denote the GA nucleotides. 
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3.2.4 DNA sequence specific binding of f-IP(C3-alkyne)I,  f-PP(C3N3)P,  
and their combination  
The chemical structures and the DNA binding models of f-IP(C3-alkyne)I, f-PP(C3N3)P 
and their combination are shown in Figure 3.8A&B. These compounds were designed 
with the same reactive groups alternated, compared to the compounds previously 
presented. As a result, they share the same corresponding cognate sequences 5’-
ACGCGT-3’, 5’-AAATTT-3’, and 5’-WCWCWW-3’ (Figure 3.6C). Figure 3.9A 
indicates that binding of f-IP(C3-alkyne)I to the cognate sequence 5’-ACGCGT-3’ is 
observed at 10 µM and therefore has a two-fold lower binding affinity than f-IP(C3N3)I 
(Figure 3.7A). However, nonspecific binding of f-IP(C3-alkyne)I begins to appear at 30 
µM, indicating this compound’s greater selectivity compared to f-IP(C3N3)I. This result 
suggests that the -C3N3 reactive group attached to the pyrrole group of f-IPI has a better 
binding affinity for the cognate site 5’-ACGCGT-3’ compared to that of the -C3-alkyne 
reactive group, but reduces the DNA sequence selectivity. Cleavage protection at the 
cognate sequence (5’-AAATTT-3’) for f-PP(C3N3)P is observed at 5 µM while non-
specific binding occurs at the 5’-ACACTT-3’ and 5’-TCACTA-3’ sites at ~10 µM 
(Figure 3.9B).  The -C3N3 reactive group attached to the middle pyrrole of f-PPP shows 
a similar binding affinity for the cognate site 5’-AAATTT-3’ at ~5 µM, as the -C3-
alkyne reactive group, while also sharing a similar pattern of non-specific binding to the 
5’-ACACTT-3’ and 5’-TCACTA-3’ sites at concentrations >10 µM (Figure 3.7B and 
3.9B). The combination of f-IP(C3-alkyne)I and f-PP(C3N3)P produces clear footprints  
(15-20 µM ) at the cognate sequences 5’-ACTCAT-3’, 5’-ACACTT-3’, 5’-TCTCAA-3’ 
and 5’-TCACTA-3’ by adding and mixing equimolar concentration of each polyamides 
f-IP(C3-alkyne)I or f-PP(C3N3)P to achieve the final concentration of the combined 
compound (Figure 3.9C). The potential hybrid shows a higher binding affinity for the 
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cognate sites 5’-ACTCAT-3’ and 5’-TCTCAA-3’ at concentrations >15 µM than either 
of the parent compounds f-IP(C3-alkyne)I or f-PP(C3N3)P. However, binding at the 5’-
ACGCGT-3’ and 5’-AAATTT-3’ sites are still observed at 15µM and 10µM 
respectively. This study suggests that the combination of f-IP(C3-alkyne)I and f-
PP(C3N3)P could form a heterodimer, yet both heterodimer and homodimer mixtures of 
the two compounds are evident. 
 
The pendant reactive group -C3N3 on the central pyrrole of f-IPI shows a higher DNA 
binding affinity but less selectivity than the -C3-alkyne group, while no DNA binding 
affinity and selectivity differences are observed with the same pendant reactive groups 
when attached to the central pyrrole of f-PPP. The combination of f-IP(C3N3)I and f-
PP(C3-alkyne)P exhibits a higher binding affinity than the combination of f-IP(C3-
alkyne)I and f-PP(C3N3)P but with a similar selectivity, suggesting that -C3N3 reactive 
group on the central pyrrole of f-IPI contributes more binding affinity to the 
heterodimer.  
A 
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Figure 3.8 A, Chemical structures of f-IP(C3-alkyne)I and f-PP(C3N3)P, and reactive 
groups (red) of the two monomer polyamides designed to form H-pin structure by an 
azide-alkyne Huisgen reaction. B, Binding models of f-IP(C3-alkyne)I, f-PP(C3N3)P and 
potentially formed hybrid. 
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Figure 3.9  DNase I footprinting was performed with a radiolabeled probe containing 
the Click-6 sequences. A, B and C, The probe was incubated with increasing 
concentrations of f-IP(C3-alkyne)I (A), f-PP(C3N3)P (B), and their combination (C)，
respectively (0.5-50 µM). Asterisks indicated the concentration of polyamide at which 
cleavage protection is initially observed. The cognate sequence binding sites are 
highlighted by double solid bars. G+A lanes denote the GA nucleotides. 
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3.2.5 DNA sequence specific binding of PPI-b-NH2, PPP-Benz-NO2, 
and their combination 
The aim of this experiment was to further probe the binding of the combination of two 
polyamide monomers, which in this case can potentially form a hairpin structure by the 
connection between ‘Head’ and ‘Tail’ groups of the two monomer polyamides. This 
time the two monomers should form heterodimers and therefore target a different 
cognate sequence-binding site compared to that of the parent compound homodimer. 
The chemical structures and DNA sequence binding models of PPI-b-NH2, PPP-Benz-
NO2 and their combination are shown in Figure 3.10A&B. The cognate sequences of 
PPI-b-NH2, PPP-Benz-NO2, and the combination of PPI-b-NH2 and PPP-Benz-NO2 are 
5’-AGACA-3’, 5’-AAATT-3’ and 5’-AGATA-3’, respectively (Figure 3.10C). The 
combination of PPI-b-NH2, and PPP-Benz-NO2 can potentially form a hairpin 
heterodimer through an acyl transfer reaction (Figure 3.10A), and thus target a new 
sequence 5’-AGATA-3’ (described in Figure 3.10B). The autoradiogram given in 
Figure 3.11A reveals no significant specific binding of PPI-b-NH2 for its cognate 
sequence at concentrations up to 50 µM and non-specific binding occurs at 100 µM. 
This was consistent with the binding pattern of the combination of PPI-b-NH2 and PPP-
Benz-NO2 (Figure 3.11C). No significant specific binding of PPP-Benz-NO2 for its 
cognate sequence appeared at concentrations <10 µM and non-specific binding occurs 
at >30 µM (Figure 3.11B).  
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C 
DNA fragment HMC-click  
           Primer 19      
5’-CTGTCCAGAAAGCCGGCACTCAGTCTACAAATAGATCATCTTGATCATATATGTTCACAG 
3’-GACAGGTCTTTCGGCCGTGAGTCAGATGTTTATCTAGTAGAACTAGTATATACAAGTGTC 
 
PPI-b-NH2                         Hairpin                              PPP-Benz-NO2 
Cognate site   Cognate site   Cognate site                     
AGACATCTCTAGATCTAGATATAACTCTAGTAAATTTCTTCAAGCAAGTGGAGCTCTCCTAACC 
TCTGTAGAGATCTAGATCTATATTGAGATCATTTAAAGAAGTTCGTTCACCTCGAGAGGATTGG 
                                                   Primer 17 
GAC-3′ 
CTG-5’-32P 
Figure 3.10 A, Chemical structures of PPI-b-NH2 and PPP-Benz-NO2, and ‘Head’ and 
‘Tail’ groups of the two monomer polyamides designed to form Hairpin structure 
through an acyl transfer reaction. B, Binding models of  PPI-b-NH2 and PPP-Benz-NO2 
and potentially formed hybrid at the respective 5’-AGACA-3’, 5’-AAATT-3’ and 5’-
AGATA-3’ sites. C, DNA fragment HMC-click. The bottom strand is 5’-labelled with 
32
P.  DNA binding sites are labeled with blue color. 
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Figure 3.11 DNase I footprinting was performed with a radiolabeled probe containing 
the HMC-click sequences. The probe was incubated with increasing concentrations of 
PPI-b-NH2 (A), PPP-Benz-NO2 (B), and their combination (C), respectively (0.1-100 
µM).  
 
 
 
 
 
 
 
 
123 
 
3.3 Discussion  
In the early studies of DNA-small molecule complexes, a large number of minor groove 
binders were synthesized based on netropsin and distamycin A (Pelton and Wemmer, 
1989, 1990; Wemmer et al., 2000). The discovery that distamycin A could form an 
antiparallel dimer in the minor groove of some AT sequences initiated the rational 
design of the original DNA sequence reading polyamides (Lown et al., 1993; Lee et al., 
1993; Dervan and Burlii, 1999). The Dervan group formulated a set of rules for Watson-
Crick base pair recognition by the dimer motif as described in the introduction (White 
and Dervan, 1997; Dervan and Burlii, 1999). A wide range of synthetic monomer 
polyamides and covalently linked dimers have been synthesized over the years offering 
a paradigm for the development of small molecules for sequence specific recognition of 
DNA. Such sequence-reading polyamides have the potential to be used as gene control 
agents by inhibition of native transcription factors at the predetermined site (Dervan et 
al., 2003). 
 
The study of the interaction of the formamido-imidazole-pyrrole-imidazole (f-IPI) 
compound to its cognate sequences (5’-ACGCGT-3’) has shown the enhanced DNA 
binding affinity of this polyamide compared to its non-formamido equivalent (PIPI), 
attributed to the formamido group (Brown et al., 2008). This is not surprising since the 
formamido group is known to confer enhanced DNA binding affinity. However, the 
formamido bearing monomers may also bind in a mixed 2:1 and 1:1 fashion, which can 
reduce the overall binding affinity. Hairpin and H-pin analogues have been designed 
and synthesized to ensure the equivalent of the 2:1 binding mode, but the size of these 
compounds results in poor cellular uptake, thus limiting their development (Best et al., 
2003; Dickinson et al., 2004; Franks et al., 2010).  
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To investigate the influence of the size of the Hairpin and H-pin polyamides on their 
cellular uptake and nuclear localization, we have developed a new class of unlinked 
precursors that contain appropriately designed pendant reactive and biocompatible 
functional groups. An orthogonally positioned diamino polyamide f-IP(C3NH2)I, in 
which P-C3NH2 is the N-(3-aminopropyl)pyrrole moiety, was designed to interact with 
f-IP(C3Cl)I, in which P-C3Cl is the N-(3-chloropropyl)pyrrole moiety, with the potential 
to produce in situ an H-pin molecule through a nucleophilic substitution reaction 
(Figure 3.2A). The DNase I footprinting experiments demonstrated that f-IP(C3NH2)I 
has the same binding affinity for the cognate site (5’-ACGCGT-3’) as f-IPI (Figure 
3.3A&B). Surface plasmon resonance (SPR) experiments, however, showed that the 
diamino polyamide displays a binding constant of 2.4 × 10
8 
M
-1
 for the cognate 
sequence 5’-ACGCGT-3’, which is 4 times higher than that of its monoamino 
counterpart f-IPI (5.4 × 10
7
 M
-1
) (Satam et al., 2012). The sequence specificity of f-
IP(C3NH2)I was found to be comparable to that of f-IPI. In addition, incorporation of 
the aminopropyl group in the polyamide backbone of f-IP(C3NH2)I offers a significant 
benefit over its monomer triamide f-IPI in terms of enhanced water solubility. In 
contrast, the chloro containing polyamide f-IP(C3Cl)I possesses a reduced DNA binding 
affinity for the cognate sequence 5’-ACGCGT-3’ (1 µM) (Figure 3.3C). When 0.025 
µM of f-IP(C3NH2)I was mixed with 0.025 µM of f-IP(C3Cl)I, their combination's 
binding, as detected by the onset at a footprint, occurs at 0.05 µM (Figure 3.3D). When 
f-IP(C3NH2)I was used alone, it also produced a footprint at 0.05 µM. The question 
raised from these results is how f-IP(C3NH2)I when used at half the concentration 
(0.025 µM) in combination with f-IP(C3Cl)I (0.025 µM), which has a lower binding 
affinity, produces the same results (i.e cleavage inhibition) at 0.05 μM as when f-
IP(C3NH2)I is used alone at double the concentration (0.05 μM). One possibility is that 
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f-IP(C3NH2)I does react with f-IP(C3Cl)I to form a favorable H-pin compound, which 
can compensate for the lower binding affinity of f-IP(C3Cl)I in the in situ reaction. 
However, it is difficult to prove whether the stable 2:1 complex is covalently formed 
with just the DNase I footprinting analysis.  
 
An orthogonally positioned azido polyamide f-P(C3CN)IP, in which P-C3CN is the N-
(3-cyanopropyl)pyrrole moiety, was designed to potentially react with f-P(C3N3)IP, in 
which P-C3N3 is the N-(3-azidopropyl)pyrrole moiety, with the potential to produce in 
situ a homodimer H-pin molecule through a dipolar cycloaddition reaction (Figure 
3.4A). The DNase I footprinting data show that f-P(C3CN)IP, f-P(C3N3)IP and the 
'combined compound' have the same binding affinity for 5’-TACGAT-3’ (5’-flank of 
ICB2) site, however again this cannot prove whether any binding occurs as a true H-pin 
or just in a 2:1 motif (Figure 3.5). It is clear, however, that the position of the pendant 
reactive groups, in this case on the heterocycle adjacent to the formamido group, does 
not significantly alter the ability to form dimer complexes in situ.  
 
One limitation of these experiments is that the individual polyamide and resulting 
potential combined molecule target the same DNA sequence, making quantification of 
the different binding possibilities impossible.   
 
The study of heterodimer formation therefore was investigated. An orthogonally 
positioned azide polyamide f-IP(C3N3)I, in which P-C3N3 is the N-(3-
azidopropyl)pyrrole moiety, was designed to react with f-PP(C3CH)P, in which P-C3CH 
is the N-(3-alkynopropyl)pyrrole moiety, with the potential to produce in situ a 
heterodimer H-pin molecule through an azide-alkyne Huisgen reaction (Figure 3.6B). 
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The hybrid heterodimer H-pin structure potentially formed by the combination of f-
IP(C3N3)I and f-PP(C3CH)P targets the new sequence 5’-WWCWW-3’, which differs 
from the parent compounds. The DNase I footprinting experiments showed that the 
combination of polyamides does target the cognate sequences 5’-ACTCAT-3’, 5’-
ACACTT-3’, 5’-TCTCAA-3’, 5’-TCACTA-3’, with higher binding affinity than either 
f-IP(-C3N3)I or f-PP(-C3CH)P alone (Figure 3.7A-C). These results suggest that the two 
monomers f-IP(C3N3)I and f-PP(C3CH)P can interact in situ to form a heterodimer.  
 
Alternating the reactive groups between f-IPI and f-PPP [f-IP(C3CH)I and f-PP(C3N3)P] 
was also tested by DNase I footprinting (Figure 3.9). The data showed that the 
combination of f-IP(C3CH)I and f-PP(C3N3)P targets the same cognate sequences 5’-
ACTCAT-3’, 5’-ACACTT-3’, 5’-TCTCAA-3’, 5’-TCACTA-3’ as the combination of 
f-IP(C3N3)I and f-PP(C3CH)P. However, in this case the hybrid polyamide f-IP(C3CH)I 
and f-PP(C3N3)P binds with a higher affinity than the monomers only at the 5’-
ACTCAT-3’ and 5’-TCTCAA-3’ sites (Figure 3.9). Although these results are 
encouraging and clearly demonstrate that the orthogonally positioned pendant groups 
can allow in situ interaction of both homodimer and heterodimer polyamides, 
footprinting analysis does not confirm the formation of proposed covalent H-pins. It is 
clear that the different pendant reactive groups, in this case on the central pyrrole of f-
IPI, can influence DNA binding affinity. However, there is no alteration of binding 
affinity found in f-PPP analogues f-PP(C3CH)P and f-PP(C3N3)P.  
 
The study of heterodimer hairpin formation was also investigated. PPI-b-NH2 and PPP-
Benz-NO2 were designed to potentially form a hairpin heterodimer through an acyl 
transfer reaction (Figure 3.10A). In this case the resulting combined compound would 
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target the new sequence 5’-AGATAT-3’. However, these compounds failed to show 
any significant binding up to 30 μM for their respective cognate sequences (Figure 
3.11). 
 
Overall, the resulting H-pin homodimer targets the same cognate sequence as its parent 
compounds, thus causing quantification of the different binding possibilities impossible. 
In contrast, the resulting heterodimer targets a different cognate sequence compared to 
its parent compounds, therefore solving the previous problem and allowing to identify 
the H-pin formation. However, DNA footprinting analysis is not enough to determine 
how the H-pin structure is formed (e.g. covalently), so further investigation is required 
using other techniques such as mass spectrometry.  
 
Only the additional amino group among the pendant reactive groups on the selected 
polyamides showed a slightly enhanced binding affinity compared to the respective 
parent compounds. Therefore, the study of positioning the additional amino group at 
different sites of the polyamides was carried out and will be discussed in the chapter 4.      
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CHAPTER 4 
EVALUATION OF NOVEL POLYAMIDES ON DNA 
BINDING AFFINITY, SPECIFICITY AND SEQUENCE 
RECOGNITION 
4.1 Introduction 
The modification of novel polyamides needs to be further studied with the aim of the 
newly synthesized polyamides possessing excellent sequence specificity, stronger 
binding affinity, high solubility in biological media and enhanced cell penetration and 
nuclear localization properties. It has been previously reported that pyrrole-imidazole-
containing polyamides with multiple cationic groups exhibit binding affinity for A/T 
rich sequences due to attraction to the negative molecular electrostatic potential in the 
minor groove of A/T rich sequences (Nickols et al. 2007; Edelson et al., 2004). In 
addition, Satz and Bruice showed that polyamides containing a pyrrole-N1-alkyl 
spermine/spermidine group target A/T rich sequences and bind with high affinity (Satz 
and Bruice, 2002). These polyamides effectively inhibit transcription factors bound to 
dsDNA compared to other minor groove binders lacking an alkyl-multiamino side 
chain. It was suggested that the additional cationic groups were attracted to the 
negatively charged phosphodiester groups of DNA (Satam et al., 2012). An 
orthogonally positioned diamino polyamide f-IP(C3NH2)I was synthesized and 
demonstrated an increased DNA binding affinity over its monoamino/monocationic 
counterpart f-IPI by DNA footprinting as shown in Chapter 3. F-IP(C3NH2)I also 
exhibits a four-fold higher binding constant than f-IPI by surface plasmon resonance 
(SPR) studies (Satam et al., 2012). The sequence specificity of f-IP(C3NH2)I was found 
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to be comparable to that of f-IPI (Chapter 3).  Incorporation of the second amino group 
in f-IP(C3NH2)I also offers a significant benefit over f-IPI in terms of increased water 
solubility. In order to investigate the benefits of having a second positively charged 
group in the form of an orthogonally positioned alkylammonium side chain, the diamino 
compounds f-I(C3NH2)PI, f-P(C3NH2)IP, f-IP(C3NH2) P and Phenyl-IP(C3NH2)I were 
synthesised.  
 
The pyrrole (P) heterocyclic moieties in distamycin stack as a 2:1 antiparallel dimer in 
the DNA minor groove and can bind indiscriminately to an A/T or a T/A base pair 
(Wade et al., 1992; 1993; Pelton and Wemmer, 1990). Alternatively, an imidazole (I) 
heterocycle moiety can be paired opposite a pyrrole to selectively target a G/C base pair 
(Kopka et al., 1985). In addition, 3-hydroxy-1H-pyrrole (Hp) has been paired opposite P 
and shown to selectively target T/A base pairs but with a significant loss in binding 
affinity. The bulky hydroxyl group on an Hp-containing polyamide (which forms an 
additional hydrogen bond to the O-2 group of thymine), makes the 2:1 complex formed 
in the minor groove sterically encumbered leading to unfavorable binding (Kielkopf et 
al., 2000). Accordingly, the additional hydrogen bonding to thymine O-2 could be 
critical for distinguishing A/T from T/A. We envisaged that a polyamide containing a 
reversed conformation P moiety [P(H) or 2,5-linked N-methylpyrrole-2-carboxamide] 
stacked over a polyamide containing P [P(H)/P] may recognize a T/A base pair. In an 
attempt to test this hypothesis, our collaborator Dr Moses Lee synthesized two 
polyamides PPPP(H)-N-dimethyl-3-aminopropylamine and IPPP(H)-N-dimethyl-3-
aminopropylamine. The new molecules incorporated only one P(H) moiety into each 
polyamide, as previous studies have shown that incorporation of multiple 2,5-linked 
(Marques et al., 2002) or 2,4-linked P(H) units may result in a loss in sequence 
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specificity, thus allowing for an increased tolerance of G/C base recognition (Bremer et 
al., 2000). 
 
Over the past decade, the development of DNA recognition elements that exhibit 
fluorescence while maintaining high sequence specificity and binding affinity has been 
demanding. Such compounds would provide an intrinsic probe for monitoring the 
cellular uptake of the molecule and ultimately the binding to nuclear DNA. The 
incorporation of fluorescent dyes such as thiazole orange, fluorescein and bodipy on 
hairpin polyamides exhibited fluorescence while maintaining a high degree of DNA 
binding affinity and specificity (Fechter et al., 2005; Best et al., 2003; Belitsky et al., 
2002). However, limited nuclear localization of such dye-containing hairpin polyamides 
restricted their usefulness. In addition, the behavior of the nonfluorescing hairpins did 
not always mimic that of its fluorescing counterpart (Chavda et al., 2011). Therefore, 
polyamide fluorophores are needed with enhanced cell and nuclear penetration abilities. 
 
The bis-benzimidazole fluorophores, such as bisbenzimide or Hoechst 33258, are 
known to selectively recognize A/T-rich sequences in the DNA minor groove and are 
capable of crossing certain cellular and nuclear membranes (White et al., 2001). On the 
basis of the sequence specificity and high affinity of the formamido-containing 
polyamides for the minor groove as ascertained from previous studies (Brown et al., 
2007; Buchmueller et al., 2005; Le et al., 2005; Liu and Wilson, 2010), our group 
envisioned the incorporation of the p-anisylbenzimidazolecarboxamido (Hx) moiety of 
Hoechst 33258 attached to imidazole pyrrole heterocyclic units (Chavada et al., 2011). 
Therefore, Hx-containing compounds were designed, synthesized and evaluated.  
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Chapter aims: 
The aim of this part of the study was therefore to contribute to the development of novel 
polyamides by evaluating 1) whether an additional amino group on polyamides can 
increase DNA binding affinity and specificity; 2) a binding preference of a P/P(H) 
pairing and a I/I(H) pairing; 3) binding characteristics of HxPI.  
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4.2 Results 
4.2.1 DNA sequence specific binding of mono- and diamino- 
polyamides: f-I(C3NH2)PP, f-P(C3NH2)IP and f-IP(C3NH2)P 
As shown in section 3.2.1, the monoamino polyamide f-IPI has a slightly lower binding 
affinity for the cognate sequence than its diamino counterpart f-IP(C3NH2)I but shows 
much higher binding affinity than its chloro counterpart f-IP(C3Cl)I. The presence of a 
second amino group improves the water solubility of f-IPI without compromising its 
DNA sequence selectivity encouraging us to further investigate the effect of an 
additional amino group on the polyamides.  
 
The chemical structure and DNA binding model for f-I(C3NH2)PI are shown in Figure 
4.1. DNase I footprinting studies were performed using a 125 bp 5'-[
32
P]-radiolabeled 
engineered DNA fragment containing the DNA sequences 5'-ACGCGT-3', 5'-
ACCGGT-3', 5'-AAATTT-3' and 5'-ACACGT-3'. The results depicted in Figure 4.2A 
provide direct evidence of footprinting at the cognate site 5'-ACGCGT-3' emerging at 
0.05 μM and becoming strong at 0.1 μM. In contrast, no footprint at the other three non-
cognate sites was apparent. However, f-IP(C3NH2)I shows a clear footprint at the non-
cognate sites 5'-ACCGGT-3' and 5'-ACACGT-3' at 1 μM (Figure 3.3B). These results 
therefore demonstrate an enhanced sequence specificity of f-I(C3NH2)PI for its cognate 
sequence over its isomer f-IP(C3NH2)I. The onset of a footprint at the cognate site 5'-
ACGCGT-3' for f-I(C3NH2)PI (0.05-0.10 μM) (Figure 4.2A) was slightly higher than 
that for f-IP(C3NH2)I (strong at 0.05 μM) (Figure 3.3B), suggesting a slightly reduced 
binding affinity (Satam et al., 2012). In Figure 3.3A, f-I(C3NH2)PI shares a similar 
binding affinity and sequence specificity to f-IPI. The binding affinities varied 
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according to the order: f-IP(C3NH2)I > f-IPI = f-I(C3NH2)PI, suggesting that the second 
amino group on the different positions can affect binding affinity, thus its position 
within the polyamide is important.  
 
A 
 
B 
 
Figure 4.1 A, Chemical structures of f-I(C3NH2)PI. B, Binding model of f-I(C3NH2)PI  
at the sequence 5'-ACGCGT-3' 
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A 
 
Figure 4.2 DNase I footprinting was performed with a radiolabeled probe containing 
the IM17/19 DNA sequences. The probe was incubated with increasing concentrations 
of f-I(C3NH2)PI (A) (0.01-1 µM). Asterisks indicated the concentration of polyamide at 
which cleavage protection is initially observed. The cognate sequence binding sites are 
highlighted by double solid bars. G+A lanes denote the GA nucleotides. 
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The chemical structures and DNA binding models for f-P(C3NH2)IP and f-IP(C3NH2)P 
are shown in Figure 4.3 and 4.5. The DNA sequence selectivity and binding affinity of 
the monoamino polyamide f-PIP and its diamino analogue f-P(C3NH2)IP, as well as the 
monoamino polyamide f-IPP and its diamino counterpart f-IP(C3NH2)P were 
investigated by DNase I footprinting using a 496bp (described in Figure 3.4C) and a 
127bp 5'-[
32
P]-radiolabeled DNA fragment, respectively (Figure 4.5C). The DNA 
sequence specificity of f-IPP and f-IP(C3NH2)P for the cognate site 5’-ATGCAT-3’, 
and the non cognate GC-rich 5’-ACGCGT-3’, AT-rich site 5’-AAATTT-3’ and 5'-
ACTAGT-3' sites were examined and are presented in Figure 4.5 and Figure 4.6. 
 
The autoradiogram depicted in Figure 4.4A shows that f-P(C3NH2)IP produces a 
footprint at the 5’-TACGAT-3’ site (5’-flank of ICB2) beginning at 10 μM, having a 3-
fold higher binding affinity than the monoamino parent compound f-PIP. Both 
compounds exhibit similar sequence specificity for the ICB2 flank site. The 
autoradiogram depicted in Figure 4.6A indicates that binding of f-IPP to the 
corresponding cognate sequence 5'-ATGCAT-3' is initially observed at 3 μM, which 
presents a 3-fold lower binding affinity than its diamino counterpart f-IP(C3NH2)P. 
However, extensive non-specific binding of f-IP(C3NH2)P is observed at concentrations 
>1.5 μM, indicating poor DNA sequence selectivity especially when compared to f-IPP, 
which shows some degree of selectivity towards 5'-ACTAGT-3' . 
 
The footprinting results of the diamino polyamides f-P(C3NH2)IP and f-IP(C3NH2)P 
show better binding affinity than their respective monoamino counterparts due to the 
presence of the additional amino group. 
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A 
 
B 
 
Figure 4.3 A, Chemical structures of f-P(C3NH2)IP. B, Binding model of f-P(C3NH2)IP  
at the 5’-TACGAT-3’ site (5’-flank of ICB2 in the human topo IIα promoter). ICB2 
labeled in the red box.  . 
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A                                                          B 
 
 
Figure 4.4 DNase I footprinting was performed with a radiolabeled probe containing 
the 496bp topo IIα promoter. The probe was incubated with increasing concentrations of 
f-PIP (A) and f-P(C3NH2)IP (1-300 μM) (B). Asterisks indicated the concentration of 
polyamide at which cleavage protection is initially observed. The cognate sequence 
binding sites are highlighted by double solid bars.  
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B 
 
C       Primer 19 
5’-CTGTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCATGCATGTTCACAG 
3’-GACAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTACGTACAAGTGTC 
AAATTTCTCTAGATCTACACGTAACTCTAGTACTAGTCTTCAAGCAAGTGGAGCTCTCCTAACC 
TTTAAAGAGATCTAGATGTGCATTGAGATCATGATCAGAAGTTCGTTCACCTCGAGAGGATTGG                                                                                                                           
                                              
GAC-3′ 
CTG-5’-32p 
Primer 17 
Figure 4.5 A, Chemical structures of f-IPP and f-IP(C3NH2)P. B, Binding model of f-
IP(C3NH2)P. C, DNA fragment IM18/20. The bottom strand is 5’-labelled with 
32
P.  
DNA cognate and non-cognate sequence binding sites are labeled with red color and 
blue color, respectively.  
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A                                                                                    B 
 
Figure 4.6  DNase I footprinting was performed with a radiolabeled probe containing 
the IM18/20 DNA sequences. The probe was incubated with increasing concentrations 
of f-IPP (A) and f-IP(C3NH2)P (B), respectively (0.1-50 μM). Asterisks indicated the 
concentration of polyamide at which cleavage protection is initially observed. The 
cognate sequence binding sites are highlighted by double solid bars. Control DNA lanes 
lack DNase I treatment and G+A lanes denote the GA nucleotides. 
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4.2.2 DNA binding studies of mono- and diamino non-formamido 
polyamides- Phenyl-IPI and Phenyl-IP(C3NH2)I 
The chemical structures and the DNA binding models of the polyamides Ph-IPI and Ph-
IP(C3NH2)I are shown in Figure 4.7. The sequence selectivity and binding affinity of 
the monoamino polyamide Ph-IPI and its diamino counterpart Ph-IP(C3NH2)I were 
investigated by DNase I footprinting using a 127bp 5'-[
32
P]-radiolabeled DNA fragment 
containing the shared cognate sequence 5'-ACGCGT-3', and the non-cognate 5'-
ACCGGT-3', 5'-ACACGT-3' and 5'-AGCGCT-3' control sites (described in Figure 
3.2C). The autoradiogram depicted in Figure 4.8A shows that Ph-IPI produces a 
footprint at the 5'-ACGCGT-3' site at 20 μM, and no other footprints are apparent even 
at 100 μM. The results for the diamino polyamide Ph-IP(C3NH2)I demonstrate markedly 
superior binding affinity compared to Ph-IPI. The footprint at 5'-ACGCGT-3' for the 
diamino polyamide Ph-IP(C3NH2)I emerges at 0.5 μM, representing a 40-fold higher 
binding affinity compared to that of the parent polyamide Ph-IPI (Figure 4.8A) (Satam 
et al., 2012). Overall, the gain in the DNA binding affinity of Ph-IP(C3NH2)I over Ph-
IPI is achieved without compromising the DNA sequence selectivity, suggesting that the 
second amino group can enhance DNA binding affinity, particularly in the non-
formamido containing polyamides.   
 
In the DNA footprinting analysis, Ph-IPI shows an increased sequence specificity but 
with a 400-fold lower binding affinity compared to f-IPI (Figure 3.3A and Figure 4.8A). 
This is not surprising since the formamido group is known to confer enhanced binding 
affinity (Lacy et al., 2002; Buchmueller et al., 2005).  
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B 
 
 
Figure 4.7 A, Chemical structures of Ph-IPI and Ph-IP(C3NH2)I. B, Binding model of 
Ph-IP(C3NH2)I. 
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A                                                                                       B                        
 
Figure 4.8  DNase I footprinting was performed with a radiolabeled probe containing 
the IM17/19 DNA sequences. The probe was incubated with increasing concentrations 
of Ph-IPI (A) and Ph-IP(C3NH2)I (B) (0.01-100 μM). Asterisks indicated the 
concentration of polyamide at which cleavage protection is initially observed. The 
cognate sequence binding sites are highlighted by double solid bars respectively. G+A 
lanes denote the GA nucleotides.  
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4.2.3 DNA sequence specific binding of Pyrrole(H) based polyamides 
Two polyamides PPPP(H)-N-dimethyl-3-aminopropylamine (PPPX) and IPPP(H)-N-
dimethyl-3-aminopropylamine (IPPX) designed to test the binding preference of a P/P 
(H) pairing [P/X] and a I/P(H) pairing [I/X]. The chemical structure and the DNA 
binding models for the polyamides PPPX and IPPX are shown in Figure 4.9. DNase I 
footprinting experiments were performed using a 127bp 5`-[
32
P]-radiolabelled DNA 
fragment containing the following sequences: 5`-AAATTT-`3; 5`-ATATAT-`3; 5`-
ACATGT-`3; 5`-AGATCT-`3 and 5`-AGAGCT-`3 (Figure 4.9C). The autoradiogram 
shown in Figure 4.10A shows that PPPX exhibits good sequence specificity for the 
A3T3 sequence and a clear footprint appears at 20 μM. PPPX displays negligible binding 
to 5`-ATATAT-`3 as shown by the appearance of a weak footprint at 100 μM. In 
contrast, IPPX shows better binding towards the sequences tested but poorer DNA 
sequence selectivity. The autoradiogram indicates that for IPPX, there is some binding 
to the 5`-AAATTT-`3, 5`-ATATAT-`3, 5`-AGATCT-`3 and 5`-ACATGT-`3 sites at 
concentration ~6 μM, indicative of poor sequence selectivity, in contrast to PPPX which 
shows some degree of sequence selectivity towards A3T3 DNA but with lower binding 
affinity. This study therefore shows that PPPX containing the P/X pairing has a weaker 
binding affinity for its cognate sequences but retains some DNA sequence selectivity as 
observed in DNase I footprinting studies. PPPX reveals no preference for T/A over A/T 
base pairs. In contrast, IPPX containing an I/X pairing indicates no preference towards 
G/C over C/G base pairs (Chavda et al., 2010). 
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C 
          Primer 19 
5’-CTGTCCAGAAAGCCGGCACTCAGTCTACAAAAATTTCATCTTGATCATATATGTTCACAG 
3’-GACAGGTCTTTCGGCCGTGAGTCAGATGTTTTTAAAGTAGAACTAGTATATACAAGTGTC 
 
AGCTCTCTCTAGATCTAGATCTAACTCTAGTACATGTCTTCAAGCAAGTGGAGCTCTCCTAACC 
TCGAGAGAGATCTAGATCTAGATTGAGATCATGTACAGAAGTTCGTTCACCTCGAGAGGATTGG 
                                                    Primer 17 
GAC-3′ 
CTG-5’-32P 
 
Figure 4.9 A, Chemical structures of PPPX and IPPX. B, DNA sequences binding 
models of PPPX and IPPX. C, DNA fragment KM-A used for the footprinting 
experiment. The bottom strand is 5’-labelled with [32P].  DNA cognate and non-cognate 
sequence binding sites are labeled with blue color.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
A                                                                           B 
  
 
Figure 4.10  DNase I footprinting was performed with a radiolabeled probe containing 
the KM-A DNA sequences. The probe was incubated with increasing concentrations of 
PPPX (A) and IPPX (0.5-100 μM) (B). Asterisks indicated the concentration of 
polyamide at which cleavage protection is initially observed. The cognate sequence 
binding sites are highlighted by double solid bars. Control DNA lanes lack DNase I 
treatment and G+A lanes denote the GA nucleotides. 
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4.2.4 DNA Binding Properties of p-Anisylbenzimidazolecarboxamido 
(Hx) imidazole/pyrrole-containing polyamides 
The chemical structure of p-anisylbenzimidazolecarboxamido-pyrrole-imidazole (Hx-
PI) is shown in Figure 4.11A. The proposed DNA binding model was shown in Figure 
4.12B. Hx moiety exhibits fluorescence and thus would provide an intrinsic probe for 
monitoring the cellular uptake of the molecule and ultimately the binding to nuclear 
DNA. Footprinting experiments were performed using a 127bp 5'-[
32
P]-radiolabeled 
DNA fragments containing the following sequences: 5'-TCTTGA-3', 5'-TCTAGA-3' 
and 5'-ACTAGT-3' (Figure 4.11C). The autoradiograms in Figure 4.12A shows binding 
of HxPI at the 5’-ACTAGT-3’ and 5’-TCTTGA-3’ cognate sites at 20 µM. The binding 
to the 5’-TCTAGA-3’ site occurs at a slightly higher concentration (~30 μM) (Figure 
4.12).  
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A 
  
B 
 
C Hx Seq 
Primer 19 
5’-CTGTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCATGCATGTTCACAG 
3’-GACAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTACGTACAAGTGTC 
AAATTTCTCTAGATCTACACGTAACTCTAGTACTAGTCTTCAAGCAAGTGGAGCTCTCCTAACC 
TTTAAAGAGATCTAGATGTGCATTGAGATCATGATCAGAAGTTCGTTCACCTCGAGAGGATTGG                                                                                                                           
                                              
 
GAC-3′ 
CTG-5’-32p 
Primer 17 
Figure 4.11 A, Chemical structure of Hx-PI. B, DNA sequences binding model of HX-
PI. C, DNA fragment Hx Seq. The bottom strand is 5’-labelled with 32P.  DNA 
sequence binding sites are labeled with blue color.  
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Figure 4.12 DNase I footprinting was performed with a radiolabeled probe containing 
the Hx DNA sequences. The probe was incubated with increasing concentrations of Hx-
PI (5-100 μM). Asterisks indicated the concentration of polyamide at which protection 
is initially observed. The cognate sequence binding sites are highlighted by solid bars 
respectively. G+A lanes denote the GA nucleotides.  
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4.3 Discussion 
The polyamide f-IPI has been previously studied (Buchmueller et al., 2006) and in this 
project f-IPI was further modified by the addition of a series of pendant reactive groups 
such as –C3NH2, -C3Cl, -C3N3 and –C3CN on its pyrrole. f-IP(C3NH2)I shows a higher 
DNA binding affinity for the cognate sequence 5’-ACGCGT-3’ than f-IPI (Figure 
3.3A&B). The position of pendant group –C3NH2 was altered and is added on the 
imidazole adjacent to the formamido group. f-I(C3NH2)PI had a similar binding affinity 
to f-IPI (Figure 4.2A) (Satam et al., 2012). The binding affinities varied according to the 
order: f-IP(C3NH2)I > f-IPI = f-I(C3NH2)PI, suggesting that the second amino group can 
affect binding affinity, thus its position within the polyamide is important. However, the 
other f-IPI analogues exhibit at least a 10-fold reduced DNA binding affinity (Figure 
3.3C, Figure 3.7A and Figure 3.9A). Therefore, we focused on investigating the effect 
of the N-(3-aminopropyl) reactive group on a series of polyamides including f-
P(C3NH2)IP and f-IP(C3NH2)P. The DNase I footprinting data showed that the diamino 
polyamides f-P(C3NH2)IP and f-IP(C3NH2)P demonstrate better binding affinity than 
their respective monoamino counterparts (Figure 4.4 and 4.6). The study was further 
extended to explore non-formamido polyamides, including diamino polyamides e.g 
phenyl-IP(C3NH2)I [Ph-IP(C3NH2)I] (Figure 4.8). Compared to its monoamino 
counterpart Ph-IPI, the diamino polyamide Ph-IP(C3NH2)I demonstrated a higher DNA 
binding affinity for the cognate sequence 5’-ACGCGT-3’ (Figure 4.8). In agreement, 
parallel SPR studies showed that the diamino polyamide Ph-IP(C3NH2)I displays a 
binding constant of 1.5 × 10
7 
M
-1
 for the cognate sequence 5’-ACGCGT-3’, which is 
~3-fold higher than that of its monoamino polyamide (4.8 × 10
6
 M
-1
) (Satam et al., 
2012). The side chain of these diamino polyamides is found to offer a significant benefit 
over the monocationic triamide in terms of enhanced water solubility as evidenced by 
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the ease in dissolving diamino polyamide over monoamino polyamide. Overall, it is 
evident that the incorporation of an orthogonally positioned aminopropyl side chain in 
the polyamide backbone can afford favorable physicochemical and DNA binding 
properties.  
 
The novel polyamides containing the 2,5-linked N-methylpyrrole-2-carboxamide, or 
pyrrole(H) [P(H) or X] moiety, were designed. The two polyamides PPPP(H) (PPPX) 
and IPPP(H) (IPPPX) tested the binding preference of a P/X pairing and an I/X pairing. 
Studies utilizing circular dichroism, thermal denaturation, biosensor-surface plasmon 
resonance and the DNase I footprinting (Figure 4.10) show that an I/X pairing prefers a 
G/C or C/G pairing whilst a P/X pairing tolerates A/T or T/A base pairs and avoids a 
G/C base pair  (Chavda et al., 2010). 
 
Our latest efforts include polyamides which exhibit increased fluorescence upon binding 
to DNA. Such compounds provide an intrinsic probe for monitoring the cellular uptake 
of polyamides and ultimately their binding to nuclear DNA. The footprinting results 
showed that Hx-PI binds to the sequence 5’-WCWWGA-3’ (W= A/T), suggesting that 
the Hx moiety behaves as PP or f-P (Figure 4.12A). This is consistent with the finding 
that Hx-PP and Hx-IP bind to their respective DNA sequences as their counterparts 
PPPP and PPIP (Chavda et al., 2011). In addition to the Hx-PP and Hx-IP footprinting, 
complementary biophysical studies (thermal denaturation, circular dichroism and 
surface plasmon resonance) also indicate that the Hx moiety behaves similarly to two 
consecutive pyrrole heterocyclic moieties or formamido-pyrrole. Fluorescence emission 
studies were performed on HxPP and HxIP to confirm the pattern of induced 
fluorescence of the Hx fluorophore upon binding to DNA (Chavda et al., 2011).  .  
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CHAPTER 5 
INVESTIGATION INTO IN VITRO BINDING 
CHARACTERISTICS OF F-IPI AND ITS ANALOGUES TO 
THE HUDBF4 AND THEIR CELLULAR EFFECTS IN 
MDA-MB231 CELLS  
5.1 Introduction 
5.1.1 Protein kinases as drug targets 
5.1.1.1 Protein kinase inhibitors 
Protein phosphorylation caused by protein kinases regulates most aspects of cell life, 
whereas abnormal phosphorylation is a cause or consequence of disease. Protein kinases 
have become the second most intensively pursued class of drug targets after G-protein-
coupled receptors. There are numerous small molecule inhibitors of protein kinases that 
have been approved or are nearing approval for clinical use, mainly for treatment of 
cancer (reviewed in Cohen, 2013, table 5.1). However, other diseases, including 
diabetes, rheumatoid arthritis, neurodegeneration and immunosuppression are also 
linked to the deregulation of protein kinase-meditated cell signalling pathways (Cohen, 
2013).  
 
It was more than 30 years ago when Ray Erikson found that the transforming factor of 
the Rous sarcoma virus was a protein kinase (Collett and Erikson, 1978). In the later 
years, Hiroyoshi Hidaka developed the first protein-kinase inhibitors, Naphthalene 
sulphonamides, which were already used as antagonists of the calcium-binding protein 
 
 
153 
 
calmodulin (Hidaka et al., 1984). However, at higher concentrations they were able to 
inhibit several protein kinases. When the naphthalene ring was replaced by isoquinoline, 
the derivatives lost the calmodulin antagonistic ability, but surprisingly could still act as 
protein kinase inhibitors. Subsequently many other isoquinolinesulphonamides were 
developed with relatively low potency and non-specificity, but only HA1077 (also 
known as AT877 or fasudil hydrochloride) was investigated in human clinical trials in 
the early 1990s and consequently was approved for the treatment of cerebral vasospasm 
after surgery in Japan in 1995 (Shibuya et al., 1992; reviewed in Cohen, 2002). HA1077 
inhibits several protein kinases, such as the RHO-dependent protein kinase ROCK, but 
it is unclear whether its clinical efficacy results from inhibition of this or other protein 
kinases, or whether it is due to a non-kinase effect (Cohen, 2002). In 2009, it was 
demonstrated that peripheral administration of the ROCK inhibitor HA1077 could also 
be used to enhance memory and improve the prognosis of Alzheimers patients 
(Huentelman et al., 2009).  
 
Rapamycin, also known as sirolimus, was first discovered as a product of the bacterium 
Streptomyces hygroscopicus in soil samples from Easter Island and characterized more 
than 40 years ago. It was later developed as an antifungal agent. However, this use was 
terminated when it was discovered to have potent immunosuppressive and 
antiproliferative properties (Garber, 2001). In September 1999, rapamycin was 
approved for clinical use by the FDA as an immunosuppressant drug. 
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Table 5.1 Small molecule inhibitors of protein kinases approved for clinical use or in 
advanced clinical trials (Taken from Cohen, 2013). 
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Rapamycin was the first cytostatic agent to be identified and be approved for clinical 
use that exerts its effects by specifically inhibiting a protein kinase (Davies et al., 2000). 
The intracellular receptor for rapamycin is the FK-binding protein (FKBP) and the 
molecular target of rapamycin-FKBP in yeast was identified as a protein kinase, which 
was termed the 'target of rapamycin' (TOR) by Heitman (Heitman et al., 1991). 
Subsequently the mammalian homologue, called mTOR or the FKBP-rapamycin-
associated protein (FRAP),  was identified and was shown to have an important role in 
the phosphatidylino-3-kinase-dependent signaling pathway that regulates cell-cycle 
progression from G1 to S phase (Neshat et al., 2001; Podsypanina et al., 2001; Ballou 
and Lin, 2008). Dysregulation of the mTOR signaling pathway occurs frequently in a 
variety of human tumors, and thus, mTOR has emerged as an important target for the 
design of anticancer agents. However, rapamycin showed very poor water solubility and 
chemical stability, severely limiting its bioavailability (Huang and Houghton, 2003; 
Huang et al., 2003). Therefore, several rapamycin analogues with better 
pharmacokinetic properties and lower immunosuppressive effects, including 
temsirolimus (CCI-779), everolimus (RAD001), and deforolimus (AP23573), have been 
developed (Ballou and Lin, 2008; Rizzieri et al., 2008). Temsirolimus and everolimus 
were recently approved by the FDA for the treatment of advanced/metastatic renal cell 
carcinoma (Motzer et al., 2008; Hess et al., 2009). 
 
The human genome encodes approximately 518 protein kinases that regulate virtually 
every signal transduction stage through a phosphotransfer cascade: from the receptor 
tyrosine kinases that initiate intracellular signaling, to the kinases that regulate cell cycle 
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and are involved in cellular fate (Cohen et al., 2002; Fabbro et al., 2002; Levitzki et al., 
2003; Zhang et al., 2009).  
 
5.1.1.2 The Cyclin-dependent kinases 
The Cyclin-dependent kinases (CDKs) are serine/threonine protein kinases which 
mediate the cell cycle progression, regulating transition from G1 to S phase and G2 to M 
phase. CDK activity is tightly dependent on binding and activation by cyclins and CDK 
inhibitors (Malumbres, 2005; Malumbres and Barbacid, 2005; Barbacid et al., 2005). A 
subset of CDK-cyclin complexes is directly involved in driving the cell cycle. This 
subset includes: CDK1 which predominantly regulates the transition from G2 to M 
phase, and CDK2/4/6 which regulates the transition from G1 to S phase (Malumbres and 
Barbacid, 2009); CDK7 on the other hand has dual roles as a CDK-activating kinase 
and a regulator of the transcriptional machinery. In addition to cell cycle regulatory 
functions of the CDKs, CDK9 plays a key role in the control of RNA polymerase II-
mediated transcription (Krystof et al., 2010; Krystof and Uldrijan, 2010). CDK 
inhibitors has been considered as relevant drug candidates for cancer therapy owing to 
their potential role in restoring control of the cell cycle (Malumbres et al., 2008; Shapiro 
et al., 2006). A new generation of CDK inhibitors undergoing clinical trials is listed in 
table 5.2 (Malumbres and Barbacid, 2009).  
 
5.1.1.3 Association between the CDKs and Cdc7 kinase 
The highly conserved Cdc7 (cell division cycle 7) kinase, a serine/threonine kinase, is 
essential for cell cycle progression, and has several structure-function connections with 
the CDKs, making it an important target for drug development. 
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Compound Primary 
target(s) 
Clinical trials Sponsor 
AG-024322 CDK1, CDK2 
CDK4 
Phase I, advanced cancer:  
Discontinued (2007) 
Pfizer 
AT-7519 CDK1, CDK2 
CDK4, CDK5 
Phase I/II, advanced or metastatic 
tumours 
Astex 
P276-00 CDK1, CDK4 
CDK9 
Phase I/II, advanced refractory  
neoplasms 
Piramal 
P1446A-05 CDK4 Phase I, advanced refractory  
malignancies 
Piramal 
PD-0332991 CDK4, CDK6 Phase I, advanced cancer Pfizer 
R547 CDK1, CDK2 
CDK4, CDK7 
Phase I, advanced solid tumours Hoffmann
-LaRoche 
Roscovitine CDK2, CDK7 
CDK8, CDK9 
Phase II, non-small cell lung cancer, 
nasopharyngeal cancer, 
haematological tumours 
Cyclacel 
SNS-032 CDK1, CDK2 
CDK4, CDK7 
CDK9 
Phase I, B-lymphoid malignancies  
Phase I, solid tumours 
Sunesis 
 
Table 5.2 Examples of specific CDK inhibitors in clinical trials (single-agent trials) 
adapted from Malumbres and Barbacid, 2009. 
 
5.1.1.3.1 Functional similarities 
Cyclin D/CDK4, cyclin E/CDK2 and cyclin A/CDK2 play important regulatory roles in 
the regulation of the G1/S progression. Activation of these kinases leads to the 
phosphorylation of the retinoblastoma protein (pRb) and its related family members, 
p107 and p130 (Kiess et al., 1995; Paggi et al., 1996; Suzuki-Takahashi et al 1995). 
This phosphorylation releases the E2F transcription factors, inducing the expression of 
other genes required for DNA synthesis (Ohtani et al., 1995). CDK2 and Cdc7, required 
for the CDC45-dependent loading of DNA polymerases, operate in a separate pathway 
to activate the origin replication complexes and progress DNA replication through 
modulation of Mcm2 (Jares et al., 2000; Zou et al., 2000). The CDK2-interacting 
protein (CINP) was proposed to be the functional link between CDK2 and Cdc7 during 
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firing of the origins of replication. CINP is a component of the active cyclin A/Cdk2, 
and also interacts with Cdc7 while it is phosphorylated by Cdc7.  The association of 
CINP with the pre-replicative complex (pre-RC) binds to chromatin in a replication-
dependent manner (Swords et al., 2010; Figure 5.1).  
 
 
 
Figure 5.1 Functional relationship between Cdc7 and CDKs. CINP interacts with both 
Cdk2 and Cdc7 but is phosphorylated only by Cdc7. CINP binds to chromatin in a 
replication-dependent manner, and associates with the Pre-RC. CINP is a part of the 
Cdc7-dependent mechanism of origin firing and becomes a functional and physical link 
between Cdk2 and Cdc7 complexes at these sites on DNA (taken from Swords et al., 
2010). 
 
5.1.1.3.2 Similarities in regulation 
The regulation and activation of the Cdc7 kinase is similar to that of the CDKs by their 
cyclin partners. In general, cyclins are unstable, appearing briefly in the cell cycle and 
regulating CDKs activity at crucial points. Their function has been best characterized in 
yeast, where they regulate transition from G1 to S phase and G2 to M phase. Both the 
Cdks and Cdc7 are dependent on the levels of associated protein subunits which 
fluctuate during the cell cycle and correspond to the kinase activities of Cyclin-Cdk and 
Cdc7-Dbf4/Drf1, respectively (Swords et al., 2010). Like Cyclin-CDKs, Cdc7 and Dbf4 
are also conserved from yeast to humans (Johnston et al., 1999; Sclafani, 2000).  
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5.2.1 Cdc7 characteristics 
5.2.1.1 Structural features of the ATP-binding domain of Cdc7 kinase 
Hydrogen bonds link ATP to the ATP-binding pocket at a hinge region connecting the 
N- and C-terminal lobes of the kinase catalytic domain (Figure 5.2; Sawa and Masai, 
2009). The hinge region with additional interactions with two hydrophobic regions 
(sites B and E in Figure 5.2) adjacent to the ATP-binding pocket has been also reported 
as a target of most kinase inhibitors. Due to the size of a single residue in the interior of 
the hydrophobic region I (site E in Figure 5.2), this region termed the gatekeeper is 
commonly referred to as the selectivity pocket and is an essential determinant of 
inhibitor sensitivity (Cherry and Williams, 2004; Vieth et al., 2004).  
 
Approximately 90 kinases contain a small threonine gatekeeper, and 190 kinases 
possess a large methionine residue according to the in-house human kinome database. 
Sawa and Nasai built in-house a homology model of Cdc7 indicating that the large 
gatekeeper residue (Met134) results in a very narrow entrance to the hydrophobic region 
I, and the back pocket of this site is in possession of residues Val120 and I1e132 (Figure 
5.3; Sawa and Masai, 2009). The formation of the adenine-binding region by a 
hydrophobic sandwich with two residues (Met118 and I1e64) at the central portion 
suggested that a flat hydrophobic core is perhaps preferred as an inhibitor scaffold. In 
the same region, typical hydrogen bonds may be formed with the backbone of the hinge 
region. The potential targets of two ionic residues (Lys90 and Asp196) could be useful 
for the design of potent inhibitors (Sawa and Masai, 2009).    
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Figure 5.2 Schematic representation of general binding of ATP; interactions with 
specific segments of protein kinases: A solvent accessible region, B hydrophobic region 
II, C adenine-binding region, D sugar pocket, E hydrophobic region I, F phosphate-
binding region (taken from Sawa and Masai, 2009).    
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A 
 
B 
 
Figure 5.3 A homology model of Cdc7 kinase. A, mapping of important residues within 
the ATP-binding pocket of Cdc7 kinase. The formation of hydrophobic area (adenine-
binding region) by a hydrophobic sandwich with two residues (Met118 and I1e64) is 
labeled with the dotted circle area. The arrows mark possible hydrogen bonds between 
an inhibitor and the ATP-biding site of Cdc7. B, the association of a model of 
staurosporine with the ATP-binding site of Cdc7 by Van der Waals surfaces. The 
negatively and positively charged regions are indicated in pink and blue respectively. 
Oxygen and nitrogen are shown in red and blue respectively. The carbon atoms in the 
ligand (staurosporine) and in the protein are shown in white and green respectively 
(Sawa and Masai, 2009).    
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5.2.1.2 The role of Cdc7 in the initiation of DNA replication 
The highly conserved Cdc7 was initially identified by Hartwell in studies of a 
temperature-sensitive mutant in budding yeast, in which Cdc7 is required for the 
initiation of DNA replication (Hartwell et al., 1971; Patterson et al., 1986). The human 
homologue Cdc7 was identified almost 20 years later and comprises a distinct group in 
the kinase family (Figure 5.4A; Masai et al., 1995; Sawa and Masai, 2009).  
 
Cdc7 is critical for viability in yeast. The Kim group first indicated that the knockout of 
murine Cdc7 results in early embryonic death. Subsequently it was found that knockout 
of Cdc7 genes in murine embryonic stem cells led to S-phase arrest, accumulation of 
nuclear DNA damage, and eventual p53-dependent cell death (Kim et al., 2002). These 
results suggest that Cdc7 kinase plays an important role in DNA replication through S-
phase, which is conserved across species, including Xenopus, mouse and human (Jiang 
and Hunter, 1997; Sato et al., 1997; Kim et al., 1998). The initiation of Eukaryotic DNA 
replication is originally fired by binding of ORC (origin recognition complex) to 
replication origins. Mcm (minichromosome maintenance complex) is delivered to the 
origins of replication after association with Cdc6 and Cdt1 as a result of generation of 
pre-RC (pre-replicative complex). Phosphorylation of Mcms (N-terminal tails of Mcm2, 
mcm4 and mcm6 proteins) by Cdc7 and Cdk facilitates the association of Cdc45, Mcms 
and GINs complex (Masai et al 2000, 2006). The generation of active replication forks 
occurs at the origin in response to the association of DNA polymerases (Sawa and 
Masai, 2009). This step is crucial for the generation of active and efficient replication 
fork structures (Figure 5.5). 
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Figure 5.4 Homology analysis of human Cdc7 kinase. CAMK (calcium/calmodulin-
depedent kinase group), TK (tyrosine kinase group), RGC (receptor guanylyl cyclase 
group), TKL (tyrosine kinase-like group), STE (sterile phenotype kinase group), CKI 
(cell kianse I/casein kinase I group), AGC (protein kinaseA, G and C group), CMGC 
(cyclin-depedent-kinase (CDK), mitogen-activated-kinase (MAPK), glycogen-synthase-
kinase (gsk) and CDK-like kinase group. The human kinome tree (taken from Sawa and 
Masai, 2009). 
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Figure 5.5 Scheme of the initiation of eukaryotic DNA replication and the role of Cdc7.  
The binding of ORC to replication origin initiates DNA replication.  The binding of 
Mcm to ORC results from the association of both Cdc6 and Cdt1, generating pre-RC. 
Both Cdc7 and Cdk2 phosphorylate elements of the MCM complex, which leads to 
loading of other accessory factors such as Cdc45 and the GINs complex. Active 
replication forks are then generated by the association of DNA polymerases that results 
in the semiconservative replication of DNA (Sawa and Masai, 2009)  
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5.2.1.3 The role of Cdc7 in checkpoint regulation 
Highly conserved DNA-repair and cell-cycle checkpoint pathways are critical for the 
viability of cells as they are continuously subjected to both endogenous and exogenous 
damage (Sonoda et al., 1998). The proper processing of stalled replication forks and the 
resumption of DNA replication is key to the stable inheritance of genetic information 
through generations. Cells respond to DNA damage and stalled replication forks by 
regulation of checkpoint  reactions. A defect in checkpoint regulation causes serious 
threats to genomic stability. Mutations in checkpoint regulators have been demonstrated 
to be responsible for various tumours or diseases (D'Andrea and Grompe 2003; 
Michelson and Weinert, 2000).  
 
The checkpoint responses consist of four phases; the sensor, the mediator, the 
transducer and the effector phases (Niida and Nakanishi 2006; Nakanishi and Shimada, 
2006). It has been indicated that Cdc7 kinase is critically involved in the mediator phase 
(activating the checkpoint effect) of DNA replication checkpoint responses (Kim et al., 
2008). Cdc7 is required for activation of the ATR (ataxia-telangiec-tasia-mutated-Rads-
related)-Chk1 checkpoint pathway through the hyperphosphorylation of Claspin (a 
mediator) in response to stalled replication forks (Kim et al., 2008). In addition, a 
critical role of Cdc7 kinase is also found in the effector phase (executing the checkpoint 
effects) suggested by the fact that Cdc7 is inactivated in xenopus egg extracts in 
response to etoposide, which generated single-strand DNA gaps. It was found that 
replication protein A (RPA) binding to single-stranded DNA in these gaps induces an 
ATR-dependent checkpoint that blocks origin firing by inactivation of Cdc7 kinase 
(Costanzo et al., 2003). Dierov's group showed that Cdc7 is inactivated by etopside in 
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human cells (Dierov et al., 2004). Accumulating evidence suggests the dual roles of 
Cdc7 kinase in the mediator and effector phases of checkpoint responses. However, it is 
not clear that these functions of Cdc7 are as critical in human cells, as Cdc7 activity 
remains unaltered by stalled replication fork in human cells (Tenca et al., 2007). What is 
clear however is that the knockout of Cdc7 in actively proliferating cells leads to 
replication fork arrest in response to DNA damage, and simultaneously causes defective 
checkpoint activation. 
 
5.2.1.4 The effects of Cdc7 depletion in cancer cells 
siRNA-mediated downregulation of Cdc7 expression has been investigated in various 
cancer cell lines. Following retardation of S phase progression caused by Cdc7 
depletion, cancer cells accumulate nuclear damage, presumably induced by replication 
fork arrest, and then undergo chromosome fragmentation and die. This occurs in both 
p53-positive and -negative cells, indicating that cell death is p53-independent 
(Montagnoli et al., 2004; Yoshizaw-Sugata et al., 2005; Im and Lee 2008; Kim et al., 
2008). In contrast, in normal fibroblasts, a p53-dependent cell cycle checkpoint actively 
prevents progression through a lethal S phase in the absence of Cdc7 kinase 
(Montagnoli et al., 2004).   
 
The precise mechanisms of cancer-specific cell death are not clear. Depletion of Cdc7 
can cause defects in firing of the replication origins as well as acute destabilization of 
replication forks which eventually collapse. Furthermore, checkpoint defects may 
trigger uncoupling of the M phase with the S phase. Therefore it is suggested that the 
combined effect of replication fork arrest and deficient checkpoint responses might 
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cause cell death by inducing aberrant cell cycle progression. Whereas normal cells have 
backup checkpoint mechanisms, cancer cells, in which checkpoint mechanisms are very 
often dysregulated, would suffer from aberrant M phase progression. It has been 
reported that ATR-induced activation of p38 MAP kinase causes caspase activation in 
Cdc7-depleted cancer cells (Im and Lee 2008).  
 
5.3.1 The roles of Cdc7/Dbf4 in yeast and mammalian cells 
5.3.1.1 Function of Cdc7/Dbf4 during origin activation 
The activation of the eukaryotic replication origins contains two steps. The first step 
consists of the sequential assembly onto replication origins of the origin recognition 
complex (ORC), Cdc6 and Mcm2-7 (the MCM proteins). This assembly occurs during 
late mitosis and G1, causing the origin to become 'licensed' for DNA replication  (Figure 
5.6).  In the second step, licensed replication origins fire at different times during S 
phase to each initiate a pair of replication forks. The two kinases CDKs and Cdc7/Dbf4 
are involved in this step (reviewed in Jares et al., 2000; Lee et al., 2012).  
 
Cdc7 is a serine/threonine kinase, conserved from yeast to humans (reviewed in 
Johnston et al., 1999; Sclafani, 2000). It is activated by binding to its regulatory protein 
Dbf4 (Jackson et al., 1993; Jiang et al., 1999). Cdc7 kinase activity reaches the highest 
levels at G1/S transition, although Cdc7 protein levels remain approximately constant 
through the cell cycle (Jackson at al., 1993; Yoon et al., 1993). This cyclic control of 
activity reflects changes in the abundance of Dbf4 (Brown and Kelly, 1999; Cheng et al., 
1999). Although Cdc7 kinase was first identified in budding yeast, orthologs of Cdc7 
and Dbf4 have been also found in the fission yeast Aspergillus, Drosophila, Xenopus, 
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mice, and human, where Dbf4 is also called the activator of S phase kinase (ASK) (Sato 
at el., 1997; Takeda et al., 1999; Jiang et al., 1999). This subunit is referred to as Dbf4 
in the thesis. The levels of Dbf4 oscillate during cell cycle and Dbf4 accumulates in the 
nuclei of late G1, S and M phase cells (Cheng et al., 1999; Jiang et al., 1999; Oshiro et 
al., 1999). Dbf4 levels are degraded in late mitosis and early G1 by a functional 
anaphase-promoting complex (Cheng et al., 1999; Weinreich and Stillman, 1999; 
Ferreira et al., 2000). Cdc7/Dbf4 is required for initiation to fire at early- and late- 
replication origin rather than acting as a global sensor for progression into S phase. 
Consistent with this proposal, Cdc7 along with its interacting factor Dbf4, have been 
shown to associate with chromatin (Weinreich and Stillman, 1999), whilst Dbf4 localise 
to a replication origin in the budding yeast (Dowell et al., 1994). 
 
In saccharomyces cerevisiae, Dbf4 binds to chromatin at the G1/S transition and 
remains attached during S phase, whilst Cdc7 shows association with chromatin through 
the cell cycle (Weinreich and Stillman, 1999). Pasero et al reported that the association 
of Dbf4 with chromatin in G1 phase depends on the presence of ORC but does not 
require Cdc6 or Mcm(2-7) (Figure 5.6A ; Pasero et al., 1999). However, in the xenopus 
cell-free system, Jares and Blow showed that Cdc7 also binds to chromatin during the 
G1 and S phase. Its association with chromatin does not require the continued presence 
of xenopus ORC or Cdc6. Once origin licensing is completed, Cdc7/Dbf4 appears to 
depend on the presence of Mcm (2-7) (i.e. licensed origin) (Figure 5.6B  ; Jares and 
Blow, 2000).  These results suggest that yeast and xenopus may recruit Cdc7/Dbf4 to 
replication fork origins differently.  
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Figure 5.6 Comparison of proposed Cdc7/Dbf4 function in S. cerevisiae and Xenopus. 
‘M’ refers to the Mcm (2-7) heterohexamer and ‘B’ refers to RLF-B component for the 
replication licensing system. A (i) Cdc6 and Cdc7/Dbf4 bind to ORC separately at a 
replication origin. (ii) Cdc6-delivering Mcm (2-7) onto origin. (iii) Phosphorylation of 
Mcm (2-7) possibly by CDK-dependent step occurs prior to Cdc7/Dbf4 function. (iv) 
Cdc7/Dbf4 function results in assembly of Cdc45 onto the origin. B  (i) ORC, Cdc6 and 
RLF-B regulate the origin licensing DNA, which once bound to Mcm (2-7) leads to 
displacement of Cdc6 and destabilization of ORC. (ii) Mcm (2-7) but not ORC or Cdc6 
is required for Cdc7/Dbf4 bound to the origin. (iii) Cdc7/Dbf4 phosphorylated Mcm (2-
7) can occur in the absence of CDKs. (iv) Cdc45-delivering to the origin depends on 
both Cdc7 and CDK activity (Taken from Jares et al., 2000).   
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The association of Cdc7/Dbf4 with replication fork origins suggests that their substrates 
may also be origin-attached. Previous reports showed that the S phase-promoting kinase 
Cdc7/Dbf4 and the putative DNA replicative helicase Mcm (2-7) play essential roles in 
the initiation of DNA replication in all eukaryotes. Mcm2 subunit of the Mcm complex 
that is selectively phosphorylated by Cdc7/Dbf4 is an excellent substrate both in vivo 
and in vitro, suggesting that Cdc7/Dbf4 may be directly involved in the initiation of 
DNA replication by targeting Mcm2 (Lei et al., 1997; Sato et al., 1997; Brown and 
Kelly, 1998; Jiang et al., 1999; Roberts et al., 1999; Jares and Blow, 2000). To 
determine the importance of the Cdc7/Dbf4 phosphorylation of Mcm2 in the initiation 
of DNA replication, Tsuji et al mapped Cdc7/Dbf4 phosphorylation sites in human 
Mcm2.  Three major sites (Ser27, Ser41, and Ser139) and two minor sites (Ser43 and 
Ser108) of Mcm2 were found to be phosphorylated in vivo. Those major sites are 
specifically phosphorylated by purified Cdc7/Dbf4 in vitro and their phosphorylation in 
vivo was significantly decreased in Cdc7 siRNA treated cells, thereby strongly 
suggesting that Ser27, Ser41, and Ser139 are in vivo Cdc7/Dbf4 phosphorylation sites in 
Mcm2 (Tsuji et al., 2006). They also examined chromatin recruitment and 
phosphorylation of chromatin-bound Mcm2 by Cdc7/Dbf4. Mcm2 accumulated on 
chromatin and was not phosphorylated by Cdc7/Dbf4 until G1/S transition and early S 
phase, which coincided with the initiation of DNA replication. In late S and G2/S 
transition, phosphorylated Mcm2 gradually disassociated from chromatin. Suppression 
of Mcm2 expression in Mcm2 siRNA-treated cells inhibits DNA replication in Hela 
cells. The inhibition of DNA replication by Mcm2 siRNA can be rescued by co-
expression of Mcm2. This confirms the essential role of phosphorylation of Mcm2 by 
Cdc7/Dbf4 kinase is involved in the initiation of DNA replication in human cells (Tsuji 
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et al., 2006), however, it alone is not sufficient (Owens et al., 1997; Zou and Stillman, 
1998; Tercero et al., 2000). 
 
A model for the regulation of the initiation of DNA replication by Cdc7/Dbf4 
phosphorylation of Mcm2 in human cells has been proposed on the basis of previous 
results (Bell and Dutta, 2002; Mendez and Stillman, 2003; Forsburg, 2004; Tsuji et al., 
2006). Mcm2 is not phosphorylated by Cdc7/Dbf4 in G1, where Cdc7/Dbf4 kinase 
activity remains at a minimum. Association of unphosphorylated Mcm2 with other 
Mcms (Mcm2-7 complex) occurs on chromatin, presumably on the replication origins 
by the Cdc6 and Cdt1 (DNA replication loading factors) to establish pre-RCs. 
Activation of Cdc7/Dbf4 kinase during G1/S transition and early S phase leads to the 
phosphorylation of chromatin-attached Mcm2. Cdc7/Dbf4 phosphorylation of Mcm2 in 
the Mcm (2-7) complex elicits the conformational change of the complex and activation 
of its helicase, which is crucial for DNA replication. MCM2-7 helicase works at a 
distance from the replication forks, pumping DNA along its helical axis by ATPase-
coupled rotation. In late S and G2/S transition, Mcm (2-7) complex is released from 
chromatin, seemingly by additional post-translational modifications to prevent DNA re-
replication (Tsuji et al., 2006). 
 
5.3.1.2 Cdc7/Dbf4 in cell cycle checkpoints 
In addition to its crucial function in the initiation of DNA replication, the Cdc7/Dbf4 
kinase is a target of the S-phase checkpoint pathway, and it plays an essential role in 
growth recovery from DNA damage in multiple organisms (Takeda et al., 1999; 
Weinreich and Stillman, 1999).  The ATR- and Chk1- dependent S checkpoint inhibits 
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the initiation of DNA replication in response to UV irradiation, which is biochemically 
distinct from that induced by ionizing radiation. The UV irradiation-induced S 
checkpoint is offset by overexpression of Dbf4 and Chk1 phosphorylated Dbf4 in vitro, 
suggesting that Dbf4-dependent kinase is a possible downstream target of ATR- and 
Chk1- checkpoint kinases in response to UV irradiation in human cells where its 
activity may be inhibited to prevent replicon initiation (Heffernan et al., 2007). 
Costanzo's group demonstrated that a DNA damage (ATR- and Chk1-) checkpoint 
targets Cdc7/Dbf4 kinase, although it is not clear if Cdc7 or Dbf4 are direct targets of 
either ATR or Chk1/2 (Costanzo et al., 2003). Cdc7/Dbf4 is thereby an important cell 
cycle regulator that is also important for genome integrity in  response to replication 
fork stalling or DNA damage.  
 
5.3.1.3 Overexpression of Cdc7/Dbf4 in multiple cancers 
Changes in Cdc7/Dbf4 protein abundance or activity might arise during tumorigenesis 
and might have an important impact on cell survival (Bardelli et al., 2003; Greenman et 
al., 2007). Nambiar's group showed that overexpression of Dbf4 protein is observed in 
primary cutaneous melanoma and cutaneous melanoma metastases, and proposed that 
up-regulated Dbf4 bound to Cdc7 in the nucleus is a novel determinant of the cutaneous 
melanoma development with prognostic value (Nambiar et al., 2007). Furthermore, 
Bonte et al found that the Cdc7 protein has a relatively low or undetectable abundance 
in normal tissues and cell lines while is highly expressed in ~50% of 62 human tumor 
cell lines tested (Bonte et al., 2008). They also found a tight correlation between the 
expression levels of Cdc7 and Dbf4. Most cell lines with increased Cdc7 protein levels 
also possess increased levels of Dbf4 protein. Seven of 14 ovarian, breast, and prostate 
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tumor cell lines tested were found to have an extra copy of the Dbf4 gene (Bonte et al., 
2008). Therefore, all the observations suggest that increased Cdc7/Dbf4 abundance is a 
common occurrence during tumorigenesis and may offset recovery or repair of 
replication forks arrest to enhance survival of some tumor cells.    
 
5.3.1.4 Importance of the MCB elements in the human Dbf4 promoter 
The mammalian homologues share many properties of the yeast Dbf4. For example, 
both mammalian and yeast Dbf4 proteins are crucial for initiation of DNA replication. 
Like in yeast, the human Dbf4 (HuDbf4) mRNA levels dramatically rise in late G1, peak 
at the G1/S boundary, and remain high in S phase (Jiang et al., 1999; Kumagai et al., 
1999). Overall HuDbf4 mRNA levels reflect those of HuDbf4 protein as is the case in 
yeast (Jiang et al., 1999). HuDbf4 protein levels correspond to the formation of the 
Cdc7-Dbf4 protein complex which correlates with Cdc7 kinase activities (Jiang et al., 
1999; Kumagai et al., 1999). It was found in both in vitro and in vivo assays that 
HuDbf4-HuCdc7 kinase can effectively phosphorylate HuMcm2 protein (Lei et al., 
1997; Nougarede et al., 2000). Accumulating data suggest that Dbf4-Cdc7 kinase is 
directly involved in the regulation of DNA replication initiation for both yeast and 
mammals (Guo and Lee, 2001).  
 
In order to further gain a understanding of how the transcription of Dbf4 is regulated, 
HuDbf4 has been cloned and characterized (Figure 5.7) and its core promoter activity 
was found within the nucleotide 211 to 285 upstream of the translation start-codon (i.e. -
211 to -285). This 75bp DNA segment contains a putative M1uI cell cycle Box (MCB) 
with a 5'-ACGCGT-3' sequence among others (Sp1 as positive regulator, HES-1 as 
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repressor and TFIIB).  A point change of the ‘C’ residue (adjacent to A) within the 
putative MCB to ‘T’ significantly reduced the promoter activity, suggesting that this 
element is critically important for the HuDbf4 core promoter activity (Wu and Lee, 
2002).  
 
 
Figure 5.7 Diagram showing the alignment of human Dbf4 promoter sequence from -
211 to -447. The putative transcription-factor binding sites are indicated in the boxes.  
The 75bp core promoter -211/-285 contains a putative MCB element (Wu and Lee, 
2002).  
 
MCB elements were also found in the promoter of most DNA synthesis genes in 
budding yeast, whose transcription in late G1 depends on copies of a short sequence 
(MCB elements; ACGCGTNA). MCB elements are regulated mainly by MBF (MCB 
binding factor), which consists of Mbp1 and Swi6 (Koch et al., 1993; Koch and 
Nasmyth, 1994).  In addition, SCB elements (Swi4 cell cycle boxes) also constitute 
important sequences present in the promoter like the MCB elements and are regulated 
by the transcription factor SBF (SCB binding factor) composed of Swi4 and Swi6 
(Breeden and Nasmyth, 1987; Andrews and Moore, 1992). Downregulation of MCB 
genes is caused by inactivation of MBF. The deletion of both MBF and SBF leads to a 
lethal arrest, indicating that transcriptional activation by MBF and SBF is involved in 
controlling cell cycle progression (Nasmyth and Dirich, 1991; Koch et al., 1993).  
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5.4.1 Aims of the project 
The sequence 5'-ACGCGT-3' (MCB) which occurs in the core HuDbf4 promoter is 
utilized in this thesis as a model system for investigating the effects of gene targeting by 
the polyamide f-IPI. The binding of f-IPI to the MCB in vitro and the cellular effects of 
f-IPI treatment (e.g. downregulation of HuDbf4, cell cycle effect, cell survival, 
proliferation and apoptosis) were assessed.  
 
Subsequently, the targeting of the MCB in the promoter by the polyamides f-
IP(C3NH2)I and f-IP(C3Cl)I was assessed as part of the in situ formation of H-pin 
approach.     
 
Lastly, polyamides containing the fluorescent Hx moiety were designed and tested with 
the aim of monitoring cellular uptake and nuclear localization. HxPI was additionally 
tested as a potential gene-control agent for the targeting of the HuDbf4 promoter model. 
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5.2 Results  
In vitro binding characteristics of f-IPI to the Dbf4 and its cellular 
effects in MDA-MB231 cells 
5.2.1 In vitro binding of f-IPI to the Dbf4 promoter  
The chemical structures of f-IPI and its binding model have been described in Figure 
3.2A&B. The binding model of f-IPI H-pin is the same as f-IPI and its chemical 
structure is shown in Figure 5.8A. F-IPI targets 5’-ACGCGT-3’ the MIuI Cell cycle 
Box (MCB), which is a critical site for transcription factor binding and activation of 
expression of the HuDbf4 core gene in mammalian cells. A DNA fragment containing 
the core HuDbf4 promoter sequences (i.e. -285/-211) including the MCB as designed 
for footprinting analysis and is shown in Figure 5.8B. 
 
To identify the pattern of f-IPI binding to the HuDbf4 promoter, DNase I footprinting 
was carried out using the fragment shown in Figure 5.8B. The autoradiograms presented 
in Figure 5.8C and D show the titration results for the two polyamides f-IPI and f-IPI H-
pin. A clear footprint is observed for both polyamides over the MCB site at 0.1 and 0.05 
μM respectively, indicating that the f-IPI H-pin exhibits a stronger DNA binding 
affinity than f-IPI (Figure 5.8C&D). A noticeable footprint at the site 5'-ACGCGC-3' is 
also observed for f-IPI and f-IPI H-pin at 0.5 μM and 0.1 μM respectively, because this 
sequence also contains the central sequence 5'-CGCG-3' required by f-IPI.   
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Figure 5.8 A The chemical structure of f-IPI-H-pin. DNase I footprinting was 
performed using (B) a 131bp 5’-[-32P]-radiolabeled DNA fragment containing the 
Dbf4 promoter. Footprint gels show the DNA sequence specific binding of f-IPI (C) and 
f-IPI H-pin (D) to the cognate, target sequence 5’-ACGCGT-3’ within the Dbf4 
promoter. Asterisk indicates the concentration of polyamide at which protection from 
DNase I cleavage is initially observed. The cognate binding site is highlighted by solid 
bar. G+A refers to the sequencing lane. 
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To further demonstrate that f-IPI can bind to the MCB motif and potentially affect the 
HuDbf4 promoter activation, electrophoretic mobility shift assay (EMSA) studies were 
carried out using radiolabeled oligonucleotides containing the MCB sequence, 
incubated with f-IPI and nuclear extracts from MDA-MB231 cells. As shown in Figure 
5.9A, pre-incubation of the radioactive oligonucleotides containing the MCB sequence 
(5’-ACGCGT-3’) with f-IPI, for 1 h and subsequent addition of nuclear extracts results 
in the inhibition of protein binding to the MCB at drug concentrations >0.1 μM. No 
effect was observed when reactions are incubated with an excess of unlabeled mutated 
oligonucleotide (labeled M in Figure 5.9A-C, sequence as shown in Figure 5.9D), while 
shifted bands (denoted by the arrows) are competed out with an excess of unlabeled 
wild-type oligonucleotide, confirming the specificity of binding (labeled C in Figure 
5.9). A supershift reaction (S1 labeled in Figure 5.9A) did not produce a supershifted 
band when incubating with the MCB transcription factor antibody (yeast anti-MBP1) 
with nuclear extracts from MDA-MB231 cells (Figure 5.9A). However, the 
disappearance of the band suggests that the MCB protein is part of the protein complex 
when compared to the band presents after treatment with a negative antibody (S2 
labeled in Figure 5.9A). There are no other specific MCB antibodies commercially 
available and therefore it is difficult to further test the effect of f-IPI on protein-DNA 
interaction. A similar EMSA study of f-PPP was considered as a negative control 
because f-PPP cannot target the MCB motif. As expected no effect was observed by f-
PPP at doses up to 100 μM (Figure 5.9B).   
 
An EMSA study of f-IPI H-pin was also carried out due to its great binding affinity 
observed by DNase I footpinting. As shown in Figure 5.8C, the inhibition of protein 
binding is found with treatment with f-IPI H-pin and the effect was observed at 0.05 
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μM, suggesting an approximately10-fold enhanced binding affinity at the MCB site 
compared to f-IPI. The EMSA results are consistent with the DNase I footprinting 
studies, which also revealed the enhanced effect of f-IPI H-pin over f-IPI on DNA 
binding affinity. The same experiments were repeated with nuclear extracts allowed to 
react with the radioactive oligonucleotides first, for 1 h, before the addition of the three 
polyamides. The protein binding inhibition patterns are identical (data not shown) 
suggesting that these polyamides can not only compete but also displace transcription 
factors already bound to DNA, including MCB.  
 
A      
                                                                              
      
                                            f-IPI 
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                                             f-PPP 
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                                           f-IPI H-pin 
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D 
MCB wild type oligo: 5’-GCGTGACGCGTTTTCAAATCTTCAACC-3’ 
MCB mutant oligo:     5’-GCGTGACTAGTTTTCAAATCTTCAACC-3’ 
 
Figure 5.9. Interaction of f-IPI and its analogues with the MCB in the HuDbf4 
promoter. A, B and C, Electrophoretic Mobility Shift Assay studies (EMSAs) were 
carried out using 10 µg MDA-MB231 nuclear extracts and the radioactive DNA probe 
shown in (D). The arrow denotes the DNA-protein complex. A dose-dependent 
inhibition of protein binding to the MCB by f-IPI (A), f-PPP (B) and f-IPI H-pin (C) 
was observed, respectively. Lane C and M represent reactions with unlabeled and 
mutated MCB oligonucleotides. S1 represents reaction using anti-MCB antibody (yeast) 
and S2 was treated with a negative antibody. 
 
5.2.2 Validation of ∆∆Ct method for RT-PCR experiments 
Before using the ∆∆Ct ( Ct is cycle threshold) method for quantitation, a validation 
experiment  was performed as shown in Figure 5.10 to demonstrate that efficiencies of 
target gene (e.g Dbf4 Figure 5.10A) and reference gene (e.g. GAPH Figure 5.10B) are 
approximately equal. The absolute value of the slope of log input amount vs.∆CT 
should be < 0.1. The slope in Figure 5.10C is 0.0936 with acceptable limits. The ∆∆Ct 
calculation method can subsequently be used for the relative quantitation of the target 
gene without running standard curves on the same plate. 
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Figure 5.10.  Standard curve of Dbf4 and GAPDH. A, The standard curve of 
amplification of the Dbf4 target detected using FAM-labeled probe. B, The standard 
curve of amplification of the GAPDH endogenous control detected using FAM-labeled 
probe. C, Relative efficiency plot of Dbf4 and GAPDH 
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5.2.3 Effects of f-IPI and f-IPI H-pin on the cellular levels of HuDbf4: 
RT-PCR and western blot analysis  
The effects of f-IPI on Dbf4 expression were analyzed in exponentially growing MDA-
MB231 cells. Following incubation of exponentially growing cells with 50, 100 and 200 
µM of f-IPI, there was a 32%, 50% and 57% reduction in Dbf4 mRNA levels at 24 h, 
respectively, compared to untreated cells (Figure 5.11A). However, no reduction of 
Dbf4 mRNA levels occurred at 24 h after incubation with 50 and 100 µM of f-IPI H-pin 
(Figure 5.11B). 
 
In order to further demonstrate whether polyamides could be developed as cellular gene 
control agents, the ability of f-IPI monomer and f-IPI H-pin to enter the nucleus of cells 
and subsequently affect protein levels was investigated using western blotting. 
Exponentially growing MDA-MB231 cells were incubated with 50 μM and 100 μM of 
f-IPI and f-IPI H-pin for 24 h. Western blot analysis of treated cells was performed and 
the results are shown in Figure 5.12A and B. The results demonstrate that f-IPI inhibits 
Dbf4 protein expression after 24 h of exposure in a dose-dependent fashion (Figure 
5.11A). This is in contrast to f-IPI H-pin, which even at 100 μM did not affect Dbf4 
protein levels after a 24 h incubation (Figure 5.11B). As a loading control, the levels of 
calnexin in the cells were probed with the appropriate antibody, and they were found to 
be unaffected. This indicates that the cells were viable and the overall gene expression 
machinery was not impaired. In addition, the Cdc7 protein levels remained unchanged 
even when cells were treated with the highest concentration (100 μM) of f-IPI.  
 
 
 
185 
 
A  
0
0.2
0.4
0.6
0.8
1
1.2
Exponential 24h
R
e
la
ti
ve
 D
b
f4
 m
R
N
A
 le
ve
l
Untreated
f-IPI 50µM
f-IPI 100µM
f-IPI 200 µM
 
B 
0
20
40
60
80
100
120
140
Exponential 24h
%
 R
e
la
ti
ve
 D
b
f4
B
 m
R
N
A
 le
ve
ls
Untreated
f-IPI H-pin 50µM 
f-IPI H-pin 100µM 
 
Figure 5.11. Exponentially growing MDA-MB231 cells were treated with f-IPI (A) and 
f-IPI H-pin (B) for 24 h. mRNA levels in f-IPI and f-IPI H-pin-treated cells were 
expressed relative to untreated cells. Results are the mean of three independent 
experiments with error bars showing the standard deviation of the mean. 
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Figure 5.12 Western blot analysis of exponentially growing MDA-MB231 cell extracts 
following treatment with f-IPI (A) and f-IPI H-pin (B). Exponential cells were treated 
with 50 and 100 μM f-IPI and f-IPI H-pin respectively and analysis was carried out on 
samples collected after 24 h of drug treatment as indicated. Calnexin is shown as a 
loading control. Protein and RNA samples from exponentially growing cells (E). 
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5.2.4 Validation of Dbf4 siRNA knockdown 
In order to elucidate the role of Dbf4 in MDA-MB231 cells, a siRNA-mediated strategy 
to knock down the endogenous levels of Dbf4 was employed. The efficiency of Dbf4 
siRNA knockdown was assessed at the mRNA level, as determined by RT-PCR (Figure 
5.13A). The Figure 5.13A shows the 80-90% reduction of Dbf4 mRNA levels at 24, 48, 
72 and 96 h post-transfection with the Dbf4 siRNA.   
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Figure 5.13. A, Dbf4 mRNA levels were quantified via RT-PCR after siRNA 
knockdown at 24, 48, 72 and 96 h. mRNA levels in scrambled and Dbf4 siRNA 
knockdown cells relative to untreated-exponentially growing cells. Results are the mean 
of two independent experiments with error bars showing the standard deviation of the 
mean. 
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5.2.5 Effects of the depletion of endogenous Dbf4 by siRNA in MDA-
MB231 cells  
To elucidate the association between loss of endogenous Dbf4 and MDA-MB231 cell 
growth, proliferation and apoptosis, the kinetics of cell viability, cell proliferation and 
cell apoptosis were measured by the presence of ATP (CellTiter-Glo assay), BrdU 
incorporation (BrdU assay), and Caspase3/7 activity (Caspase3/7 assay), respectively.  
 
The luminescence levels of Dbf4 siRNA-treated MDA-MB231 cells in the cell viability 
assay (CellTiter-Glo assay) are proportional to the number of metabolically active cells. 
Figure 5.14A shows the luminescence levels of Dbf4 siRNA-treated cells which were 
then converted to the relative percentage of cell viability (Figure 5.14B). There is a 
11.4%, 14% and 16.6% reduction of cell viability compared to the scrambled siRNA-
treated control at 24, 48 and 72 h post-transfection, respectively (Figure 5.14B). The 
luminescence levels of Dbf4 siRNA treated cells in the cell apoptosis assay (Caspase3/7 
assay) represent the number of dead cells. Figure 5.14C and D show the luminescence 
levels of treated cells with the resulting percentages of cell apoptosis. The Dbf4 siRNA-
treated cells show higher levels of apoptosis compared to the untreated, transfection 
reagent treated and scrambled siRNA-treated cells at 24, 48 and 72 h, however the 
percentage of apoptosis is  <3% at each time point, suggesting that siRNA-mediated 
knockdown of Dbf4 is not significantly cytotoxic (Figure 5.14D).  
 
The absorbance of Dbf4 siRNA-treated MDA-MB231 cells in the proliferation assay 
(BrdU assay) is proportional to the cellular DNA content. Figure 5.14E shows the 
absorbance of Dbf4 siRNA treated cells, converted to the relative percentages of cell 
proliferation in Figure 5.14F. Figure 5.14F shows the decreased proliferation of treated 
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cells (~10%) compared to the scrambled siRNA treatment at 24, 48 and 72 h, 
respectively.  
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Figure 5.14 Cell survival, apoptosis and proliferation analysis of siRNA-treated MDA-MB231 cells. A, 
Kinetics of cell survival after siRNA treatment of MDA-MB231 cells (CellTiter-Glo assay at 24, 48 and 
72 h). B, Relative percentage of viable cells at 24, 48 and 72 h after siRNA treatment. C, Kinetics of cell 
apoptosis after siRNA treatment of MDA-MB231 cells (Caspase-Glo 3/7 assay at 24, 48 and 72 h). D, 
Percentage of apoptotic cells at 24, 48 and 72 h after siRNA treatment. E, Kinetics of cell proliferation 
after siRNA treatment of MDA-MB231 cells (BrdU incorporation assay at 24, 48 and 72 h). F, Relative 
percentage of cell proliferation at 24, 48 and 72 h after siRNA treatment. Results are the mean of three 
independent experiments with error bars showing the standard deviation of the mean.  
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5.2.6 Dbf4 siRNA knockdown-induced G1 arrest in MDA-MB231 cells 
To further investigate the effect of Dbf4 on the MDA-MB231 cells, cell cycle analysis 
of untreated, scrambled-control and Dbf4 siRNA knockdown cells was performed after 
24 and 48 h post-transfection. Harvested cells were subjected to analysis by flow 
cytometry, which used DNA content as a measure of progression in the cell cycle. There 
was no significant difference in the percentage of cells in each phase of the cell cycle 
between different treatments, 24 h post-transfection (Figure 5.15A). However, at 48 h, 
there was an 8% increase in the number of Dbf4 siRNA treated cells at G1 compared to 
scrambled control (Figure 5.15B). The data suggest that the Dbf4 siRNA knockdown 
induces a small G1 arrest in MDA-MB231 cells. This is consistent with the previous 
finding that Dbf4 is required for the initiation of DNA replication and presents high 
levels in G1/S, thus the downregulation of Dbf4 could result in G1 arrest of cells.  
 
5.2.7 Effects of f-IPI treatment on the cell growth, proliferation and 
apoptosis in the MDA-MB231 cells  
To investigate the effects of f-IPI in MDA-MB231 cells, the same assays as in section 
5.2.5 were carried out.  
 
The luminescence levels of f-IPI treated cells in the viability assay gradually reduce in 
response to increasing concentrations of f-IPI at 24, 48 and 72 h, respectively (Figure 
5.16A). The relative percentages of cell viability are presented in Figure 5.16B. The 
dose-dependent treatments of f-IPI (50 µM, 100 µM and 200 µM) exhibit respective 
70%, 40% and 22% cell survival at 72 h compared to the untreated control (Figure 
5.16B). Similarly, the luminescence levels in the apoptosis assay increase in response to 
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increasing concentrations of f-IPI at 24, 48 and 72 h, respectively (Figure 5.16C). As 
shown in Figure 5.16D, 200 µM f-IPI treatment induces the highest levels of apoptosis 
at each time point. f-IPI treatments are much more cytotoxic than siRNA knockdown.  
 
The absorbance of f-IPI treated cells in the cell proliferation assay decreases in response 
to increasing concentrations of f-IPI at 24, 48 and 72 h, respectively (Figure 5.16E). The 
relative percentages of cell proliferation are shown in Figure 5.16F. There is a 32%, 
35% and 37% decrease of cell proliferation in the 200 µM f-IPI treated cells at 24, 48 
and 72 h, respectively (Figure 5.16F). 
 
5.3.8 f-IPI treatment-induced G1 arrest in MDA-MB231 cells 
Cell cycle analysis of control and f-IPI treated-cells was performed at 24 h (Figure 
5.17). 7% and 10.3% increase of cells in G1 were observed at 24 h after f-IPI treatments 
compared to the untreated-control (Figure 5.17 middle and lower panel). F-IPI 
treatment-induced G1 arrest in MDA-MB231 cells might therefore be associated with 
alteration of the Dbf4 protein levels, downregulated by f-IPI binding to the MCB site in 
the Dbf4 promoter. 
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Figure 5.15. Flow cytometry analysis after siRNA treatment of MDA-MB231 cells. A 
and B, untreated-(upper panel), scrambled siRNA (middle panel) and Dbf4 siRNA 
(lower panel) treated- MDA-MB231 cells 24 h and 48 h post-transfection, respectively. 
Percentage of cells at different phases of the cell cycle was counted using Summit 4.3 
software. 
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Figure 5.16 Cell survival, proliferation and apoptosis analysis of f-IPI-treated MDA-MB231 cells. A, 
Kinetics of cell survival after 50 and 100 µM f-IPI treatment of MDA-MB231 cells (CellTiter-Glo assay 
at 24, 48 and 72 h). B, Relative percentage of viable cells at 24, 48 and 72 h after f-IPI treatment. C, 
Kinetics of cell apoptosis after 50 and 100 µM f-IPI treatment of MDA-MB231 cells (Caspase-Glo 3/7 
assay at 24, 48 and 72 h). D, Percentage of apoptotic cells at 24, 48 and 72 h after f-IPI treatment. E, 
Kinetics of cell proliferation after 50 and 100 µM f-IPI treatment of MDA-MB231 cells (BrdU 
incorporation assay at 24, 48 and 72 h). F, Relative percentage of cell proliferation at 24, 48 and 72 h 
after f-IPI treatment. Results are the mean of three independent experiments with error bars showing the 
standard deviation of the mean. 
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Figure 5.17 Flow cytometry analysis after f-IPI treatment. Untreated-(upper panel), 50 
µM of f-IPI treated-(middle panel) and 100 µM of f-IPI treated-(lower panel) MDA-
MB231 cells after 24 h respectively. Percentage of cells at different phases of the cell 
cycle was counted using Summit 4.3 software. 
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Study of the potential formation of in situ H-pin using the Dbf4 
promoter as a model system 
5.2.9 In vitro binding of f-IP(C3NH2)I, f-IP(C3Cl)I and their 
combination to the Dbf4 promoter 
The chemical structures and DNA binding models of f-IP(C3NH2)I, f-IP(C3Cl)I and 
their combination have been shown in Figure 3.2A&B. These polyamides were 
designed to target the same binding sequence (5'-ACGCGT-3') as f-IPI, which is the 
core MCB sequence of the HuDbf4 promoter.  
 
To identify the pattern of binding of f-IP(C3NH2)I, f-IP(C3Cl)I and their combination to 
the Dbf4 promoter, DNase I footprinting was carried out using the fragment shown in 
Figure 5.18. The autoradiogram given in Figure 5.18A shows the initial footprint by f-
IP(C3NH2)I at 0.5 μM, having a 10-fold higher DNA-binding affinity than f-IP(C3Cl)I 
(5 μM) (Figure 5.18B). When equimolar concentrations of f-IP(C3NH2)I and f-IP(C3Cl)I 
were used, the combination binding starts to occur at 0.1 µM, thus indicating a higher 
DNA-binding affinity than either of f-IP(C3NH2)I (0.5 μM) or f-IP(C3Cl)I (5 μM) 
(Figure 5.18A-C). These results suggest that the combination can form a favorable 
complex in situ at the target MCB sequence, potentially forming an H-pin structure.     
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Figure 5.18 Sequence binding of compounds [A, B and C; f-IP(C3NH2)I, f-IP(C3Cl)I 
and their combination, respectively] to their cognate, target sequence 5’-ACGCGT-3’ 
within the Dbf4 promoter. DNase I footprinting was performed using a 131bp 5’- 
[
32
P]-radiolabeled DNA fragment containing the Dbf4 core promoter sequence from -
285 to -211. Asterisk indicates the concentration of polyamide at which protection from 
DNase I cleavage is initially observed. The cognate binding site is highlighted by solid 
bar. G+A refers to the sequencing lane.  
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To further demonstrate that f-IP(C3NH2)I, f-IP(C3Cl)I and their combination can bind to 
the MCB motif, EMSA studies were carried out using radiolabelled oligonucleotides 
containing the MCB element, incubated with the respective compounds and nuclear 
extracts from confluent MDA-MB231 cells. 
 
As shown in Figure 5.19A, pre-incubation of the radioactive oligonucleotides 
containing the MCB target sequence (5'-ACGCGT-3') with f-IP(C3NH2)I, for 1 h and 
subsequent addition of nuclear extracts causes the inhibition of protein binding to the 
MCB at 0.5 µM. In contrast, there is limited inhibition of protein binding to the MCB 
after the incubation with f-IP(C3Cl)I at 10 µM (Figure 5.19B). When an equimolar 
concentration of f-IP(C3NH2)I was mixed with f-IP(C3Cl)I, the inhibition of protein 
binding to the MCB by the combination occurs at 0.5 µM as was the case for f-
IP(C3NH2)I alone (Figure 5.19C). The EMSA results are consistent with DNA 
footprinting analysis, also suggesting the favorable interaction in situ and partial 
formation of an H-pin structure.  
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                      f-IP(C3NH2)I + f-IP(C3Cl)I 
D 
MCB wild type oligo: 5’-GCGTGACGCGTTTTCAAATCTTCAACC-3’ 
MCB mutant oligo:     5’-GCGTGACTAGTTTTCAAATCTTCAACC-3’ 
 
Figure 5.19 Interaction of compounds [f-IP(C3NH2)I, f-IP(C3Cl)I and their 
combination] and the MCB in the promoter of human Dbf4. A, B and C, EMSA was 
carried out using 10 µg MDA-MB231 nuclear extracts and the radioactive DNA 
oligonucleotides shown in (D). The arrow denotes the DNA-protein complex. MCB 
“wild type” oligonucleotides were incubated with increasing concentration (µM) of 
compounds f-IP(C3NH2)I, f-IP(C3Cl)I and their combination (0.1-100 µM). An 
equimolar concentration of f-IP(C3NH2)I mixed with f-IP(C3Cl)I indicate the total 
concentration (C).  Lane C and M represent reactions with unlabeled and mutated MCB 
oligonucleotides, respectively. 
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5.2.10 Effects of f-IP(C3Cl)I, f-IP(C3NH2)I and their combination on 
the cellular levels of Dbf4: RT-PCR and Western Blot analysis   
The effects of compounds f-IP(C3Cl)I, f-IP(C3NH2)I and their combination on Dbf4 
expression were analyzed in exponentially growing MDA-MB231 cells. Following 
incubation of the cells with 50 μM and 100 μM f-IP(C3Cl)I, there is a 7% and 13% 
reduction in Dbf4 mRNA levels at 24 h, respectively, compared to untreated cells 
(Figure 5.20A). Higher reduction of Dbf4 mRNA levels (15% and 26%, respectively) 
by 50 μM and 100 μM f-IP(C3NH2)I is shown at 24 h in Figure 5.20B and C compared 
to that of f-IP(C3Cl)I treatments. Furthermore, when 25 µM or 50 µM of f-IP(C3NH2)I 
were mixed with 25 µM or 50 µM of f-IP(C3Cl)I, their combination results in the 
reduction of Dbf4 mRNA levels by 30% and 46%, respectively at 24 h, which 
represents a greater effect than either of the compounds alone (Figure 5.20B&C).  
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Figure 5.20 Cell survival, apoptosis and proliferation analysis after f-IP(C3Cl)I, f-IP(C3NH2)I and their 
combination treatments. A, Exponentially growing MDA-MB231 cells were treated with 50 and 100 µM 
of f-IP(C3Cl)I for 24 h. B, The cells were treated with 50 µM of f-IP(C3NH2)I and the combination (25 
µM from each compounds) respectively for 24h. C, The cells were treated with 100 µM of f-IP(C3NH2)I 
and the combination (50 µM  from each) respectively for 24 h. mRNA levels in the chemical compounds-
treated cells were expressed relative to exponentially growing cells. Results are the mean of three 
independent experiments with error bars showing the standard deviation of the mean. 
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Exponentially growing MDA-MB231 cells were incubated with 50 µM and 100 µM of 
f-IP(C3Cl)I, f-IP(C3NH2)I and their combination for 24 h. Western blot analysis of 
treated cells was performed and the results are shown in Figure 5.21A and B. The 
results demonstrate that f-IP(C3Cl)I has no effect on Dbf4 protein expression after 24 h 
of exposure (Figure 5.21A). In contrast, f-IP(C3NH2)I treatments result in a reduction in 
the Dbf4 protein levels in a dose-dependent fashion after a 24 h incubation (Figure 
5.21B). When 25 µM or 50 µM of f-IP(C3NH2)I were mixed with 25 µM or 50 µM of f-
IP(C3Cl)I, the combination exhibits a higher reduction of Dbf4 protein levels than either 
f-IP(C3Cl)I or f-IP(C3NH2)I alone at 24 h at 50 µM and 100 µM, respectively (Figure 
5.21B). The immunoblotting data is therefore consistent with the RT-PCR analysis, thus 
suggesting that f-IP(C3Cl)I interacts in situ with f-IP(C3NH2)I to potentially form a H-
pin structure in the cell.   
A 
 
B 
 
Figure 5.21 Immunoloting analysis of MDA-MB231 cell extracts following treatment with f-IP(C3Cl)I, 
IP(C3NH2)I and their combination. A and B, Immunoblotting of cell nuclear extracts following 50 µM 
and 100 µM of f-IP(C3Cl)I, IP(C3NH2)I and their combination treatment. An equimolar concentration of 
f-IP(C3NH2)I mixed with f-IP(C3Cl)I indicate the total concentration (B). Protein and RNA samples from 
exponentially growing cells (E). 
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5.2.11 Effects of f-IP(C3Cl)I, f-IP(C3NH2)I and their combination on 
the cell cycle 
To further investigate the effect of Dbf4 on exponentially growing MDA-MB231 cells, 
cell cycle analysis of 50 µM and 100 µM of each of f-IP(C3Cl)I and f-IP(C3NH2)I 
treated-cells and 50 µM and 100 µM of their combination treated-cells were performed 
after a 24 h incubation. As shown in Figure 5.22A, f-IP(C3Cl)I has no effect on the cell 
cycle at 50 µM and 100 µM after a 24 h of exposure. In contrast, there is a 4.21% 
increase of 100 µM f-IP(C3NH2)I treated-cells in G1 compared to the untreated cells 
(Figure 5.22A). However, when 50 µM of f-IP(C3NH2)I were mixed with 50 µM of f-
IP(C3Cl)I, the combination at 100 µM induces a 9.48% increase of treated-cells in G1 at 
24 h, indicating a greater effect of the combination than either f-IP(C3NH2)I or f-
IP(C3Cl)I treatment alone (Figure 5.22B). 
 
5.2.12 Effects of f-IP(C3Cl)I, f-IP(C3NH2)I and their combination on 
cell growth, apoptosis and proliferation in the MDA-MB231 cells 
To investigate the effects of f-IP(C3Cl)I, f-IP(C3NH2)I and their combination in MDA-
MB231 cells, the same assays as in section 5.2.5 were carried out.  
 
As shown in Figure 5.23A and B, the luminescence levels and the relative cell viability 
percentages of f-IP(C3Cl)I-treated cells decrease slightly in response to increasing 
concentrations of f-IP(C3Cl)I at 24 and 48 h, respectively. The luminescence levels in 
the cell apoptosis assay and the corresponding cell apoptosis percentages of f-IP(C3Cl)I-
treated cells increase slightly in response to increasing concentrations of f-IP(C3Cl)I at 
24 and 48 h (Figure 5.23C&D). The absorbance and the relative cell proliferation 
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percentages of f-IP(C3Cl)I-treated cells exhibit the similar pattern as shown in the cell 
viability assay (Figure 5.23E&F).  
 
As shown in Figure 5.24A and B, cell viability percentages of f-IP(C3NH2)I and the 
combination-treated cells decrease in a dose-dependent fashion at 24, 48 and 72 h. At 72 
h, f-IP(C3NH2)I at either 50 µM or 100 µM shows a higher reduction of cell viability 
than the combination. Cell apoptosis percentages of f-IP(C3NH2)I and the combination-
treated cells increase in response to increasing concentrations of these compounds 
(Figure 5.24C&D). At 72 h, f-IP(C3NH2)I at either 50 µM or 100 µM produces a greater 
level of apoptosis than the combination. The cell proliferation percentages of f-
IP(C3NH2)I and the combination-treated cells decrease in a dose-dependent fashion at 
24, 48 and 72 h (Figure 5.24 E&F). The combination at either 50 µM or 100 µM 
produces a higher decrease of cell proliferation than f-IP(C3NH2)I at 72 h. Overall, f-
IP(C3NH2)I at 100 µM has a greater effect on cell viability and apoptosis than either f-
IP(C3Cl)I or the combination. However, the combination at 100 µM exhibits a higher 
reduction of cell proliferation than either f-IP(C3NH2)I or f-IP(C3Cl)I alone, suggesting 
the potential formation of an H-pin structure.   
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Figure 5.22. Flow cytometry analysis of f-IP(C3Cl)I, f-IP(C3NH2)I and the 
combination-treated MDA-MB231 cells. A, Untreated-(upper panel), 50 µM f-IP(C3Cl)I 
treated-(left middle panel) and 100 µM f-IP(C3Cl)I treated-(left lower panel) MDA-
MB231 cells after 24 h respectively. 50 µM f-IP(C3NH2)I treated-(right middle panel) 
and 100 µM f-IP(C3NH2)I treated-(right lower panel) MDA-MB231 cells after 24 h 
respectively. B, Untreated-(upper panel), 50 µM the combination [25 µM each of f-
IP(C3Cl)I and f-IP(C3NH2)I] treated-(middle panel) and 100 µM the combination [50 
µM each of f-IP(C3Cl)I and f-IP(C3NH2)I] treated-(lower panel) MDA-MB231 cells 
after 24 h respectively. Percentage of cells at different phases of the cell cycle was 
counted using Summit 4.3 software. 
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Figure 5.23 Cell survival, apoptosis and proliferation analysis of f-IP(C3Cl)I-treated MDA-MB231 cells. 
A, Kinetics of cell viability after 50 and 100 µM f-IP(C3Cl)I treated MDA-MB231 cells at 24 and 48 h 
respectively. B, Relative percentage of viable cells after 50 µM and 100 µM f-IP(C3Cl)I treated MDA-
MB231 cells at 24 and 48 h respectively. C, Kinetics of cell apoptosis after 50 µM and 100 µM f-
IP(C3Cl)I treated MDA-MB231 cells at 24 and 48 h respectively. D, Percentage of apoptotic cells after 50 
µM and 100 µM f-IP(C3Cl)I treated MDA-MB231 cells at 24 and 48 h respectively. E, Kinetics of cell 
proliferation after 50 µM and 100 µM f-IP(C3Cl)I treated MDA-MB231 cells at 24 and 48 h respectively. 
F, Relative percentage of cell proliferation after 50 µM and 100 µM f-IP(C3Cl)I treated MDA-MB231 
cells at 24 and 48 h respectively. Results are the mean of three independent experiments with error bars 
showing the standard deviation of the mean. 
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Figure 5.24 Cell survival, apoptosis and proliferation analysis of f-IP(C3NH2)I/the combination-treated 
MDA-MB231 cells. A, Kinetics of cell viability after 50 and 100 µM f-IP(C3NH2)I/the combination 
treated MDA-MB231 cells at 24, 48 and 72 h, respectively. B, Relative percentage of viable cells after 50 
and 100 µM f-IP(C3NH2)I/the combination treated MDA-MB231 cells at 24, 48 and 72 h, respectively. C, 
Kinetics of cell apoptosis after 50 and 100 µM f-IP(C3NH2)I/the combination treated MDA-MB231 cells 
at 24, 48 and 72 h, respectively. D, Percentage of apoptotic cells after 50 and 100 µM f-IP(C3NH2)I/the 
combination treated MDA-MB231 cells at 24, 48 and 72 h, respectively. E, Kinetics of cell proliferation 
after 50 and 100 µM f-IP(C3NH2)I/the combination treated MDA-MB231 cells at 24, 48 and 72 h, 
respectively. F, Relative percentage of cell proliferation after 50 and 100 µM f-IP(C3NH2)I/the 
combination treated MDA-MB231 cells at 24, 48 and 72 h, respectively. Results are the mean of three 
independent experiments with error bars showing the standard deviation of the mean.  
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Investigation of the effects of fluorescent analogues in vitro and in 
MDA-MB231 cells  
5.2.13 In vitro binding of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-
PI(C3NH2) to the Dbf4 promoter 
The compounds contain a p-anisylbenzimidazolecarboxamido (Hx) containing an 
additional nitrogen as an Aza-Hx moiety attached to PI, P(C3NH2)I or PI(C3NH2) unit, 
giving compounds Aza-Hx-PI, Aza-Hx-P(C3NH2)I or Aza-Hx-PI(C3NH2), respectively. 
The chemical structures of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) are 
shown in Figure 5.25A. The proposed DNA sequence binding model for the tested 
compounds is shown in Figure 5.25B, based on the previous finding that Hx moiety can 
mimic pyrrole-pyrrole or formamido-pyrrole (Chavda et al., 2011). The binding of Aza-
Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) to the MCB (5'-ACGCGT-3') 
present in the 131bp radiolabeled Dbf4 promoter sequence (Figure 5.8A) was 
investigated by DNase I footprinting. The autoradiograms depicted in Figure 5.26A and 
B show that an initial footprint is observed for Aza-Hx-PI and Aza-Hx-P(C3NH2)I at the 
binding site 5'-ACGCGT-3' at 5 µM. However, Aza-Hx-PI(C3NH2)'s footprint occurs at 
1 µM and becomes clearer at 5 µM, thus suggesting a slightly higher binding affinity 
than either Aza-Hx-PI or Aza-Hx-P(C3NH2)I (Figure 5.26C). The DNA footprinting 
analysis suggest that Aza-Hx behaves as a formamido-imidazole or pyrrole-imidazole 
unit as designed. Binding of Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) at the non-
specific binding site 5'-AAACGA-3' occurs at 5 µM and 1 µM, respectively (Figure 
5.26B&C). However, no binding is observed for Aza-Hx-PI, suggesting a greater 
specificity for this compound (Figure 5.26A).  
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Figure 5.25 A, Chemical structures (A) and binding model (B) of Aza-Hx-PI and its 
analogues.  
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Figure 5.26 Sequence binding of compounds (A, B and C; Aza-Hx-PI, Aza-Hx-
P(C3NH2)I and Aza-Hx-PI(C3NH2) respectively) to their cognate, target sequence 5’-
ACGCGT-3’ within the Dbf4 promoter. DNase I footprinting was performed using a 
131bp 5’--[32P]-radiolabeled DNA fragment containing the Dbf4 promoter sequence 
from -285 to -211 (described in Figure 5.8A). Asterisk indicates the concentration of 
polyamide at which protection from DNase I cleavage is initially observed. The cognate 
binding site is highlighted by double solid bar. G+A refers to the sequencing lane. 
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To further demonstrate that Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) 
can bind to the MCB motif and potentially affect the HuDbf4 promoter activity, EMSA 
studies were carried out using radiolabeled oligonucleotides containing the MCB, 
incubated with the respective compounds and nuclear extracts from MDA-MB231 cells. 
As shown in Figure 5.27A, pre-incubation of the radioactive oligonucleotides 
containing the MCB with Aza-Hx-PI, for 1 h and subsequent addition of nuclear 
extracts results in the inhibition of protein binding to the MCB at drug 
concentrations >0.5 μM. The inhibition of protein binding with Aza-Hx-P(C3NH2)I and 
Aza-Hx-PI(C3NH2) treatment is observed at the concentrations >1 μM, thus suggesting 
a lower binding affinity than Aza-Hx-PI (Figure 5.27B&C). The same experiments 
were repeated with the nuclear extracts incubated with the radioactive oligonucleotides 
first, for 1 h, before addition of the tested compounds. The MCB binding inhibition 
patterns were identical (data not shown) suggesting that the tested compounds can not 
only compete but also displace transcription factors bound to DNA, including the MCB. 
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Figure 5.27 Interaction of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) 
with the MCB within the Dbf4 promoter. The oligonucleotide (described in Figure 
5.9D) was incubated with Aza-Hx-PI (A), Aza-Hx-P(C3NH2)I (B) and Aza-Hx-
PI(C3NH2) (C) (concentrations ranging from 0.1–50 μM) for 1 h at room temperature 
prior to incubation with nuclear extracts from MDA-MB231 cells. Cold (C) and 
mutated (M) lanes represent reactions carried out in the presence of excess unlabeled 
and mutated MCB oligonucleotides. The same nuclear extracts were used under the 
same experimental conditions in all lanes. 
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5.2.14 Effects of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) 
on the cellular levels of HuDbf4: RT-PCR and western blot analysis 
The effects of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) on Dbf4 
expression were analyzed in exponentially growing MDA-MB231 cells. Following 50 
µM and 100 µM of Aza-Hx-PI, there is a 16.76% and 43% reduction in Dbf4 mRNA 
levels at 24 h, respectively, compared to untreated cells (Figure 5.28A&B). Dbf4 
mRNA levels do not change noticeably when treated with 50 µM of Aza-Hx-P(C3NH2)I 
and Aza-Hx-PI(C3NH2) respectively at 24 h (Figure 5.28C). However, after 100 µM of 
Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) treatment, there is a 22% and 24% 
reduction in Dbf4 mRNA levels at 24 h, respectively (Figure 5.28D). At 100 µM, Aza-
Hx-PI produces ~2-fold greater inhibition of mRNA levels at 24 h than either Aza-Hx-
P(C3NH2)I or Aza-Hx-PI(C3NH2).  
 
The ability of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) to affect protein 
expression was investigated using immunoblotting. MDA-MB231 cells were incubated 
with 50 μM and 100 μM  Aza-Hx-PI for 24 h. Western blot analysis was performed and 
the results are shown in Figure 5.29.  
 
As shown in Figure 5.29A, Aza-Hx-PI reduces the levels of Dbf4 protein after 24 h of 
exposure in a dose-dependent manner. In contrast, Aza-Hx-P(C3NH2)I has no effect on 
Dbf4 protein levels at even 100 μM after a 24 h incubation (Figure 5.29B). However, in 
Figure 5.29B, Aza-Hx-PI(C3NH2) shows inhibitory effects on Dbf4 protein levels at 100 
μM at 24 h. As a loading control, the levels of calnexin in the cells were probed and 
found to be unaltered by polyamide exposure.  
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Figure 5.28 Exponentially growing MDA-MB231 cells were treated with up to 100 µM 
Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) for 24 h. mRNA levels in Aza-
Hx-PI-(A), Aza-Hx-P(C3NH2)I-(B) and Aza-Hx-PI(C3NH2)-(C) treated cells were 
expressed relative to untreated exponentially growing MDA-MB231 cells. Results are 
the mean of three independent experiments with error bars showing the standard 
deviation of the mean. 
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Figure 5.29 Western blot analysis of nuclear extracts following treatment with Aza-Hx-
PI (A), Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) (B). Exponential cells were treated 
with 50 and 100 μM Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) 
respectively and analysis was carried out on samples collected after 24 h of drug 
treatment as indicated. Calnexin is shown as a loading control. Protein and RNA 
samples from exponentially growing cells (E). 
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5.2.15 Cellular uptake and nuclear localization of Aza-Hx-PI, Aza-Hx-
P(C3NH2)I and Aza-Hx-PI(C3NH2) 
MDA-MB231 breast cancer cells were used in this study of the nuclear uptake of 
compounds Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2). Figure 5.30A 
shows confocal microscopy images of MDA-MB231 cells exposed to Aza-Hx-PI. The 
cells were treated with Aza-Hx-PI at 10 µM, 30 µM and 50 µM for 2 h at 37°C, washed, 
fixed with 2.5% paraformaldehyde, and then counterstained 20 µg/µl propidium iodide 
(PI), which binds strongly to nucleic acids and stains principally the nucleus in red. 
With increasing concentrations, Aza-Hx-PI is more efficiently localized in the cell 
nuclei and its fluorescence (blue) colocalizes with PI (Figure 5.30A). Accumulation of 
the blue fluorescence in the nuclear compartment at 10 µM, 30 µM and 50 µM after 2 h 
exposure of Aza-Hx-PI is observed respectively while no fluorescence is detected in the 
untreated cells, suggesting a dose-dependent effect (Figure 5.30A). Figure 5.30B-D 
shows confocal images of MDA-MB231 cells exposed to Aza-Hx-PI, Aza-Hx-
P(C3NH2)I and Aza-Hx-PI(C3NH2) at 50 µM for 10 min, 30 min and 2 h with the same 
experimental conditions described above. In all cases, the tested compounds at 50 µM 
are efficiently localized in the cell nuclei within minutes and their blue fluorescence 
signal and therefore their nuclear DNA binding increase in a time-dependent fashion 
(Figure 5.30B-D).  
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Figure 5.30 Confocal image of MDA-MB231cells stained with Aza-Hx-PI (A, 0, 10, 
30 and 50 µM treatments for 2 h; B, 0 and 50 µM treatments for 10 min, 30 min and 2 
h), Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) (C and D, 0 and 50 µM treatments for 
10 min, 30 min and 2 h respectively), with PI (in red). The cells were incubated with 
the test compounds for the indicated time, washed, fixed with 2.5% paraformaldehyde, 
and then labelled with PI (20 µg/µl) before the microscopy observation (× 63).  
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5.3 Discussion 
A previous study has indicated that Cdc7/Dbf4 protein levels are very low or 
undetectable in normal tissues (e.g., lung, breast and ovary) and cell lines (e.g., WI-38) 
but have increased expression in ~50% of the 62 human tumour cell lines examined 
(Bonte et al., 2008). The MDA-MB231 cell line has also been shown to exhibit 
increased Cdc7 and Dbf4 protein levels (Bonte et al., 2008). 
 
Wu and Lee (2002) generated genomic libraries with a DNA segment containing 20kb 
upstream of the human Dbf4 (HuDbf4) promoter. Subsequently, the genomic libraries 
were pooled and transiently transfected into MDA-MB231 cells to identify the HuDbf4 
DNA fragments containing promoter activity. Consequently, they found that the 
HuDbf4 core promoter is localized within -211 to -285 (75bp) of the translation ATG 
start-codon. They also showed that the MCB element present on the promoter of human 
Dbf4 is essential for promoter activation and a point mutation within the MCB element 
significantly decreases promoter activity (Wu and Lee, 2002).  
 
The binding of polyamides to the MCB sequence in the core HuDbf4 promoter was 
utilized as a model system to test our rationally designed polyamide compounds, e.g. f-
IPI. Many published papers have shown that f-IPI has an exceptionally high DNA-
binding affinity and selectivity (e.g. Buchmueller., et al 2005, 2006). The cognate 
sequence 5’-ACGCGT-3’of f-IPI is a binding site of interest because it is present in the 
core sequence of the MCB transcriptional element found in the promoter of the human 
Dbf4 gene (Wu and Lee, 2002). This is an example where rationally designed 
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polyamides could interact with a transcriptional element and potentially control gene 
expression.   
 
This study shows that sequence-specific polyamides can be used to block transcription 
factor/DNA interactions and therefore modulate cell-cycle progression.  
 
The thesis investigated the potential for f-IPI, which can block MCB-targeted 
transcription factor/DNA interactions, to downregulate Dbf4 expression in MDA-
MB231 cells. DNase I footprinting was initially employed to demonstrate that f-IPI 
exhibits a good binding affinity for the MCB present in the core Dbf4 promoter (Figure 
5.8B). In comparison to f-IPI, its H-pin derivative showed a 2-fold improved binding 
affinity at the MCB (Figure 5.8C). This is consistent with the f-IPI H-pin ensuring the 
staggered binding motif of a 1:1 ligand/DNA complex as has been shown by our 
previous study (O'Hare et al., 2007). Although f-IPI prefers such a 2:1 formation, it may 
not always be energetically favorable. In addition, f-IPI may also bind in a mixed 2:1 
and 1:1 motif, thus reducing the overall affinity. EMSA studies can provide direct 
evidence for the ability of small molecules to interfere with the binding of proteins to 
target DNA sequences. The involvement of MCB-targeted proteins in the transcriptional 
regulation of Dbf4 in cells was shown with EMSAs (Figure 5.9), indicating that the 
MCB-targeted proteins are displaced by f-IPI addition in a dose-dependent fashion 
(Figure 5.9A). Not surprisingly, f-IPI H-pin exhibits a greater effect on the inhibition of 
the MCB-targeted proteins binding compared to f-IPI (Figure 5.9C), which is consistent 
with the DNase I footprinting analysis.  
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The concept of sequence specificity achieved by polyamides is based on the pioneering 
work of Dervan and Lown groups (Lown et al., 1986; Swalley et al., 1996; Dervan and 
Edelson, 2003). The ability of these compounds to block DNA interactions in some 
genes at nanomolar concentrations have been shown in vitro, although higher 
concentrations need to be used in vivo (Best et al., 2003; Dickinson et al., 2004). 
However, nuclear penetration problems by these compounds have been raised as the 
size of the polyamide is increased as in hairpin or cyclic polyamides (Best et al., 2003; 
Franks et al., 2010). 
 
The cellular effects of f-IPI and f-IPI H-pin treatments were assessed in exponentially 
growing MDA-MB231 cells by using RT-PCR and western blot analysis. These studies 
showed a reduction of Dbf4 mRNA and protein levels by f-IPI treatment in a dose-
dependent fashion, suggesting a correlation between inhibition of the MCB-targeted 
proteins binding and down-regulation of HuDbf4 in cells (Figure 5.11 and Figure 5.12). 
However, in contrast to the f-IPI monomer, the H-pin analogue had no effect on the 
levels of HuDbf4 in cells, suggesting that the H-pin molecule does not enter the nucleus, 
presumably due to the large molecular size. This result is interesting in that it directly 
compares a monomer and an H-pin that, despite having similar binding characteristics, 
demonstrate such vastly different cellular properties.  
 
The role of Dbf4 was demonstrated using a siRNA-mediated specific depletion of Dbf4 
in MDA-MB231 cells. Depletion of Dbf4 at 72 h after siRNA treatment was found to be 
associated with a detectable reduction in cell survival (17%) and proliferation (10%) 
without any significant alteration in apoptosis levels (Figure 5.14). However, a previous 
study showed that depletion of Dbf4 in the melanoma cell line MV3, 72 h after siRNA 
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treatment was associated with a 40.7% and 65% decrease in cell survival and 
proliferation without any significant change in apoptosis (Nambiar et al., 2007). The 
different outcomes in the two different Dbf4 siRNA knockdown cell lines may suggest 
that the role of Dbf4 varies in different cell lines. This inability to produce a complete 
loss of cell survival and proliferation in MDA-MB231 cells and in MV3 cells may be 
explained by the redundancy of proliferative pathways in such cancer. Alternatively, it 
is also possible that in the absence of Dbf4, its homolog Drf1 may have a role in driving 
cell proliferation (Yoshizawa-Sugata., et al 2005). Flow cytometry analysis of untreated, 
scrambled-control and Dbf4 siRNA knockdown cells was performed at 24 and 48 h post 
transfection (Figure 5.15). Detectable G1 arrest was observed at 48 h in siRNA-treated 
cells as compared to scrambled or untreated control cells.  
 
The effects of f-IPI on cell growth, apoptosis and proliferation in MDA-MB231 cells 
were investigated using cell survival, apoptosis and proliferation assays. Without any 
significant effect on apoptosis, there was a respective 27.2% and 33.5% reduction in cell 
survival and proliferation after treatment with 200 M f-IPI for 24 h (Figure 5.16). 
Compared to siRNA-mediated specific depletion of Dbf4, 200 M f-IPI showed a 2-3 
fold greater effect on cell survival and proliferation at 24 h. However, 200 M f-IPI 
only induced a 57% depletion of Dbf4 mRNA levels at 24 h, compared to >90% 
depletion by Dbf4 siRNA knockdown. These results suggest that f-IPI might target 
other key genes (e.g., Drf1) that have a complementary role in driving cell proliferation 
or Dbf4 might be partially involved in the DNA replication and cell growth regulation 
in MDA-MB231 breast cancer cells. Subsequently, flow cytometry analysis of 50 and 
100 M f-IPI-treated MDA-MB231 cells was carried out (Figure 5.17). f-IPI induces a 
noticeable G1 arrest in MDA-MB231 cells in the dose-dependent manner. This result 
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suggests that the alteration of the Dbf4 protein levels is associated with a role in cell 
cycle regulation, in addition to Dbf4 siRNA knockdown-induced G1 arrest in MDA-
MB231 cells.  
 
The f-IPI H-pin analogue showed improved DNA binding affinity and greater inhibition 
of protein binding in vitro than its monomer f-IPI. However, it did not exhibit cellular 
effects, suggesting that it cannot enter the nucleus, presumably because of its large 
molecular size. Therefore, the subsequent study aimed to test the in situ reaction of two 
rationally designed polyamide monomers [f-IP(C3NH2)I and f-IP(C3Cl)I] capable of 
potentially forming H-pin structure by click chemistry in the nucleus.  
 
DNase I footprinting was employed and a footprint was produced at 0.5 M by f-
IP(C3NH2)I, indicating a 10-fold higher DNA-binding affinity for the MCB than f-
IP(C3Cl)I. In comparison, when 0.05 M of f-IP(C3NH2)I were mixed with 0.05 M of 
f-IP(C3Cl)I, a footprint occurs, which suggest that the hybrid molecule possesses a 
higher DNA-binding affinity than either f-IP(C3NH2)I or f-IP(C3Cl)I alone (Figure 5.18).  
 
The EMSA studies showed that a dose-dependent inhibition of the MCB-targeted 
protein binding is caused by f-IP(C3NH2)I treatment with the inhibitory effect observed 
from 0.1 M. In contrast, there is only a limited inhibition of protein binding by f-
IP(C3Cl)I at 10 M. When 0.25 M of f-IP(C3NH2)I were mixed with 0.25 M of f-
IP(C3Cl)I, the inhibition of the MCB-targeted protein binding by the combination 
occurs as was the case for 0.5 M f-IP(C3NH2)I alone (Figure 5.19). The question raised 
from these results is how f-IP(C3Cl)I when used at half the concentration (0.25 M) in 
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combination with f-IP(C3NH2)I, which generates a lower protein binding inhibition, 
produces the same results as when f-IP(C3NH2)I is used alone at double the 
concentration (0.5 M). One possibility is that f-IP(C3NH2)I does react with f-IP(C3Cl)I 
to form a favorable H-pin compound, which can compensate for the lower inhibitory 
effect of f-IP(C3Cl)I on protein binding to the MCB in the in situ reaction. 
 
The cellular effects of compounds f-IP(C3NH2)I, f-IP(C3Cl)I and their combination 
were tested in exponentially growing MDA-MB231 cells by using RT-PCR, western 
blot analysis and flow cytometry analysis. f-IP(C3NH2)I caused a greater reduction of 
Dbf4 mRNA and protein levels at either 50 M or 100 M at 24 h than f-IP(C3Cl)I 
(Figure 5.20A&B and Figure 5.21A&B). However, when 25 M of f-IP(C3NH2)I were 
mixed with 25 M of f-IP(C3Cl)I, the combination produced the greatest reduction of 
Dbf4 mRNA and protein levels at 24 h when compared to either 50 M of f-IP(C3NH2)I 
or 50 M of f-IP(C3Cl)I alone (Figure 5.20 and Figure 5.21). The effects were more 
pronounced at a higher concentration, when 50 M of f-IP(C3NH2)I were mixed with 50 
M of f-IP(C3Cl)I.  Flow cytometry analysis showed that the combination (50 M of 
each compound) induces a greater G1 arrest at 24 h than either 100 M of f-IP(C3NH2)I 
or 100 M of f-IP(C3Cl)I alone (Figure 5.22).  
 
The effects of the tested compounds f-IP(C3NH2)I, f-IP(C3Cl)I and their combination on 
cell growth, apoptosis and proliferation in MDA-MB231 cells were investigated using 
cell survival, apoptosis and proliferation assays (Figure 5.23 and Figure 5.24). The 
dose-dependent effects of f-IP(C3NH2)I on cell survival were shown and this polyamide 
presented a greater decrease of cell survival than either the combination or f-IP(C3Cl)I 
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(Figure 5.24A&B). F-IP(C3NH2)I also exhibited higher apoptosis levels than either the 
combination or f-IP(C3Cl)I in a dose-dependent fashion (Figure 5.24C&D). However, 
the combination showed a greater reduction of DNA replication in the cell proliferation 
assay than either f-IP(C3NH2)I or f-IP(C3Cl)I in a dose-dependent fashion, suggesting a 
potential H-pin structure formation (Figure 5.24E&F).  
 
Together the results suggest that f-IP(C3NH2)I may react with f-IP(C3Cl)I under a 
nucleophilic substitution reaction, to produce in situ H-pin formation. The resulting H-
pin molecule would be expected to have a greater DNA-binding affinity and be capable 
of producing inhibition of the MCB-targeted protein binding in vitro more efficiently. 
Additionally, it would be expected to elicit a higher reduction of Dbf4 mRNA and 
protein levels, and cause G1 arrest at a higher level with a greater reduction in DNA 
replication in cells. 
 
With the aim of incorporating a recognition element that acts as a fluorescent probe 
upon binding to DNA, three novel pyrrole (P) and imidazole (I)-containing polyamides 
were synthesized. The compounds Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-
PI(C3NH2) were then tested.  
 
These fluorescent analogues were designed to target the 5’-ACGCGT-3’ sequence and 
this was therefore tested against the MCB by using DNase I footprinting and EMSAs 
analysis. DNA footprinting revealed a footprint for Aza-Hx-PI and Aza-Hx-P(C3NH2)I 
over the MCB site at the same concentration (Figure 5.26A&B). In comparison, Aza-
Hx-PI(C3NH2) exhibited a slightly higher binding affinity than either Aza-Hx-PI or 
Aza-Hx-P(C3NH2)I (Figure 5.26C). However, Aza-Hx-P(C3NH2)I and Aza-Hx-
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PI(C3NH2) also showed binding over the non-cognate 5’-AAACGA-3’ sequence 
compared to Aza-Hx-PI, suggesting that Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) 
possessed less sequence specificity. In EMSA studies, a dose-dependent inhibition of 
MCB-targeted protein binding was observed after treatment with Aza-Hx-PI and the 
effect was shown at doses as low as 0.5 M. Aza-Hx-PI exhibited a greater inhibition 
than either Aza-Hx-P(C3NH2)I or Aza-Hx-PI(C3NH2) (Figure 5.27). The DNase I 
footprinting and EMSAs analysis confirmed that these fluorescent hybrids mimic f-IPI 
or PIPI, targeting the MCB present in the Dbf4 core promoter sequences.  
 
RT-PCR and western blot analysis were also employed in the study for investigating the 
cellular effects of Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) in 
exponentially growing MDA-MB231 cells (Figure 5.28 and Figure 5.29). Aza-Hx-PI 
treatment of cells resulted in reduced Dbf4 mRNA and protein levels in a dose-
dependent fashion at 24 h (Figure 5.29A). In contrast, Aza-Hx-P(C3NH2)I and Aza-Hx-
PI(C3NH2) resulted in a much lower decrease of Dbf4 mRNA and protein levels at 24 h 
than Aza-Hx-PI (Figure 5.29B).  
 
Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) were found to efficiently 
localize in the cell nuclei by as early as 10 min at 50 M, suggesting that these 
fluorescent analogues can be used as probes for monitoring cellular uptake and nuclear 
localization in cells, in addition to the specific modulation of gene expression. 
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CHAPTER 6   
CONCLUSION 
The limited success of many current chemotherapies requires a new generation of 
anticancer strategies, able to discriminate more effectively between tumour and normal 
tissues. In the past, it has been attempted to regulate the transcription of key disease-
related genes either indirectly by targeting gene transcripts or alternatively by direct 
interaction with genomic DNA (Pandolfi, 2001; Darnell, 2002). Many minor groove-
binding polyamides have been developed for this purpose and demonstrate the strong 
DNA sequence recognition that would be required for specific targeting of genomic 
DNA. The discovery that distamycin A can form an antiparallel dimer in the minor 
groove of AT-rich sequences initiated the rational design of the original DNA sequence 
reading polyamides (Urbach and Dervan, 2001; Dervan and Burlii, 1999). Pyrrole-
imidazole containing polyamide analogues of distamycin A can bind in the minor 
groove of DNA at specific DNA sequences in a stacked fashion (Mitra et al., 1999; 
Pelton and Wemmer, 1999). After extensive research, the basic ‘pairing rules’ were 
developed for the minor groove binding of polyamides containing pyrrole and imidazole 
groups (Wade et al., 1992; Gottesfeld et al., 1997; Dervan et al., 1999, 2003). Such 
polyamides can target predetermined DNA sequences with high affinity and potentially 
modulate gene expression by interfering with the binding of transcription factors to 
DNA (Gottesfeld et al., 1997; Dickinson et al., 1999; Mapp et al., 2000; Hochhauser et 
al., 2007; Kotecha et al., 2008).  
 
H-pin analogues have been previously designed and tested by our group, showing 
enhanced DNA binding affinity and selectivity compared to monomer polyamides 
243 
 
(O'Hare et al., 2007). However, their large molecular size is associated with poor 
cellular uptake (Franks et al., 2010). A new class of unlinked polyamide precursors 
containing appropriate pendant reactive and biocompatible functional groups was 
designed and synthesized. In this thesis, the approach of the in situ reaction of two 
rationally designed polyamide monomers capable of potentially forming either H-pin or 
Hairpin conjugates in the nucleus was tested. DNase I footprinting results suggest that f-
IP(C3NH2)I has the potential of interacting with f-IP(C3Cl)I to form a favorable H-pin 
compound under a nucleophilic substitution; the two monomers f-IP(C3N3)I and f-
PP(C3-alkyne)P can interact in situ to form a heterodimer H-pin molecule under an 
azide-alkyne Huisgen reaction; f-IP(C3-alkyne)I can interact with f-PP(C3N3)P to allow 
in situ formation of a heterodimer H-pin polyamide. Although the footprinting data 
suggest H-pin formation, it was difficult to prove whether a stable 2:1 complex is 
covalently formed. Further studies and assessment by other techniques is therefore 
required. It is interesting to find that the different pendant reactive groups on 
polyamides [e.g. f-IP(C3NH2)I vs f-IP(C3Cl)I] can influence binding affinity, so further 
evaluation of different reactive groups on the same parent polyamides is also required.  
 
The f-IPI analogues were modified with the aim of acquiring analogues with improved 
sequence specificity, stronger binding affinity and high solubility in biological media. 
The polyamides containing a pyrrole-N1-alkyl spermine/spermidine group target A/T 
rich sequences and bind with high affinity because the additional cationic groups 
interact with the negatively charged phosphodiester groups of DNA (Satz and Bruice, 
2002). The diamino f-I(C3NH2)PI, f-P(C3NH2)IP, f-IPP(C3NH2) and phenyl-IP(C3NH2)I 
were designed and tested, showing higher DNA binding affinity than their non-amino 
counterparts. Compared to the monoamino polyamides, the diamino polyamides possess 
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enhanced water solubility because of the ease in dissolving in media. Overall, it is 
evident that the incorporation of an orthogonally positioned aminopropyl side chain in 
the polyamide backbone can afford favorable physicochemical and DNA binding 
properties. In addition, positioning the pendant reactive group at different sites on the 
polyamides can influence binding affinity [e.g. f-IP(C3NH2)I vs f-I(C3NH2)PI], thus its 
position within the polyamides is important and required for a further evaluation.  
 
The identification of novel molecular targets is essential for the development of new 
and efficient cancer therapies. Previous studies on the molecular basis of various 
diseases have revealed that kinases are one of the most common drug targets, associated 
with many disease states, particular cancer (Noble et al., 2004). Therefore, modulating 
aberrant kinase activities in cancer cells may form an effective cancer therapy, with 
fewer side effects than traditional cytotoxic drugs. Cell cycle progression is regulated by 
a number of kinases, some of which are being developed to treat cancer. Cell death is 
caused by acute genomic instability, induced by the combined effects of the aberrant 
cell cycle progression, destabilization of replication forks, impaired DNA damage 
responses and uncoupling of S phase with mitosis due to checkpoint defects. Cancer 
cells are generally associated with defects in checkpoint response pathways, and hence 
indicate greater sensitivity to S phase perturbation than normal cells. Thereby the 
critical importance of Cdc7-Dbf4 kinase in the survival of tumour cells and the tumor-
specific cell death observed with Cdc7 inhibition or depletion (Kim et al., 2003) makes 
this a potential target for anti-cancer drug development.  
 
Dbf4 is the regulatory subunit of Cdc7 (cyclin dependent 7) kinase, which is a 
conserved serine/threonine kinase essential for the initiation of DNA replication, likely 
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by activating the MCM DNA helicase at the G1- to S-phase transition (Bousse and 
Diffley, 1998). Cdc7 kinase activity is cell-cycle dependent as it is low during G1 and 
becomes activated with the initiation of the S phase, whereas its mRNA and protein 
levels are relatively constant throughout the cell cycle (Jiang et al., 1999; Kumagai et al., 
1999; Ferreira et al., 2000). High levels of Dbf4 protein are generally associated with 
Cdc7 kinase activity and are critically important for its regulation (Jackson et al., 1993; 
Nougarede et al., 2000). Therefore, maintaining appropriate levels of Dbf4 protein is a 
primary control point at the initiation of DNA replication (Chapman and Johnston, 1989; 
Lepke et al., 1999). Cdc7 and Dbf4 proteins form a complex in vivo to generate an 
active protein kinase (Kumagai et al., 1999), which is a target of the S-phase checkpoint 
pathway, and plays an important role in promoting DNA damage response in multiple 
organisms (Takeda et al., 1999; Weinreich and Stillman, 1999). Human Cdc7-Dbf4 
kinase activity is essential for cell proliferation by activating DNA replication. High 
levels of the human Cdc7/Dbf4 kinase activity have been implicated in a large number 
of aggressive solid cancers
 
(Hess et al., 1998; Yamada et al., 2002). 
 
An investigation into the in vitro binding characteristics of f-IPI to the HuDbf4 and its 
cellular effects in MDA-MB231 cells was carried out in Chapter 5. f-IPI has a good 
binding affinity for the MCB sequences present in the core Dbf4 promoter and can also 
inhibit protein binding to the MCB in vitro. However, the f-IPI H-pin derivative shows 
an enhanced DNA binding affinity and a higher degree of inhibition of MCB-targeted 
protein binding.  
 
The cellular studies in this thesis showed a f-IPI dose-dependent reduction in the levels 
of Dbf4 mRNA and protein in MDA-MB231 cells, suggesting a good correlation 
246 
 
between inhibition of the MCB-targeted protein binding and down-regulation of Dbf4 in 
cells. However, in contrast to the f-IPI monomer, the f-IPI H-pin exhibits no effect on 
the Dbf4 protein levels in cells, suggesting that the H-pin polyamide does not enter the 
nucleus, presumably due to its large molecular size and cannot bind the MCB in vivo. 
Flow cytometry analysis showed that both f-IPI and Dbf4 siRNA knockdown can 
induce G1 arrest in MDA-MB231 cells, confirming that Dbf4 plays an important role in 
regulating cell cycle.  
 
The Dbf4 siRNA treatment in MDA-MB231 cells at 72 h results in greater reduction of 
Dbf4 mRNA levels compared to treatment with 200 M f-IPI. However, f-IPI has a 
higher effect on cell survival and proliferation than the Dbf4 siRNA treatment, 
suggesting that f-IPI targets other key genes (e.g., Dbf4's homolog Drf1) that have a 
complementary role in driving cell proliferation or Dbf4 might only have a partial role 
in DNA replication and cell growth regulation in MDA-MB231 cells. Nambiar and co-
workers reported that siRNA-mediated depletion of Dbf4 in the melanoma cell line 
MV3 at 72 h cause a greater decrease of cell survival and proliferation without any 
significant change in apoptosis, when compared to Dbf4 siRNA knockdown in MDA-
MB231 cells (Nambiar et al., 2007). This suggests that the role of Dbf4 varies in 
different cancer cell lines. Further investigation of the involvement of Drf1 and the role 
of Dbf4 in different cancer cell lines is therefore required.  
 
Collectively, the pyrrole-imidazole polyamides represent a class of small molecules that 
can be designed to recognize predetermined DNA sequence. These molecules have 
affinities and specificities that equal or exceed natural eukaryotic transcriptional 
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regulatory proteins, and are potent inhibitors of protein-DNA interactions, thus they can 
be potentially used as a gene control agent, especially for anti-cancer drug development.   
The Dbf4 promoter was utilized as a model system for f-IPI and was also employed for 
the study of the in situ formation of H-pin approach in vitro and in cells. The studies 
demonstrated that f-IP(C3NH2)I does react with f-IP(C3Cl)I, forming in situ the H-pin 
structure that is capable of eliciting higher DNA-binding affinity and greater inhibition 
of the protein binding to the MCB in vitro. Moreover, the H-pin molecule 
downregulates Dbf4, produces G1 arrest and prevents DNA replication at a higher level 
than each compound alone in MDA-MB231 cells. The data confirmed that the approach 
is feasible and can be used to design the next generation of polyamides that form H-pin 
structure in the nucleus, having greater DNA binding affinity and selectivity.  
 
Hx-polyamide compounds bind DNA in a highly sequence selective manner (Chavda et 
al., 2011). The Hx moiety when incorporated into polyamides provides a direct means 
to measure polyamide binding in the minor groove of DNA in a test tube or in cells by 
fluorescence. The fluorescent hybrids, Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-
PI(C3NH2), mimic f-IPI and target the MCB sequences present in the core Dbf4 
promoter. Aza-Hx-PI, Aza-Hx-P(C3NH2)I and Aza-Hx-PI(C3NH2) were found to 
efficiently localize in the cell nuclei within minutes. The Hx moiety represents a 
significant advancement in the polyamide field, owing to its simple molecular design 
and ease of synthesis. Sequence targeted Hx polyamides such as those presented in this 
study provide a direct and simple way to monitor binding, without the incorporation of a 
bulky fluorescent tag. Therefore such fluorophores can be used to detect polyamides' 
cellular uptake and nuclear localization, in addition to their ability to target the DNA 
sequences as a potential gene-control agents. 
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 In conclusion the in vitro study of the DNA selectivity and affinity of polyamides, the 
effects of structural modifications on their interactions with DNA and the incorporation 
of fluorophores for monitoring their nuclear localization, enable us to further improve 
their use for gene targeting purposes. In addition, for the prediction of the biological 
consequences of polyamide binding in cells to be possible, a greater understanding is 
required of the accessibility of sequences in genomic DNA, the dynamics of 
nucleosomal organization and the mechanisms of transcriptional activation. 
Consequently, the design of the next generation of polyamides will require a more 
thorough understanding of these factors to achieve realistic therapeutic utility.    
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